

abbvie

janssen
LABORATOIRES JANSSEN
et Johnson & Johnson

LA ROCHE-POSAY
LABORATOIRE DERMATOLOGIQUE

GALDERMA

Lilly

NOVARTIS
PHARMACEUTICALS

Celgene



IAD

IRISH ASSOCIATION
OF DERMATOLOGISTS

AUTUMN MEETING

Thursday 6th & Friday 7th October 2016
Hilton Hotel, Templepatrick, Co Antrim

The first approved treatment for moderate to severe Hidradenitis Suppurativa^{1,2}



Fewer abscesses^{3,4}

Feeling good about myself

The joy of being connected

Hidradenitis Suppurativa (HS)¹:

HUMIRA is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adult patients with an inadequate response to conventional systemic HS therapy.

Prescribing Information (PI) Humira (adalimumab) 40 mg solution for injection in pre-filled pen or pre-filled syringe or paediatric vial containing 40 mg solution for injection. Refer to Summary of Product Characteristics (SmPC) for full information.

Presentation: Each single dose pre-filled pen (0.4 ml), pre-filled syringe (0.4 ml) or vial (0.8 ml) contains 40 mg of adalimumab. **Indications:** Rheumatoid arthritis (RA), adults: In combination with methotrexate (MTX) for moderate to severe, active RA with inadequate response to disease-modifying anti-rheumatic drugs (DMARDs) including MTX. In combination with MTX for severe, active and progressive RA when not previously treated with MTX. Can be given as monotherapy if intolerance to or when continued treatment with MTX is inappropriate. Reduces rate of progression of joint damage on X-ray and improves physical function, in combination with MTX. Polyarticular juvenile idiopathic arthritis (pJIA), paediatrics 2 years and above: In combination with MTX, for active pJIA with inadequate response to one or more DMARDs; or monotherapy if intolerance to or when continued treatment with MTX is inappropriate. Enthesitis-related arthritis (ERA), paediatrics 6 years and above: For active ERA with inadequate response or intolerance to conventional therapy. Ankylosing spondylitis (AS), adults: For severe active AS with inadequate response to conventional therapy. Axial spondyloarthritis without radiographic evidence of AS (nr-axSpA), adults: For severe nr-axSpA with objective signs of inflammation (elevated CRP and/or MRI), and an inadequate response to or intolerance to nonsteroidal anti-inflammatory drugs (NSAIDs). Psoriatic arthritis (PsA), adults: For active and progressive PsA with inadequate response to DMARDs. Reduces rate of progression of peripheral joint damage on X-ray in polyarticular symmetrical subtypes of the disease and improves physical function. Psoriasis, adults: For moderate to severe chronic plaque psoriasis who are candidates for systemic therapy. Psoriasis, paediatrics 4 years and above: For severe chronic plaque psoriasis with inadequate response, or if topical therapy and phototherapies are inappropriate. Hidradenitis suppurativa (HS), adults: For active moderate to severe hidradenitis suppurativa (acne inversa) in patients with an inadequate response to conventional systemic HS therapy. Crohn's disease (CD), adults: For moderately to severely active CD with inadequate response, contraindication or intolerance to corticosteroid and/or an immunosuppressant therapy. Crohn's disease (CD), paediatrics 6 years and above: For moderately to severely active CD with inadequate response, contraindication or intolerance to conventional therapy including primary nutrition therapy and a corticosteroid, and/or an immunomodulator. Ulcerative colitis (UC), adults: For moderately to severely active UC with inadequate response, contraindication or intolerance to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA). Uveitis, adults: For the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. **Dosage and administration:** A specialist physician experienced in diagnosis and treatment of the indicated condition, to initiate and supervise treatment. Provide patients with special alert card. Patients may self-inject after proper injection training, with physician approval and appropriate medical follow-up. Optimise other concomitant therapies. RA, adults: 40 mg dose every other week. Concomitant MTX should be continued. During monotherapy, patients may require 40 mg each week if they have experienced a decrease in clinical response. Treatment beyond 12 weeks should be reconsidered if no clinical response in that time. Consider need for dose interruption, e.g. before surgery or if serious infection occurs. Reintroduction after 70 day dose interruption gave same magnitudes of clinical response and similar safety profile as before dose interruption. pJIA, paediatrics 2 years and above: Treatment beyond 12 weeks reconsidered if no clinical response in that time. pJIA, paediatrics 2-4 years: 24 mg/m² body surface area up to 20 mg maximum single dose every other week (see SmPC for height/weight dosing chart). pJIA, paediatrics 4-12 years: 24 mg/m² body surface area up to 40 mg maximum single dose every other week (see SmPC for height/weight dosing chart). pJIA, paediatrics 13 years and above: 40 mg every other week regardless of body surface area. ERA, paediatrics 6 years and above: 24 mg/m² body surface area up to 40 mg maximum single dose every other week (see SmPC for height/weight dosing chart). AS, nr-axSpA and PsA, adults: 40 mg every other week. Treatment beyond 12 weeks should be reconsidered if no clinical response in that time. Psoriasis, adults: 80 mg induction dose at week 0, 40 mg every other week from week 1. Treatment beyond 16 weeks should be reconsidered if no clinical response in that time. Beyond 16 weeks, patients with inadequate response can increase dosing frequency to 40 mg every week. If adequate response is achieved with an increased dosing frequency, the dose may subsequently be reduced to 40 mg every other week. If there is inadequate response to the increased frequency, carefully reconsider treatment. Psoriasis, paediatrics 4 years and above: 0.8 mg/kg body weight (maximum 40 mg/dose) weekly for the first 2 doses then every other week (see SmPC for weight dosing chart). Treatment beyond 16 weeks should be reconsidered if no response in that time. HS, adults: 160 mg initially at Day 1 (given as four 40 mg injections in one day or as two 40 mg injections per day for two consecutive days), followed by 80 mg two weeks later at Day 15 (given as two 40 mg injections in one day). Two weeks later (Day 29) continue with a dose of 40 mg every week. Antibiotics may be continued if necessary. Concomitant topical antiseptic wash on HS lesions should be used

on a daily basis. Treatment beyond 12 weeks should be reconsidered in a patient with no improvement in that time. Reintroduction after interruption: 40 mg every week. Evaluate periodically the benefit and risk of continued long-term treatment. CD, adults: Induction: 80 mg Week 0 and 40 mg at Week 2. For a more rapid response: 160 mg at Week 0 (either as 4 injections in 1 day or 2 injections/day for 2 consecutive days) and 80 mg at Week 2; risk of adverse events higher during induction. Maintenance: 40 mg every other week. If decrease in clinical response, can increase dose to 40 mg weekly. Corticosteroids may be tapered in maintenance phase in accordance with clinical guidelines. Patients with no response by Week 4 may benefit from continued therapy to Week 12. Treatment beyond 12 weeks should be reconsidered if no clinical response in that time. CD, paediatrics 6 years and above < 40 kg: Induction: 40 mg Week 0, 20 mg at Week 2. For a more rapid response: 80 mg Week 0 (2 injections in 1 day), 40 mg at Week 2; risk of adverse events higher during induction. Maintenance: 20 mg every other week. If insufficient response, consider 20 mg every week. Treatment beyond 12 weeks should be reconsidered if no clinical response in that time. CD, paediatrics 6 years and above ≥ 40 kg: Induction: 80 mg Week 0, 40 mg at Week 2. For a more rapid response: 160 mg at Week 0 (4 injections in 1 day or 2 injections/day for 2 consecutive days) and 80 mg at Week 2; risk of adverse events higher during induction. Maintenance: 40 mg every other week. If insufficient response, consider 40 mg every week. Treatment beyond 12 weeks should be reconsidered if no clinical response in that time. UC, adults: Induction: 160 mg at Week 0 (as 4 injections in 1 day or 2 injections/day for 2 consecutive days) and 80 mg at Week 2. Maintenance: 40 mg every other week. During maintenance, corticosteroids may be tapered in accordance with clinical guidelines. If insufficient response, consider 40 mg every week. Treatment beyond 8 weeks should be reconsidered if no clinical response in that time. Uveitis, adults: 80mg induction dose at week 0, maintenance dose; 40 mg every other week starting at week 1. Treatment can be initiated in combination with corticosteroids and/or with other non-biologic immunomodulatory agents. Concomitant corticosteroids may be tapered in accordance with clinical practice starting two weeks after initiating treatment with Humira. **Contraindications:** Active tuberculosis (TB), severe infections (e.g. sepsis), and opportunistic infections; moderate to severe heart failure (NYHA class III/IV); hypersensitivity to adalimumab or any excipients. **Warnings and precautions:** Clearly record trade name and batch number of administered product to improve traceability of biological products. **Infections:** Patients are more susceptible to serious infections especially if impaired lung function. Monitor for infections, including TB, before, during and for 4 months after treatment. Do not initiate treatment with an active infection, until it is controlled. Consider risk/benefit prior to treatment in patients exposed to high risk of TB or endemic mycoses. Evaluate new infections during treatment and monitor closely. Stop treatment if new serious infection or sepsis, and treat appropriately. Exercise caution in patients with a history of recurring infections or who are predisposed to infections. **Serious infections:** Serious infections, including those with hospitalisation or death, reported in patients receiving treatment. **TB:** Consult SmPC for details. Reactivation and new onset TB, both pulmonary and extra-pulmonary (disseminated) reported. Screen all patients before therapy initiation for active or latent TB. If latent TB suspected, consult physician with appropriate expertise and follow local treatment recommendations for prophylaxis prior to initiation of Humira. Despite prophylaxis, TB reactivation has occurred on Humira. If active TB is diagnosed, do not initiate treatment. **Other opportunistic infections:** Opportunistic infections observed in patients receiving Humira. Stop treatment in patients with signs and symptoms of such infections. Consult with physician with appropriate expertise for diagnosis and administration of empiric antifungal therapy in these patients. **Hepatitis B reactivation:** Reactivation has occurred in chronic carriers (surface antigen positive) tested for HBV infection before initiating treatment. HBV carriers should consult a specialist physician and be closely monitored for reactivation of HBV infection throughout therapy and for several months following termination of treatment. If reactivation occurs stop treatment and initiate appropriate anti-viral and supportive treatment. **Neurological events:** Caution in patients with pre-existing or recent-onset central or peripheral nervous system demyelinating disorders. Rare association with new onset or exacerbation of symptoms and/or radiographic evidence of central and peripheral demyelinating disease. Discontinuation of treatment should be considered if any of these disorders develop. Neurologic evaluation should be performed in patients with non-infectious intermediate uveitis prior to initiation of treatment and regularly during treatment, to assess for existing or developing central demyelinating disorders. **Allergic reactions:** Reports of serious allergic reactions including anaphylaxis received. For serious allergic or anaphylactic reaction stop Humira immediately and initiate appropriate therapy. **Malignancies and lymphoproliferative disorders:** A possible risk of malignancy, including lymphomas and leukaemia, in all patients, including paediatric patients, treated with TNF antagonists. Examine all patients, especially those with a medical history of extensive immunosuppressant or PUVA treatment, for non-melanoma skin cancer prior to and during treatment; caution in COPD patients, and in patients with increased risk for malignancy due to heavy smoking. Consider the potential risk with the combination of AZA or 6-MP and Humira (hepatosplenic T-cell lymphoma has occurred). Risk of

hepatosplenic T-cell lymphoma cannot be excluded. Caution in patients with a history of malignancy. Risk of developing dysplasia or colon cancer is unknown. Patients with UC, history of dysplasia or colon carcinoma to be screened for dysplasia before and during treatment. **Haematologic reactions:** Adverse events of the haematologic system reported with Humira. Patients should seek immediate medical attention if signs and symptoms of blood dyscrasias. **Vaccinations:** Patients may receive concurrent vaccinations, except for live vaccines. Bring paediatric patients up to date with all immunisations prior to Humira treatment. **Congestive heart failure:** See contraindications. Caution is advised with mild heart failure (NYHA class I/II). Discontinue treatment for new or worsening symptoms of congestive heart failure. **Autoimmune processes:** Autoimmune antibodies may form. Stop treatment if development of a lupus-like syndrome with positive antibodies against double-stranded DNA. **Surgery:** Consider the long half-life of Humira for planned surgical procedures. Monitor for infections. **Small bowel obstruction:** Failure to respond to treatment for CD may indicate the presence of fixed fibrotic stricture requiring surgical treatment. **Elderly patients:** Serious infections were higher in patients over 65 years of age, some of whom had a fatal outcome. Consider risk of infections. **Interactions:** Combination of adalimumab with other biologic DMARDs (e.g. anakinra and abatacept) or other TNF-antagonists is not recommended. **Fertility, pregnancy and lactation:** Not recommended during pregnancy. Women of childbearing age to use adequate contraception, and continue its use for at least 5 months after the last treatment. Women must not breast feed for at least 5 months after the last treatment. **Side effects:** Very common ≥ 1/10: Infections, leucopenia, anaemia, lipids increased, headache, abdominal pain, nausea and vomiting, elevated liver enzymes, rash (including exfoliative rash), musculoskeletal pain, injection site reaction. Common ≥ 1/100 to < 1/10: skin cancer excluding melanoma (including basal cell carcinoma and squamous cell carcinoma), benign neoplasm, leucocytosis, thrombocytopenia, hypersensitivity, allergies (including seasonal allergy), hypokalaemia, uric acid increased, blood sodium abnormal, hypocalcaemia, hyperglycaemia, hypophosphatemia, dehydration, mood alterations (including depression), anxiety, insomnia, paraesthesia, migraine, nerve root compression, visual impairment, conjunctivitis, blepharitis, eye swelling, vertigo, tachycardia, hypertension, flushing, haematoma, asthma, dyspnoea, cough, GI haemorrhage, dyspepsia, gastroesophageal reflux disease, sicca syndrome, worsening or new onset of psoriasis (including palmoplantar pustular psoriasis), urticaria, bruising (including purpura), dermatitis (including eczema), onychodosis, hyperhidrosis, alopecia, pruritus, muscle spasms (including blood creatine phosphokinase increased), renal impairment, haematuria, chest pain, oedema, pyrexia, coagulation and bleeding disorders, autoantibody test positive, blood lactate dehydrogenase increased, impaired healing. **Serious, including fatal, side effects have been reported** including infections/sepsis, intestinal perforation, opportunistic infections, TB, endemic mycoses, demyelinating disease, malignancies including lymphoma, (including hepatosplenic T-cell lymphoma), leukaemia and skin cancer (including melanoma and Merkel cell carcinoma), cytopenias, worsening heart failure, myocardial infarction, pulmonary embolism, pleural effusion, pulmonary fibrosis, cerebrovascular accident, interstitial lung disease, Stevens-Johnson syndrome, angioedema, anaphylaxis, sarcoidosis, hepatitis, liver failure and worsening of symptoms of dermatomyositis. **Other less common and rarely reported side effects are listed in the SmPC. Basic NHS price:** £704.28 (for 2 pens or 2 syringes or 2 vials). **Legal category:** POM. **Marketing Authorisation numbers:** EU/1/03/256/001, EU/1/03/256/013, EU/1/03/256/017. **Further information:** available from AbbVie Ltd., Maidenhead, SL6 4UB, United Kingdom. **Date of revision of PI:** July 2016, PI/ Humira(combined)/36.

References: 1. European Medicines Agency. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/06/news_detail_002354.jsp&mid=WC0b01ac058004d5c. 2. HUMIRA [SmPC], AbbVie, Ltd.; www.medicines.ie. 3. Kimball AB, et al. Safety and Efficacy of Adalimumab in Patients with Moderate to Severe HS: Results from First 12 Weeks of PIONEER I, a Phase 3, Randomized, Placebo-Controlled Trial, Poster presented at the 11th Annual Advances in Cosmetic and Medical Dermatology, Maui Derm Conference, Maui, HI, January 26-30, 2015. 4. Jemec GBE, et al. Efficacy and Safety of Adalimumab in Patients with Moderate to Severe Hidradenitis Suppurativa: Results from PIONEER II, a Phase 3, Randomized, Placebo-Controlled Trial, Poster presented at the 11th Annual Advances in Cosmetic and Medical Dermatology, Maui Derm Conference, Maui, HI, January 26-30, 2015.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to AbbVie.ukadverseevents@abbvie.com

For the Republic of Ireland adverse events should be reported to HPRa Pharmacovigilance, Earlsfort Tce, Dublin 2. Tel. +353 16764971; Fax +353 16762517; Email medsafety@hpra.ie. Adverse events should also be reported to AbbVie.on.IREpharmacovigilance@abbvie.com

Date of preparation: July 2016
AXHUD161208

abbvie



Welcome Message from the President Dr Kevin McKenna

Welcome to the Autumn meeting of the IAD 2016 at the Hilton Hotel, Templepatrick. I hope you all had a great summer and are looking forward to the year ahead. This venue is well known to IAD members and the meeting should be both interesting and educational.

The theme of this meeting is therapeutics. Our guest speakers include Professor Catherine Nelson-Piercy, Professor Eli Sprecher and Dr Ian Coulson. We look forward to their presentations which will cover topics including the use of drugs in pregnancy, disorders of pigmentation and aspects of medical dermatology.

At the Registrars Symposium our junior colleagues have the opportunity to compete for the Rogers' Prize. This is the fourth year this prestigious prize has been awarded. I would like to thank the scientific committee for all their hard work in selecting abstracts for this meeting.

I would like to thank the members of the Executive Committee and Jacqui Carroll for their support and also our pharmaceutical colleagues who so generously sponsor our meetings.

I look forward to meeting you all.

Yours sincerely,

Dr Kevin McKenna
President
Irish Association of Dermatologists

SOOLANTRA® TOUGH ON ROSACEA KIND TO SKIN



Now GMS
reimbursed

A ONCE-DAILY TOPICAL THAT TREATS INFLAMMATORY LESIONS OF ROSACEA IN ADULTS

- More effective than metronidazole cream (0.75%)¹
- Significant improvements as early as week 2²
- A generally well tolerated topical for everyday use³



REFERENCES

1. Taieb A *et al.*, *Br J Dermatol* 2015;172:1103-10.
2. SOOLANTRA Summary of Product Characteristics, March 2015.
3. Stein Gold L *et al.*, *J Drugs Dermatol* 2014;13(11):1380-86.

SOOLANTRA® 10mg/g Cream Prescribing Information (UK & IRE)

Presentation: 10mg/g ivermectin cream. **Indications:** Topical treatment of inflammatory lesions of rosacea (papulopustular) in adult patients. **Dosage and Administration:** One application per day for up to 4 months. The treatment course may be repeated. Treatment should be discontinued after 3 months if no improvement. Apply a pea sized amount to each of the 5 areas of the face: forehead, chin, nose, each cheek. Cutaneous use only. Apply only to the face; avoiding the eyes, lips and mucosa. Hands should be washed immediately after application. There is no data on use in patients under 18 years. Cosmetics may be applied after the medicinal product has dried. **Contraindications:** Hypersensitivity to the active substance or any excipients. **Precautions and Warnings:** Soolantra has not been studied in patients with renal or hepatic impairment. Caution should be exercised in patients with severe hepatic impairment. Contains cetyl alcohol and stearyl alcohol which may cause local skin reactions (e.g. contact dermatitis), Methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) which may cause allergic reactions (possibly delayed) and propylene glycol which may cause skin irritation. **Interactions:** No

interaction studies have been performed. Concomitant use of Soolantra with other topical or systemic medicinal products for the treatment of rosacea has not been investigated. In vitro studies have shown that ivermectin is primarily metabolised by CYP3A4. Consequently, caution is advised when ivermectin is administered concomitantly with potent CYP3A4 inhibitors as the plasma exposure may be significantly increased. **Pregnancy and Lactation:** Soolantra is not recommended during pregnancy. A risk to a suckling child cannot be excluded; a decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Soolantra therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman. **Undesirable Effects:** In clinical trials the most common adverse reactions were typically mild to moderate in severity, and usually decreased when treatment was continued. Adverse reactions include: Common ($\geq 1/100$ to $< 1/10$) Skin burning sensation; Uncommon ($\geq 1/1,000$ to $< 1/100$) Skin irritation, pruritus, dry skin. **Packaging Quantities and Cost:** 30g UK £18.29 IRE €22.00 **MA Number:** PL 10590/0063, PA 590/28/1 **Legal Category:** POM **Full Prescribing Information is Available From:** Galderma (UK) Ltd, Meridien House, 69-71 Clarendon Road, Watford, Herts, WD17 1DS, Telephone: +44 (0) 1923 208950 Fax: +44 (0) 1923 208998 **Date of Revision:** December 2015

Date of preparation: May 2016

Code: S00/088/0516a

Adverse events should be reported. Suspected adverse events can be reported via
HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971;
Fax: +353 1 6762517. Website: www.hpra.ie; E-mail: medsafety@hpra.ie.
Adverse events should also be reported to Galderma (UK) Ltd.

IAD Directors

Dr Keith Armstrong,
Royal Victoria Hospital,
Belfast.

Dr Colin Buckley
Whitfield Clinic,
Cork Rd,
Waterford.

Dr Gillian Gibson,
Bon Secours Hospital,
College Road,
Cork.

Dr Kevin McKenna,
Belfast City Hospital,
Belfast.

Dr Art O'Hagan,
Craigavon Area Hospital,
Armagh.

Dr Gillian Murphy,
Beaumont Hospital,
Dublin 9

Dr Rosemarie Watson,
Our Lady's Children's Hospital,
Crumlin,
Dublin 12

Scientific Committee

Dr Clare Devereux
Consultant Dermatologist
Antrim Area Hospital,

Dr Susannah Hoey
Consultant Dermatologist
Royal Victoria Hospital, Belfast

Dr Dermot McKenna
Consultant Dermatologist
Sligo Regional Hospital

Dr Fergal Moloney - Chair
Consultant Dermatologist
Mater Hospital, Dublin

Dr Donal O'Kane
Consultant Dermatologist
Royal Victoria Hospital, Belfast

Dr Anne-Marie Tobin
Consultant Dermatologist
Tallaght Hospital, Dublin



IAD Directors

IAD Past Presidents

- 1965/7** Dr R. Hall, Belfast,
who was followed by:
1967/9 Dr D.O'C Donelan
1969/71 Dr J.M. Beare
1971/3 Dr D.M. Mitchell
1973/5 Dr D.B. Buckley
1975/7 Prof D. Burrows
1977/9 Dr F.O.C. Meenam
1979/81 Dr Agnese M.T. Kelly
1981/3 Dr Count H. Viani
1983/5 Dr Grace Allen
1985/7 Dr Marjory Young
1987/9 Dr Roddy Matthews
1989/91 Dr David O'Gorman
1991/3 Dr Rory Corbett
1993/5 Prof Sarah Rogers
1995/7 Dr E.A. Bingham
1997-9 Dr. Fergus Lyons
1999-01 Dr Clifford McMillan
2001-3 Prof Frank Powell
2003-5 Dr Raymond Fulton
2005-7 Prof Louise Barnes
2007-9 Dr Hilary Jenkinson
2009-11 Dr Gillian Murphy
2011-13 Dr Pat Podmore
2013-2015 Dr Rosemarie Watson
2015-Present Dr Kevin McKenna

Biographical Sketches

Dr Gary Meenagh.

Dr. Meenagh studied medicine at Queen's University Belfast, Northern Ireland, where he graduated with Honours and trained in Rheumatology at Musgrave Park Hospital and at the University of Ancona, Italy. In 2005 he was awarded a Doctorate of Medicine from Queen's University Belfast. He received a Diploma in Clinical Education from Queen's University Belfast in 2013.

He is a Fellow of the Royal College of Physicians (London) and a Fellow of the Royal College of Physicians of Ireland. He is a member of the British Society for Rheumatology and the Irish Society for Rheumatology.

He is a member of the organising committee for the Advanced Rheumatology Sonography website promoting the diffusion of musculoskeletal ultrasound within rheumatology in Europe.

Currently he acts as an Educational Supervisor for Queens University Belfast overseeing the training needs of junior doctors at Antrim Hospital.

Dr. Meenagh has a wide research portfolio including osteoarthritis, systemic lupus erythematosus and early inflammatory arthritis. He continues to collaborate with co-workers at the University of Ancona, Italy publishing articles regularly on musculoskeletal ultrasound in rheumatology.



Professor Kingston Mills

Kingston Mills is Professor of Experimental Immunology, School of Biochemistry and Immunology, Trinity College Dublin (TCD). He is Head of The Centre for the Study of Immunology at Trinity Biomedical Sciences Institute and Theme Champion for Immunology, Inflammation and Infection at TCD. He is a graduate of TCD and trained at as a Postdoctoral Fellow at University College London and the National Institute for Medical Research, Mill Hill, London, before joining the Scientific Staff of NIBSC, Herts, UK. He returned to Ireland in 1993 to take up an academic position at National University of Ireland, Maynooth. He was appointed to a Personal Chair at Trinity College Dublin in 2001 and was Head of the School of Biochemistry and Immunology from 2008-2011. He heads an active research team focusing on T cells in infection, autoimmunity and cancer. He is co-founder of Opsona Therapeutics and TriMod Therapeutics, biotech companies focusing on the development of immunotherapeutics for inflammatory diseases and cancer.



Celgene Sponsored Symposium

From Bench to Bedside: Understanding the Clinical Potential of Targeted Small-Module Therapies in Psoriatic Disease

Thursday 6th October 2016
Hilton Hotel, Templepatrick

9.30am	REGISTRATION, Tea & Coffee
10.30 - 10.35am	Opening Remarks Chair: Dr Kevin McKenna, Consultant Dermatologist, Belfast City Hospital <i>From Bench...: What Research Has Taught us About Intracellular Pathways of Inflammation and How We Can Manipulate them to Control Inflammatory Disease</i>
10.35 - 11.05am	Professor Kingston Mills Professor of Experimental Immunology, Trinity College Dublin. <i>An overview of Molecular and Cellular pathways of inflammation and their role as therapeutic targets</i> <i>...To Bedside: Understanding the Multiple Inflammatory Manifestations of Psoriatic Disease and the Therapeutic Potential of Targeted Small-Molecule Therapies</i>
11.05am - 11.50am	Dr Gary Meenagh Consultant Rheumatologist, Northern Trust Belfast <i>Psoriatic Disease</i>
11.50 - 12.20pm	Case Studies <i>(Psoriasis and Psoriatic Arthritis)</i>
12.20 - 12.30pm	Q & A

Introducing A NOVEL ORAL THERAPY THAT MAY CHANGE THE WAY YOU TREAT PSORIASIS



- ◆ Proven efficacy in clinical trials vs. placebo¹
- ◆ Favourable safety profile with no increased risk of malignancy, serious infection, or tuberculosis vs. placebo, demonstrated in clinical trials^{1,2}
- ◆ Oral dosing¹
- ◆ No requirement for tuberculosis prescreening or any ongoing laboratory monitoring^{1,2}

INDICATION

Otezla is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light (PUVA).¹



Prescribing Information: OTEZLA[®] (apremilast) 10mg, 20mg and 30mg film coated-tablets.

Refer to the Summary of Product Characteristics (SPC) before prescribing.

Presentation: 10mg, 20mg and 30mg film coated-tablets. **Indications:** Psoriatic arthritis: OTEZLA[®], alone or in combination with Disease Modifying Antirheumatic Drugs (DMARDs), is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy. Psoriasis: OTEZLA[®] is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light (PUVA). **Dosage and administration:** Treatment with OTEZLA[®] should be initiated by specialists experienced in the diagnosis and treatment of psoriasis or psoriatic arthritis. The recommended dose of OTEZLA[®] is 30mg twice daily taken orally, morning and evening, approximately 12 hours apart, with no food restrictions. The film-coated tablets should be swallowed whole. To reduce risk of gastrointestinal symptoms, an initial dose titration is required according to the following schedule: Day 1: 10mg in morning; Day 2: 10mg in morning and 10 mg in evening; Day 3: 10mg in morning and 20mg in evening; Day 4: 20mg in morning and 20mg in evening; Day 5: 20mg in morning and 30mg in evening; Day 6 and thereafter: 30mg twice daily. No re-titration is required after initial titration. If patients miss a dose, the next dose should be taken as soon as possible. If it is close to the time for their next dose, the missed dose should not be taken and the next dose should be taken at the regular time. During pivotal trials the greatest improvement

was observed within the first 24 weeks of treatment. If a patient shows no evidence of therapeutic benefit after 24 weeks, treatment should be reconsidered. The patient's response to treatment should be evaluated on a regular basis. Clinical experience beyond 52 weeks is not available in psoriasis. **Special populations:** Paediatric population: The safety and efficacy of apremilast in children aged 0 to 17 years have not been established. No data are available. **Elderly patients:** No dose adjustment is required for this patient population. **Patients with renal impairment:** No dose adjustment is needed in patients with mild and moderate renal impairment. The dose of apremilast should be reduced to 30mg once daily in patients with severe renal impairment (creatinine clearance of less than 30mL per minute estimated by the Cockcroft-Gault equation). For initial dose titration in this group, it is recommended that OTEZLA[®] be titrated using only the morning doses and the evening doses be skipped. **Patients with hepatic impairment:** No dose adjustment is necessary for patients with hepatic impairment. **Contraindications:** Hypersensitivity to the active substance(s) or to any of the following excipients: Microcrystalline cellulose, Lactose monohydrate, Croscarmellose sodium, Magnesium stearate, Polyvinyl alcohol, Titanium dioxide (E171), Macrogol 3350, Talk, Iron oxide red (E172). The 20mg tablets also contain iron oxide yellow (E172). The 30mg tablets also contain iron oxide yellow (E172) and iron oxide black (E172). OTEZLA[®] is contraindicated in pregnancy and should be excluded before treatment can be initiated. **Special warnings and precautions:** Patients with rare hereditary problems of galactose intolerance, lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product. OTEZLA[®] should be dose reduced to 30mg once daily in patients with severe renal impairment. Apremilast

may cause weight loss. Patients who are underweight at the start of treatment should have their body weight monitored regularly. In the event of unexplained and clinically significant weight loss, these patients should be evaluated by a medical practitioner and discontinuation of treatment should be considered. Women of childbearing potential should use an effective method of contraception to prevent pregnancy during treatment. Apremilast should not be used during breast-feeding. No fertility data is available in humans. **Interactions:** Co-administration of strong cytochrome P450 3A4 (CYP3A4) enzyme inducer, rifampicin, resulted in a reduction of systemic exposure of apremilast, which may result in a loss of efficacy of apremilast. Therefore, the use of strong CYP3A4 enzyme inducers (e.g. rifampicin, phenobarbital, carbamazepine, phenytoin and St. John's Wort) with apremilast is not recommended. In clinical studies, apremilast has been administered concomitantly with topical therapy (including corticosteroids, coal tar shampoo and salicylic acid scalp preparations) and UVB phototherapy. There was no clinically meaningful drug-drug interaction between ketoconazole and apremilast. Apremilast can be co-administered with a potent CYP3A4 inhibitor such as ketoconazole. There was no pharmacokinetic drug-drug interaction between apremilast and methotrexate in psoriatic arthritis patients. Apremilast can be co-administered with methotrexate. There was no pharmacokinetic drug-drug interaction between apremilast and oral contraceptives containing ethinyl estradiol and norgestimate. Apremilast can be co-administered with oral contraceptives. **Side effects:** The most commonly reported adverse reactions in Phase III clinical studies have been gastrointestinal disorders including diarrhoea and nausea. The other most commonly reported adverse reactions included upper respiratory tract infections, headache,

and tension headache. The most common adverse reactions leading to discontinuation during the first 16 weeks of treatment were diarrhoea, and nausea. The overall incidence of serious adverse reactions was low and did not indicate any specific system organ involvement. Prescribers should consult the summary of product characteristics in relation to other side-effects. **NHS list price:** £265.18 per 14 day titration pack; £550 per pack of 56 tablets (30mg). **Legal category:** POM. **Marketing authorisation numbers:** EU/1/14/981/001, EU/1/14/981/002 and EU/1/14/981/003. **Marketing authorisation holder:** Celgene Ltd, 1 Longwalk Road, Stockley Park, Uxbridge, UB11 1DB, United Kingdom. **Date of preparation:** January 2015. **Approval code:** UK-18140036.

Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk Adverse events should also be reported to Celgene Drug Safety Tel: 0800 238 9908; Fax: 0844 801 0468

References:
1. OTEZLA Summary of Product Characteristics available at www.medicines.org.uk
2. Reich K, et al. Oral presentation FC05.2 given at the 23rd EADV Congress, Amsterdam, October 10, 2014.
Date of Preparation: February 2015 UK-18140057b



Autumn Meeting
Thursday 6th & Friday 7th October 2016
Hilton Hotel, Templepatrick, co Antrim

Thursday 6th October 2016

9.30am	REGISTRATION
10.30am-12.30pm	Celgene Sponsored Satellite Symposium
12.30pm - 2.00pm	LUNCH, EXHIBITION & REGISTRATION
	<i>IAD Autumn Meeting – Theme “Therapeutics”</i>
2.00pm - 2.45pm	Professor Catherine Nelson-Piercy Consultant Obstetric Physician, Professor of Obstetric Medicine, St Thomas' Hospital London <i>'A Dermatologists guide to drugs during conception and pregnancy'</i>
2.45pm - 3.30pm	Professor Eli Sprecher Professor and Chair Department of Dermatology, Tel Aviv Sourasky Medical Centre <i>'Pigmentation disorders of the skin'</i>
3.30pm - 4.00pm	COFFEE & EXHIBITION
4.00pm - 4.45pm	Dr Ian Coulson Consultant Dermatologist, East Lancashire NHS Trust, Burnley General Hospital <i>'A taste of Lancashire in Medical Dermatology'</i>
5.00pm - 6.00pm	IAD Business Meeting
7.30pm	IAD CONFERENCE DINNER

Friday 7th October 2016

9.30 - 11.00am	Registrars' Symposium - Rogers Prize
11.00am	COFFEE & EXHIBITION
11.30 - 1.00pm	Case presentations
1-1.15	Presentation of prizes
1.15pm - 2.00pm	LUNCH & CLOSE

Biographical Sketches

Dr Ian Coulson Biography

After schooling in Durham City, Dr. Coulson qualified in Medicine in 1978 from St. Thomas's Hospital Medical School London, and commenced training in dermatology after gaining higher qualifications in general internal medicine in 1981. After working at the national skin hospital, St. John's Hospital for Diseases of the Skin in London, he had posts as Registrar and Senior Registrar at St. George's Hospital in South London. During this period he was awarded the Registrars' Prize by St. John's Hospital Dermatological Society in 1986. He had research interests in the mechanisms of inflammation in atopic eczema and has written over 60 clinical and research papers.



He commenced Consultant practice in North East Lancashire in 1990, and has broad interests in all areas of clinical dermatology and skin surgery. He was skin cancer network chairman for the North Lancashire, South Cumbria area between 2005 to 2010.

He has lectured widely and regularly presents research material both at the American Academy of Dermatology and British Association of Dermatologists Annual meetings. He was awarded jointly the Bristol Cup prize for best poster presentation in 2006, and silver prize in 1999 at the BAD. He is enthusiastic about the teaching of dermatology and has produced a nationally used elearning module covering the core undergraduate medical curriculum, as well as practical patient information material available on YouTube.

He co-edited a new text book of dermatological treatment, entitled "Treatment of Skin Disease" published in 2002, and this became global dermatology best seller in 2004; the book is a continued success with edition 4 due for release in 2013. He was therapy section editor of the British Journal of Dermatology between 2004 and 2009.

He co-wrote 3 chapters for the internationally renowned Rook's Textbook of Dermatology. When President of the Dowling Club (tenure summer 2007-8), a national foundation for dermatology trainees with an international membership, he took 50 dermatologists to South Africa.

Between 2012-13, he will preside over the North of England Dermatological Society.

Spare moments are dedicated to recreational cycling (a veteran of 2 London to Paris rides); he is an under appreciated guitarist!.

Professor Catherine Nelson-Piercy

Catherine Nelson-Piercy is a Consultant Obstetric Physician at Guy's and St. Thomas' Hospitals Trust and Queen Charlotte's and Chelsea Hospital in London. In 2010 she was awarded the title of Professor of Obstetric Medicine at King's College London. Her undergraduate studies were at King's College, Cambridge University and St Bartholomew's Hospital. She trained as a physician, and was taught Obstetric Medicine by Professor Michael de Swiet.



Professor Nelson-Piercy is the immediate past President of the International Society of Obstetric Medicine (ISOM). She is founding co-editor in chief of the journal 'Obstetric Medicine: the medicine of pregnancy.'

Professor Nelson-Piercy has been involved in the development of several evidence-based National Guidelines notably for "Contraception in Women with Heart Disease", BTS / SIGN "Asthma in Pregnancy" and RCOG Green top guidelines on "Reducing the risk of thromboembolism during pregnancy, birth & the puerperium" and 'Management of nausea vomiting of pregnancy and hyperemesis gravidarum'. She has over 200 publications and has edited five books and written the successful Handbook of Obstetric Medicine, now in its fifth edition. She is also one of the central physician assessors for the UK Confidential maternal deaths enquiry.

Biographical Sketches

Professor Eli Sprecher

Eli Sprecher, MD, PhD serves as a Member of Clinical Advisory Board-International at PsoriasisDX, LLC. Dr. Sprecher serves as the Director of the Department of Dermatology at the Tel Aviv Sourasky Medical Center, Israel, he is also Director of the Center for Translational Genetics of the Rappaport Family Institute for Research in the Medical Sciences at the Technion-Israel Institute of Technology, Israel. Dr. Sprecher is Associate Editor for the Journal of Investigative Dermatology, Section Editor for the British Journal of Dermatology and is on the Advisory Editorial Board for the Clinical and Experimental Dermatology.



Dr. Sprecher's large library of published research has merited worldwide recognition. His work has been honored with the Belgian Government Prize (1981), the Rector's Prize from the Hebrew University (1983), the Dean's Prize from the Hebrew University (1983 - 1987), the Senta Foulkes Research Award (1994), the Tsipora Friedman Research Award (1998), the Israel Society of Dermatology Research Award, the Everett C. Fox Award from the American Academy of Dermatology (2002), the Bill Reed Award (2002), the Henry Taub Prize for Academic Excellence from Technion - Israel Institute of Technology (2006), and the Alfred Marchionini Award from the International Society of Dermatology (2007). Dr. Sprecher graduated with a B.Med. and M.D. in Medicine from the Hebrew University of Jerusalem, a Ph.D. in Molecular Virology from the Hebrew University of Jerusalem, and completed a fellowship program in Genetics of Skin Diseases at the Thomas Jefferson University of Philadelphia.

Are You Making The Most Of Your Medicines?



25%
LESS expensive than Epaderm Ointment²
A Directly Equivalent Formulation



Hydromol Ointment

- ✓ Last year the NHS spent **£5.5 million** on Epaderm Ointment¹
- ✓ **3 in 1 all-purpose emollient, bath additive and soap substitute**
- ✓ **Free from preservatives, colours, fragrances and Sodium Lauryl Sulfate (SLS)**

Up to **25%**
LESS expensive than other leading brand emollients²



Hydromol Bath and Shower

Light Liquid Paraffin, Isopropyl Myristate

- ✓ **Contains no known sensitisers**
- ✓ **Fragrance-free wash product, in line with NICE guidelines CG57³**
- ✓ **Leaves less residue on the bath than other leading competitors⁴**

24%
LESS expensive than Calmurid²



Hydromol Intensive

10% Urea

- ✓ **Can be used alongside a Complete Emollient Therapy regime**
- ✓ **Hydrating action helps soothe itching and irritation**
- ✓ **Contains urea for deep, effective moisturisation⁵**

References. 1. IMS MAT June 2014. 2. dm+d database (www.dmd.medicines.org.uk) (accessed March 2016). 3. NICE Clinical Guideline CG57: Atopic eczema in children. December 2007. 4. Data on file Mass residue experiment University of Edinburgh. School of physics. 5. Carbajo 2004.

PRESCRIBING INFORMATION

Please refer to full Summary of Product Characteristics or Product Information before prescribing.

Hydromol® Ointment

Presentation: All purpose ointment containing Cetomacrogol Emulsifying Wax, Yellow Soft Paraffin and Liquid Paraffin. **Indications:** For the management of eczema, psoriasis and other dry skin conditions. **Dosage and Administration:** Emollient - Apply liberally and as often as required to the affected area. Bath additive - Melt Hydromol Ointment in warm water in a suitable container, add mixture to the bath. Soap substitute - Use as required when washing. **Contra-indications:** Hypersensitivity to any of the ingredients. **Warnings & Precautions:** Avoid eyes. Beware of slipping in bath. **Side-effects:** None known. **Legal Category:** Class 1 Medical Device. **Packs and basic NHS price:** 125g - £2.88, 500g - £4.89, 1kg - £9.09.

Hydromol® Bath & Shower Emollient

Presentation: Colourless liquid containing light liquid paraffin (37.8%) and isopropyl myristate (13%). **Indications:** For the treatment of dry skin conditions such as eczema, ichthyosis and senile pruritus. **Dosage and Administration:** Children, Adults and Elderly: Add 1-3 capfuls to an 8 inch bath of water, soak for 10-15 minutes. Alternatively, apply to wet sponge or flannel and rub onto

wet skin. Rinse and pat dry. Infants: Add ½ to 2 capfuls to a small bath of water. **Contra-indications:** Known hypersensitivity to any of the ingredients. **Warnings & Precautions:** Avoid eyes. Beware of slipping in bath. **Side-effects:** None known. **Legal Category:** GSL Packs and basic NHS price: 350ml - £3.88, 500ml - £4.42, 1 litre - £8.80 **Marketing Authorisation number:** PL 16853/0090.

Hydromol® Intensive

Presentation: Smooth, unperfumed, non-greasy, off-white cream containing urea Ph.Eur 10% w/w in white soft paraffin. **Indications:** For the treatment of ichthyosis and hyperkeratotic skin conditions associated with atopic eczema, xeroderma, iasteatosis and other chronic dry skin conditions. **Dosage and Administration:** Apply sparingly twice daily. **Contra-indications:** Known hypersensitivity to any of the ingredients. **Warnings & Precautions:** Hydromol Intensive may increase the penetration through the skin of other topical agents. **Side-effects:** May produce local irritations (including erythema, burning or pruritus) and oedema when applied to sensitive, moist or fissured skin. **Legal Category:** P Packs and basic NHS price: 30g - £1.64, 100g - £4.37 **Marketing Authorisation number:** PL 16853/0061.

Full prescribing information is available from: Alliance Pharmaceuticals Ltd, Avonbridge House, Bath Road, Chippenham, Wiltshire, SN15 2BB.

Adverse Event Reporting

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Alliance Pharmaceuticals (tel: 01249 466966, email: pharmacovigilance@alliancepharma.co.uk) www.alliancepharma.co.uk



www.hydromol.co.uk

Alliance Pharmaceuticals Ltd, Avonbridge House, Bath Road, Chippenham, Wiltshire SN15 2BB
Tel: 01249 466 966 Fax: 01249 466 977 www.alliancepharma.co.uk

AL/1802/09.14/0.001 Date of preparation/last revised: March 2016

Sponsors & Date for Your Diary

IAD would like to thank the following sponsors and exhibitors for their generous support

- Abbvie
- Celgene
- Galderma
- Janssen-Cilag
- La Roche Posay
- Lilly
- Novartis
- Bioderma
- Leo Pharma
- T & R Derma
- Alliance
- Almirall
- Dermacea
- Dermal
- Fannin
- GSK
- Johnson & Johnson
- Meda Ireland
- Meda UK
- Ovelle

DATE FOR DIARY...

IAD Spring Meeting 2017

MELANOMA

Thursday 27th, Friday 28th & Saturday 29th April

Stormont Hotel & Belfast City Hospital

Desunin®

Cholecalciferol 800IU Tablets & 4000IU Tablets



DESUNIN®:

- Available in 800IU tablets and 4000IU tablets
- Daily flexible dosing of 800IU - 4000IU Vitamin D₃
- Prescription only medicine

Desunin® 800IU is indicated for the treatment and prevention of Vitamin D deficiency in adults and adolescents¹

Desunin® 4000IU is indicated for the treatment of Vitamin D deficiency in adults and adolescents²

ABBREVIATED PRESCRIBING INFORMATION

Desunin® 800IU Tablets

Please consult the Summary of Product Characteristics (SPC) for full prescribing information.

Presentation: Tablet. White to light yellow, biconvex, 7 mm in diameter. **Indication:** Prevention and treatment of vitamin D deficiency in adults and adolescents. Vitamin D deficiency is defined as serum levels of 25-hydroxycholecalciferol (25(OH)D) < 25 nmol/l. In addition to specific osteoporosis treatment of patients who are at risk of vitamin D deficiency, preferably in combination with calcium. **Dosage and Administration:** Recommended dose: One tablet per day. Higher doses can be necessary in treatment of vitamin D deficiency, where the dose should be adjusted dependent upon desirable serum levels of 25-hydroxycholecalciferol (25(OH)D), the severity of the disease and the patient's response to treatment. The daily dose should not exceed 4000IU (five tablets per day). Pediatric population: The safety and efficacy of Desunin in children under 12 years have not been established. **Dosage in hepatic impairment:** No dose adjustment is required. **Dosage in renal impairment:** Desunin should not be used in patients with severe renal impairment (see full SPC section 4.3). **Method of administration:** The tablets can be swallowed whole or crushed. The tablets can be taken with food. **Contraindications:** Diseases and/or conditions resulting in hypercalcaemia or hypercalcaemia. Nephrolithiasis. Nephrocalcinosis. Hypervitaminosis D. Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 of full SPC. **Warnings and precautions:** Desunin should be prescribed with caution to patients suffering from sarcoidosis due to risk of increased metabolism of vitamin D into its active form. These patients should be monitored with regard to the calcium content in serum and urine. During long-term treatment, serum calcium levels should be followed and renal function should be monitored through measurements of serum creatinine. Monitoring is especially important in elderly patients on concomitant treatment with cardiac glycosides or diuretics (see section 4.5) and in patients with a high tendency to calculus formation. In case of hypercalcaemia (exceeding 300 mg (7.5 mmol)/24 hours) or signs of impaired renal function the dose should be reduced or the treatment discontinued. Desunin should be used with caution in patients with impairment of renal function and the effect on calcium and phosphate levels should be monitored. The risk of soft tissue calcification should be taken into account. In patients with severe renal insufficiency, vitamin D in the form of colecalciferol is not metabolised normally and other forms of vitamin D should be used. The content of vitamin D (800 IU) in Desunin should be considered when prescribing other medicinal products containing vitamin D. Additional doses of vitamin D should be taken under close medical supervision. In such cases it is necessary to monitor serum calcium levels and urinary calcium excretion frequently. Desunin contain sucrose and isomalt. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrose-isomaltase insufficiency should not take this medicine. **Interactions:** Thiazide diuretics reduce the urinary excretion of calcium. Due to the increased risk of hypercalcaemia, serum calcium should be regularly monitored during concomitant use of thiazide diuretics. Concomitant use of phenytoin or barbiturates may reduce the effect of vitamin D since the metabolism increases. Excessive dosing of vitamin D can induce hypercalcaemia, which may increase the risk of digitalis toxicity and serious arrhythmias due to the additive inotropic effects. The electrocardiogram (ECG) and serum calcium levels of patients should be closely monitored. Glucocorticoid steroids may increase vitamin D metabolism and elimination. During concomitant use, it may be necessary to increase the dose of Desunin tablets. Simultaneous treatment with ion exchange resins such as cholestyramine or laxatives such as paraffin oil may reduce the gastrointestinal absorption of vitamin D. **Fertility, pregnancy and lactation:** **Fertility:** There are no data on the effect of Desunin on fertility. However, normal endogenous levels of vitamin D are not expected to have any adverse effects on fertility. **Pregnancy:** Desunin should be used during pregnancy, only in the case of a vitamin D deficiency. Desunin is not recommended during pregnancy in patients without a vitamin D deficiency as the daily intake should not exceed 600 IU vitamin D. Studies in animals have shown reproductive toxicity of high doses of vitamin D (see section 5.3). There are no indications that vitamin D at therapeutic doses is teratogenic in humans. **Breast-feeding:** Vitamin D can be used during breast-feeding. Vitamin D₃ passes into breast milk. This should be considered when giving additional vitamin D to the child. **Undesirable effects:** Immune system disorders - Hypersensitivity reactions such as angio-oedema or laryngeal oedema. Metabolism and nutrition disorders - Hypercalcaemia and hypercalcaemia. Skin and subcutaneous disorders - Pruritus, rash and urticaria. Consult the Summary of Product Characteristics for full list of side effects. **Legal Category:** POM **Marketing Authorisation Holder:** Meda Health Sales Ireland Limited, Unit 34/35, Block A, Dunboyne Business Park, Dunboyne, Co Meath, Ireland. **Marketing Authorisation Number:** PA1332/044/001 **Date of first authorisation:** 8th June 2012 **Date of revision of text:** July 2016

Desunin® 4000IU Tablets

Please consult the Summary of Product Characteristics (SPC) for full prescribing information.

Presentation: Tablet. White to light yellow, oblong, 16 mm in diameter, with a line score. The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses. **Indication:** Treatment of vitamin D deficiency in adults and adolescents. Vitamin D deficiency is defined as serum levels of 25-hydroxycholecalciferol (25(OH)D), the severity of the disease and the patient's response to treatment. The daily dose should not exceed 4000 IU (one tablet per day). Pediatric population – the safety and efficacy of Desunin in children under 12 years have not been established. Dosage in hepatic impairment – no dose adjustment is required. Dosage in renal impairment – Desunin should not be used in patients with severe renal impairment. The tablets can be swallowed whole or crushed. The tablets can be taken with food. **Contraindications:** Diseases and/or conditions resulting in hypercalcaemia or hypercalcaemia. Nephrolithiasis. Nephrocalcinosis. Hypervitaminosis D. Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 of full SPC. **Warnings and precautions:** Desunin should be prescribed with caution to patients suffering from sarcoidosis due to risk of increased metabolism of vitamin D into its active form. These patients should be monitored with regard to the calcium content in serum and urine. During long-term treatment, serum calcium levels should be followed and renal function should be monitored through measurements of serum creatinine. Monitoring is especially important in elderly patients on concomitant treatment with cardiac glycosides or diuretics (see section 4.5) and in patients with a high tendency to calculus formation. In case of hypercalcaemia (exceeding 300 mg (7.5 mmol)/24 hours) or signs of impaired renal function the dose should be reduced or the treatment discontinued. Desunin should be used with caution in patients with impairment of renal function and the effect on calcium and phosphate levels should be monitored. The risk of soft tissue calcification should be taken into account. In patients with severe renal insufficiency, vitamin D in the form of colecalciferol is not metabolised normally and other forms of vitamin D should be used. The content of vitamin D (4000 IU) in Desunin should be considered when prescribing other medicinal products containing vitamin D. Additional doses of vitamin D should be taken under close medical supervision. In such cases it is necessary to monitor serum calcium levels and urinary calcium excretion frequently. Desunin contain sucrose and isomalt. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrose-isomaltase insufficiency should not take this medicine. **Interactions:** Thiazide diuretics reduce the urinary excretion of calcium. Due to the increased risk of hypercalcaemia, serum calcium should be regularly monitored during concomitant use of thiazide diuretics. Concomitant use of phenytoin or barbiturates may reduce the effect of vitamin D since the metabolism increases. Excessive dosing of vitamin D can induce hypercalcaemia, which may increase the risk of digitalis toxicity and serious arrhythmias due to the additive inotropic effects. The electrocardiogram (ECG) and serum calcium levels of patients should be closely monitored. Glucocorticoid steroids may increase vitamin D metabolism and elimination. During concomitant use, it may be necessary to increase the dose of Desunin tablets. Simultaneous treatment with ion exchange resins such as cholestyramine or laxatives such as paraffin oil may reduce the gastrointestinal absorption of vitamin D. **Fertility, pregnancy and lactation:** **Fertility:** There are no data on the effect of Desunin on fertility. However, normal endogenous levels of vitamin D are not expected to have any adverse effects on fertility. **Pregnancy:** Desunin should be used during pregnancy, only in the case of a vitamin D deficiency. Desunin is not recommended during pregnancy in patients without a vitamin D deficiency as the daily intake should not exceed 600 IU vitamin D. Studies in animals have shown reproductive toxicity of high doses of vitamin D (see section 5.3). There are no indications that vitamin D at therapeutic doses is teratogenic in humans. **Breast-feeding:** Vitamin D can be used during breast-feeding. Vitamin D₃ passes into breast milk. This should be considered when giving additional vitamin D to the child. **Undesirable effects:** Immune system disorders - Hypersensitivity reactions such as angio-oedema or laryngeal oedema. Metabolism and nutrition disorders, uncommon - Hypercalcaemia and hypercalcaemia. Skin and subcutaneous disorders, rare - Pruritus, rash and urticaria. Consult the Summary of Product Characteristics for full list of side effects. **Legal Category:** POM **Marketing Authorisation Holder:** Meda Health Sales Ireland Limited, Unit 34/35, Block A, Dunboyne Business Park, Dunboyne, Co Meath, Ireland. **Marketing Authorisation Number:** PA1332/044/004 **Date of first authorisation:** 11th December 2015 **Date of revision of text:** July 2016

REFERENCES

1. Desunin® 800IU Summary of Product Characteristics.
2. Desunin® 4000IU Summary of Product Characteristics.

Adverse Events

Adverse Events should be reported to Meda Health Sales Ireland Limited on 01 802 6624 or PV@meda.ie.

Registrars' Symposium - Rogers Prize

- 01. 9.30am A novel use of reflectance confocal microscopy (RCM) to detect Pagetoid Melanocytosis (PM)**
L Griffin, L Roche, S McCarthy, M Lynch, K Ahmad, C Hackett, N Leonard, B Ramsay. Department of Dermatology, University Hospital Limerick.
- 02. 9.40am Prospective Randomised Trial comparing Electroporation to Surgery for primary BCC Treatment**
AJP Clover¹, S Salwa², J McKiernan¹, C Buckley¹, M Bourke², EJ Kelly¹, ST O'Sullivan¹, D Soden²
¹ Department of Plastic Surgery, Cork University Hospital, Cork, Ireland
² Cork Cancer Research Centre, University College Cork, Cork, Ireland
Corresponding author: D Soden
- 03. 9.50am Methotrexate for Severe Childhood Atopic Dermatitis: Real Life Experience in a Tertiary Centre**
V. Dvorakova, G. O'Regan. A. Irvine
Our Lady's Children's Hospital, Crumlin.
- 04. 10.00am Enhancing medical student's dermatology skills through the use of precision teaching**
C. McGrath, G. Gormley, C. McCourt, A. Corry, K. Dillenburger, K. Douvani. Belfast Trust. Queens University Belfast.
- 05. 10.10am The burden of chronic itch-a questionnaire based evaluation of clinical characteristics, associated**
I. McDonald, A. Gábor Szollosi, B. Kirby, M. Steinhoff. Charles Institute of Dermatology UCD. St Vincent's University Hospital
- 06. 10.20am Trends in Preservative Contact Allergy In Cork**
R. O'Connor, S. McCarthy, M. Murphy, J. Bourke. SIVUH Cork
- 07. 10.30am Can Referral Management Enhance Access to Paediatric Dermatology Services?**
E.Gilhooley, S. Collins. Our Lady of Lourdes Hospital, Drogheda.
- 08. 10.40am Utility of lymphocyte transformation testing in the diagnosis of drug hypersensitivity.**
J. Boggs, M. Keogan, M. O'Kane. Department of Dermatology, Connolly Hospital Blanchardstown/Beaumont Hospital
- 09. 10.50am Analysis of 10 years of phototherapy data from one centre and its implications**
S. Mohamed*^{1,2}, D. R. Wall*^{2, 3}, B. Q. Huang¹, M. Greenwood⁴, A. D. Irvine^{2,3,5}, M-T. Kechadi¹, N. O'Hare^{3,5}, A-M. Tobin⁴
* Indicates joint first authors.
Insight Centre for Data Analytics, University College Dublin, The Irish Skin Foundation, Charles Institute UCD, University College Dublin, St James's Hospital, Dublin, The Adelaide and Meath Hospital, Incorporating the National Children's Hospital, Tallaght, Trinity College Dublin,

30 mg/g diclofenac sodium Active Ingredient: Each gram contains 30 mg diclofenac sodium (3% w/w). For excipients, see section 6.1. **Indication:** For the treatment of actinic keratoses. **Dosage and Administration:** Solaraze is applied locally to the skin twice daily. Normally 0.5 grams (the size of a pea) of the gel is used on a 5 cm x 5 cm lesion site. A maximum of 8 grams daily should not be exceeded. **Consult SmPC and package leaflet for method of administration.** **Contraindications, Special warnings etc:** **Contraindications:** Hypersensitivity to diclofenac sodium or to any of the excipients. Patients with a history of hypersensitivity reactions such as symptoms of asthma, allergic rhinitis, urticaria, acetylsalicylic acid or other non-steroidal anti-inflammatory agents. **Contraindicated** in third trimester of pregnancy. **Special warnings, etc.:** The possibility of systemic adverse events from application of topical diclofenac cannot be excluded if the preparation is used on large areas of skin and over a prolonged period (see product information on systemic forms of diclofenac). This product should be used with caution in patients with a history of and/or active gastrointestinal ulceration or bleeding, or reduced heart, liver or renal function. Caution should be used in patients with intracranial haemorrhage and bleeding diathesis. Direct sunlight, including solarium, should be avoided during treatment. Solaraze should not be applied to skin wounds, infections or exfoliative dermatitis. It should not be allowed to come into contact with the eyes or mucous membranes and should not be ingested.


Discontinue the treatment if sensitivity reactions or a generalised skin rash develop after applying the product. Should not be used with an airtight occlusive dressing. **Interactions:** Since systemic absorption of diclofenac from a topical application is very low, such interactions are very unlikely. **Pregnancy and lactation:** Not recommended in pregnancy or lactation unless clearly necessary. **Consult SmPC.** If diclofenac is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low (< 30% of the body surface) and duration of treatment as short as possible (not longer than 3 weeks). **Contraindicated** during the third trimester of pregnancy and not to be applied to breasts of nursing mothers. **Ability to drive and use machines:** Cutaneous application of topical diclofenac has no influence on the ability to drive and use machines. **Adverse Effects:** These are ranked under heading of frequency using the following convention: *very common* (>1/10); *common* (≥1/100 <1/10); *uncommon* (≥1/1,000 <1/100); *rare* (≥1/10,000 <1/1,000); *very rare* (<1/10,000). **Common:** Conjunctivitis, application site reactions (including inflammation, irritation, pain and tingling or blistering at the treatment site), hyperaesthesia, hypertonia, localised paraesthesia, dermatitis (including contact dermatitis), eczema, dry skin, erythema, oedema, pruritus, rash, scaly rash, skin hypertrophy, skin ulcer, vesiculobullous rash. **Very rare:** Gastrointestinal haemorrhage, renal failure, asthma. Topical application of large amounts may lead to systemic effects including all types of hypersensitivity. **Consult SmPC in relation to other side-effects.** **Legal Category:** POM **Product Authorisation Numbers:** PL 18973/0012 **NHS cost (excluding VAT):** £38.30 – 50 g tube £76.60 – 100 g tube **Marketing Authorisation Holder:** Almirall S.A., Ronda General Mitre, 151,

08022 Barcelona Spain. **Further information is available from:** Almirall Limited, 1 The Square, Stockley Park Uxbridge, Middlesex, UB11 1TD, UK. Tel: +44 (0) 207 160 2500. Fax: +44 (0) 208 7563 888. Email: almirall@professionalinformation.co.uk **Date of Revision:** 09/2015 **Item code:** UKDCF1389a Solaraze is a trademark.

Adverse events should be reported.
Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. **Adverse events should also be reported to Almirall Ltd.**

References:
1. Nelson C and Rigel D. *J Clin Aesthetic Dermatol.* 2009;2(7):20–25.
2. Solaraze Summary of Product Characteristics.
3. Ulrich M, et al. *Eur J Dermatol* 2014;24(2):158–167.
4. Martin GM, et al. *J Drugs Dermatol* 2012;11(5):600–608.
5. PCDS Actinic Keratosis Primary Care Treatment Pathway. Available from www.pcds.org.uk/ee/images/uploads/general/AK_guidelines_2014_final_av2.pdf. Accessed April 2016.
6. Zalaudek I, et al. *Clin Dermatol* 2014;32(1):80–87.
7. Dodds A, et al. *Dermatol Ther (Heidelberg)* 2014;4(1):11–31.
PCDS – primary care dermatology society
SCC – squamous cell carcinoma
September 2016 UKDCF3574I

His actinic keratosis doesn't have to get worse before it gets better



Proven over ten years to deliver effective AK treatment¹ via a generally well-tolerated regimen,²⁻⁴ and the only topical therapy strongly recommended by the PCDS for both small and large field change,⁵ Solaraze™ helps you treat AK early, to prevent progression to more pronounced lesions and SCC.^{6,7}

solaraze™
3% w/w diclofenac sodium

Orals - Abstracts

■ A novel use of reflectance confocal microscopy (RCM) to detect Pagetoid Melanocytosis (PM)

L Griffin, L Roche, S McCarthy, M Lynch, K Ahmad, C Hackett, N Leonard, B Ramsay.
Department of Dermatology, University Hospital Limerick.

Introduction: MM diagnosis by RCM usually relies on detecting pagetoid cells in 5 of 6 criteria using horizontal vivablock technique.¹ However, the vivastack function on RCM works as a rapid, non-invasive in vivo punch biopsy recording a series of 34 high resolution consecutive images on a single spot (0.5x0.5mm) from the surface through the epidermal layers. Using this we observed striking pagetoid spread in invasive MM and decided to study if this finding helps distinguish MM from other lesions.

Methodology and results: We studied 60 patients attending our pigmented lesion clinic with suspicious lesions where a clinical decision to excise had been made and RCM vivastack images were taken. The RCM operator was unaware of the eventual histologic diagnosis. The presence of PM, its level of onset and cessation were measured and expressed as a percentage of the total vivastack of images.

All 22 patients who were histologically confirmed to have benign diagnoses had no PM. 2 out of 6 patients with spitz naevi had PM reflecting the heterogenous nature of this tumour. 6 of 8 patients with dysplastic naevi (DN) had PM. 3 out of 4 patients with lentigo maligna had PM. Of the 22 patients with invasive MM PM occurred within the 1st 10 frames in 18 patients with mainly rounded/pleomorphic PM. The percentage PM stack involvement ranged from 26% for amelanotic melanoma to 97% in a patient with 2.3 mm breslow MM.

Conclusions: RCM visualises the epidermis in its physiologic state in contrast to retraction bias from fixation, tissue staining and sectioning seen in histopathology. RCM vivastack enables the operator to focus it on the most dermatoscopically suspicious areas of the lesion taking less than 30 seconds to capture the stack images. It is easier to identify PM by CFM as there at least 34 images in contrast to histology. CFM requires no special stains and injures no cells.

No patients with benign lesions had PM. The presence of PM confirms significant melanocytic pathology. Stack analysis allows enhanced recognition of vertical growth phase of melanoma. The novel finding of this study is that if there is no PM on stack function it is likely one is dealing with a benign lesion.

1. Pellacani G et al. Reflectance-mode confocal microscopy for the in vivo characterisation of pagetoid melanocytosis in melanomas and naevi. *JID* 2005 125: 532-537

■ Prospective Randomised Trial comparing Electroporation to Surgery for primary BCC Treatment

AJP Clover¹, S Salwaz, J McKiernan¹, C Buckley¹, M Bourke², EJ Kelly¹, ST O'Sullivan¹, D Soden²
¹ Department of Plastic Surgery, Cork University Hospital, Cork, Ireland

² Cork Cancer Research Centre, University College Cork, Cork, Ireland

Corresponding author: D Soden

Introduction: Basal Cell Carcinoma (BCC) is the most common cutaneous malignancy with incident rates increasing throughout the world. Surgery remains the primary treatment standard for these tumours due to its excellent overall curative outcome. Electroporation in combination with local chemotherapy injection has demonstrated efficiency for the treatment of BCC but has not been assessed in a prospective randomised setting. This study hypothesised that Electroporation had an equal outcome over 5 years to surgery and could offer a cosmetic benefit to patients due to the fact that in contrast to other ablative technologies electroporation preserves healthy tissue structures.

Method: A prospective randomised control trial was established to determine the efficiency of Electroporation and local bleomycin injection as a primary treatment modality for BCC with the current standard of surgery as the control arm. Initial response rates to treatment were assessed and recurrence rate over a one, three and five year period

Results: In total 86 patients with 105 lesions were enrolled, treated and completed minimum follow up of 1 year (Electroporation group 45 patients - 60 lesions; Surgery 41 patients - 45 lesions). All patients responded to their primary treatment modality, however 5 patients in the ECT group required a second Electroporation treatment and 2 patients in the surgical group required further excision. There were no recurrences in either group for the first two years of follow up. At the year 5 follow up the results demonstrate a disease free progression of 94% (47/50) (10 lost to follow up) in those lesions treated with Electroporation and 94% (31/33) (12 lost to follow up) in those treated with surgery (P = 0.37).

Discussion: Electroporation involves the delivery of very short (millisecond) electrical pulses directly to target tissue. We have demonstrated in this clinical study that in combination with the low dose injection of bleomycin it is an extremely effective treatment for primary BCC. Significantly it has also proven to have a durable curative effect that is comparable with surgery at five years of follow up.

This data also demonstrates that electroporation can be a useful utility in the management of BCC lesions with its preservation of healthy tissue structures providing additional cosmetic advantages in the treatment of lesions located in sensitive regions of the body.

It should be noted that the suitability of electroporation for widespread BCC treatment has to date been reduced by the discomfort generated by delivery of the electrical pulses. This has required administration of local anesthesia and sedation to patients. However technological improvements with the electroporation generator system have recently been achieved which have eliminated the muscular contractions and pain induced allowing for more widespread application of the technology. In addition recent research has demonstrated efficacy with the use of CaCl₂ as a replacement for bleomycin further enhancing its application.

DERMAL TOPICAL INNOVATION FOR EVERY BODY

Dermal's extensive experience in developing highly effective, yet cosmetically elegant treatments for application to the skin, has benefitted millions of people for over half a century.

Dermal remains committed to building on our history of successful topical innovation for the benefit of future generations.

Orals - Abstracts

■ Methotrexate for Severe Childhood Atopic Dermatitis: Real Life Experience in a Tertiary Centre

V. Dvorakova, G. O'Regan, A. Irvine
Our Lady's Children's Hospital, Crumlin.

Background: Atopic dermatitis (AD) affects up to 20% of children. While the majority of patients are adequately controlled with emollients, topical corticosteroids, topical calcineurin inhibitors or phototherapy, children with moderate-to-severe AD often require systemic treatment.

Objectives: To evaluate methotrexate (MTX) efficacy and safety in real life use in a paediatric population with severe AD attending a tertiary referral centre.

Methods: A retrospective chart review was undertaken of all children who received MTX for severe AD at our tertiary referral centre from November 2010 to August 2015.

Results: 47 children were commenced on MTX for AD during this time period. Mean IGA at 3-5 months' follow-up improved from 4.25 to 2.8, with further improvement to 1.9 in the group of patients that continued therapy beyond 10 months of treatment. Changes in CDLQI mirrored changes in IGA with improvement in mean CDLQI of 14.4 at the start of the treatment to a mean CDLQI 7.5 at 3-5 months' follow up. The continued improvement in disease control beyond medium-term therapy was confirmed by a further improvement in CDLQI to 6.6 in patients that continued MTX beyond 10 months of treatment. The treatment was well tolerated in our cohort.

Conclusions: MTX appears to be a safe treatment for paediatric severe atopic dermatitis. Its therapeutic effects continue to improve beyond medium-term treatment period as reflected by further improvement in IGA and CDLQI scores in patients who continued MTX therapy beyond 10 months of treatment.

■ Enhancing medical student's dermatology skills through the use of precision teaching

C. McGrath, G. Gormley, C. McCourt, A. Corry, K. Dillenburger, K. Douvani. Belfast Trust & Queens University Belfast.

Dermatology is often considered to be underrepresented in undergraduate medical curricula and students nearing graduation may lack confidence in assessing and diagnosing skin conditions. Therefore new teaching methods are required to enhance medical student's acquisition of dermatological skills and knowledge. Precision Teaching (PT), is a pedagogical strategy stemming from behaviour analysis that can be used to improve learners' knowledge retention. This teaching method uses frequent, brief, timed measures of student performance on specific learning points, in this case reviewing multiple dermatological images, with the aim of improving speed and accuracy sufficient to ensure retention and improve learning efficiency. Already established in other educational fields, PT has only recently been applied to medical education. In this study we aimed to determine the impact of PT (using dermatology flashcards) on dermatology diagnostic skills compared to traditional teaching alone.

Third year medical students were invited by email to participate in this study. During their one-week attachment, consenting third year medical students completing placements on two hospital sites were randomly allocated either to the intervention group (PT+ traditional teaching) or the control group (traditional teaching). For our PT method, we designed 50 dermatology image flashcards. Repeated practice with the flashcards during timed periods of one minute took place 2-3 times per teaching day and students' data on accuracy were recorded. Pre and post-training tests, in the form of a 30 question picture quiz, were carried out to determine whether students' diagnostic skills improved as a result of the training.

A total of 135 participants were recruited over the academic year, 70 were randomised to the intervention group and 65 to the control group. Statistical analysis was carried out using analysis of covariance to take into account the differing baseline level of students. Primary analysis of the 'change score' (comparing pre- and post-test scores) demonstrated a statistically significant improvement of 8.8% (95% CIs 4.9-12.7 $p < 0.001$) in the intervention group compared with the control group. This was independent of the teaching week or hospital site. Interestingly, secondary analysis of the intervention group demonstrated a 'dose' effect: the post-test score increased by an average of 1.61% per additional 'try' (95% CIs 0.97 to 2.25). Our study highlights that Precision Teaching has a positive effect on enhancing diagnostic and recognition skills. It is an effective and quick adjunctive teaching method that educators could use in their blended approach of teaching dermatology.

■ The burden of chronic itch-a questionnaire based evaluation of clinical characteristics, associated

I. McDonald, A. Gábor Szollosi, B. Kirby, M. Steinhoff. Charles Institute of Dermatology UCD, St Vincent's University Hospital

Itch is the most common symptom in dermatology associated with a significant impact on patient's quality of life. With new therapeutic options on the horizon it is important to clinically differentiate our "itchy" patients, evaluating this symptom independently and with objective measures.

Aims: 1) Characterize clinical features of itch in a cohort of patients attending the dermatology department. 2) Evaluate the impact of itch on quality of life, sleep and mental health. 3) Evaluate the efficacy of treatments as reported by patients.

Methods: Patients with a diagnosis of prurigo nodularis (PN), atopic dermatitis (AD), psoriasis (PSO) and pruritus of undetermined origin (PUO) were recruited from the dermatology OPD of SVUH. A pruritus questionnaire was developed, incorporating the itch VAS. The DLQI, PSQI and HADS were also used.

Results: 73 patients were recruited. Itch was a symptom for more than 5 years in 62.67% of patients. 45.9% reported "always" feeling itchy. Bedtime was the most bothersome time (36.49%) while heat and stress were the commonest exacerbating factors. The mean VAS was 6.69 indicating moderate to severe itch. This was greatest in patients with PN (7.50) and lowest in patients with psoriasis (5.89) with a significant difference in severe and very severe itch between the two groups (83.3% vs 47.2%, $P < 0.05$). The VAS for itch

BOOSTING HYDRATION FOR YOUNGER LOOKING SKIN.

TREAT
SKIN
RIGHT



Available in Pharmacy.
Buy online at
elaveskincare.com

was found to be a significant predictor of DLQI, PSQI, and HADS. Importantly it remained a significant predictor of DLQI independent of PASI (regression coefficient $B=1.881$, $p<0.05$). 77.73% of patients had abnormal sleep patterns (PSQI score $>$ than 5). The mean PSQI was highest in patients with PUO and lowest in patients with psoriasis. 34.7% of patients had a borderline or abnormal HADS for anxiety. This was proportionally greatest in patients with PN (50%). Most patients felt that topical and systemic treatments were only partially effective (71.67% and 72.73% respectively) while phototherapy was found to be the most efficacious of therapeutic options overall.

Conclusion: In this patient cohort itch was found to be a chronic and pervasive symptom. There was significantly less severe itch in patients with psoriasis where it had less impact on sleep than the other groups. Measurement of itch by VAS was an important predictor of DLQI and was independent of PASI. Systemic and topical treatment efficacy remains partial for most patients. This highlights the unmet medical need in pruritus management and the need for its evaluation independent of other disease measures.

■ Trends in Preservative Contact Allergy In Cork

R. O'Connor, S. McCarthy, M. Murphy, J. Bourke. SIVUH Cork

Several epidemics of preservative contact allergy have emerged, namely formaldehyde in the 1960s, MCI/MI in the 1980s, methyl-dibromo glutaronitrile in the 1990s, and the recent epidemic of MI following European Union (EU) approval in 2005 allowing MI to be used in stronger concentrations in leave-on and rinse-off cosmetic products.

The aim of our study was to evaluate the trends in preservative allergy in our dermatology unit in Cork. Over a nineteen-year period (1997 to 2015) we analyzed the patch test results of 2,636 patients who were investigated for a contact allergy. The reports were reviewed via access to four patch test databases. Over this time period the incidence of allergy to parabens, formaldehyde and formaldehyde releasers have fallen. Isothiazolinone allergy has risen sharply and these results are in keeping with European figures. In 2015 we were surprised at persistent high rates of positive patch tests to methylisothiazolinone (MI) (15.4%) given recent recommendations from the Scientific Committee for Consumer Safety (SCCS). We examined over a thousand cosmetic products in local supermarkets and pharmacies and found MI still to be present in wash off products and some wipes but also were surprised to find it in 'leave-on' products (moisturizer, sunblock). This may explain the current high rates of positive patch tests to MI in Ireland. The incidence of sodium metabisulphite allergy has also increased but this is difficult to explain. From 1997 to 2009 418 patients were patch tested to sodium metabisulphite as part of the medicament series and all had a negative result. From 2010 to 2015 776 patients were patch tested and 42 had positive results to sodium metabisulphite (5.4%). Of those 42 patients only 3 results were of confirmed relevance. This recent increase in sodium metabisulphite contact allergy is difficult to explain.

■ Can Referral Management Enhance Access to Paediatric Dermatology Services?

Gilhooley E., Collins S.

Our Lady of Lourdes Hospital, Drogheda, Co Louth.

Paediatric dermatology encompasses a variety of dermatoses ranging from common inflammatory skin diseases to the rare genodermatoses. The National Clinical Care Programme (NCCP) for dermatology has recently issued referral exclusions for benign and self-limited conditions. In the setting of limited resources and excessive waiting times we sought to determine referral patterns to our department that serves a 400,000 catchment area.

An analysis of all paediatric referral letters received over a six-month period triaged as non-urgent was conducted. Referral letters were examined for inclusion of information for appropriate triage, diagnosis and details of first line treatments.

Of 464 referrals, 20% were for atopic dermatitis (AD) [91/464], 19% pigmented lesions [89/464], 16% viral warts [73/464], 10% non-specific rash [46/464], 7% acne vulgaris [34/464], and 28% other (other lesions, hair disorders, fungal infections and other inflammatory disorders).

AD represented the commonest diagnosis. 78% were referred for AD control [71/91] and 22% requesting allergy testing [20/91]. 31% provided details of severity: recurrent infections, sleep disruption and school absenteeism. None recorded psychological impact. Details of first line treatment was recorded in 69% [63/91]. Pigmented lesions represented 19% [89/464] of referrals, mean age of 10 years. 85% [76/89] reported new and changing moles. 15% [13/89] were referred for general mole checks, none reported a family history of melanoma. 16% were referred for management of viral warts. 45% [33/73] recorded multiple warts, 47% [34/73] detailed failed treatments. 14% requested surgical excision. Acne accounted for 9% of referrals, at a mean age of 15 years. 29% [9/34] of referrals included information on severity/presence of scarring, 9% of psychological impact.

We determined that 55% of all referrals received were for 3 conditions: atopic dermatitis, pigmented lesions and viral warts. The education of primary care providers in the first line management of atopic eczema along with referral criteria to secondary care is required. The rarity of melanoma in childhood is not reflected in referral patterns suggesting low awareness amongst primary care and/or the public who would benefit from education in this regard. The exclusion of viral warts as per the NCCP criteria has the potential to reduce referrals significantly. Our data demonstrates that a detailed breakdown of referrals, by diagnostic categories, can provide valuable data for identifying the educational needs of primary care providers. In addition, referral management may be enhanced, with the objective of promoting access by clinical priority.

THE SKIN ITSELF

INSPIRED BIODERMA
TO FIND A WAY
TO STIMULATE ITS REPAIR.
IN A LASTING WAY.



Cicabio SPF 50+

THE 2-IN-1 SKINCARE
WHICH REPAIRS AND LIMITS
POST-SCARRING MARKS

Cicabio SPF 50+ helps repair damaged skin, even when exposed to the sun, and limits the appearance of post-scarring marks. It protects from UV rays, relieves discomfort and reduces the urge to scratch.

BIOLOGY AT THE SERVICE OF DERMATOLOGY

BIODERMA
LABORATOIRE DERMATOLOGIQUE

■ Utility of lymphocyte transformation testing in the diagnosis of drug hypersensitivity.

J. Boggs, M. Keogan, M. O'Kane. Department of Dermatology, Connolly Hospital Blanchardstown/Beaumont Hospital

Adverse cutaneous reactions to drugs are common, affecting 2-3% of hospitalised patients. An estimated 1 in 1000 hospitalised patients develop a serious cutaneous drug reaction. Diagnosis of drug hypersensitivity may be complex, particularly Type IV reactions which are delayed in onset (days to weeks) following exposure to the culprit drug. Reactions can take many different forms, varying from inconvenient to life threatening, morphology is diverse and multiple drugs may be suspected. Type IV reactions may be evaluated with various diagnostic tests including lymphocyte transformation testing (LTT), which aims to detect circulating drug specific memory T cells which proliferate upon drug stimulation. We aimed to evaluate whether LTT helped to define the incriminating drug in our patients with drug reactions.

All patients who had LTT performed under Dermatology care between 03/2009- 03/2016 were identified from a patient database (n=34). Retrospective review of their medical records was performed. Of 34 patients, (21 female, 13 male), with mean age of 52.8 years (range 18-85); 97% presented with a skin eruption and 20% had systemic symptoms at presentation. The predominant morphology was maculopapular (29%); 30/34 patients were hospitalised. The mean duration between drug exposure and onset of reaction was 10.9 days. Of the 56% that underwent biopsy, 79% had histology consistent with a drug eruption. The average number of drugs requested for LTT per patient was 3 (range 1-9 drugs). 76% (26/34) had a positive LTT. 69% (18/26) had positive LTT reactions to an antibiotic, of which the majority were Beta-lactams, comprising 61% (11/18). 7/34 patients had a Severe Cutaneous Adverse Reaction (SCAR), all 7 had a positive LTT. The causative drugs were withdrawn once the diagnosis of drug reactions were made in 82% (28/34), followed by significant improvement in 82% of patients. There were 2 fatalities secondary to multi-organ failure and 1 patient required haemodialysis. Two known accidental re-challenges occurred, both with more severe recurrences of the skin eruption, with one patient developing DRESS.

In conclusion we found that a positive LTT was a valuable contribution in the diagnosis of drug allergy and in identifying the drug involved. However as sensitivity of LTT is limited, a negative LTT cannot exclude a drug hypersensitivity. False negatives may occur with mistiming of the test and in patients on high dose systemic prednisolone. Nevertheless we feel that LTT is a useful test in the armamentarium of the dermatologist when faced with this challenging situation.

■ Analysis of 10 years of phototherapy data from one centre and its implications

S. Mohamed*^{1,2}, D. R. Wall*^{2, 3}, B. Q. Huang¹, M. Greenwood⁴, A. D. Irvine^{2,3,5}, M-T. Kechadi¹, N. O'Hare^{3,5}, A-M. Tobin⁴

* Indicates joint first authors.

1. Insight Centre for Data Analytics, University College Dublin,
1. The Irish Skin Foundation, Charles Institute UCD, University College Dublin,
2. St James's Hospital, Dublin

3. The Adelaide and Meath Hospital, Incorporating the National Children's Hospital, Tallaght
4. Trinity College Dublin,

Introduction: Since its introduction to mainstream dermatology in the 1970s, phototherapy has flourished and is considered amongst the first line treatments for a number of conditions, though moderate to severe psoriasis is the main indication.^{1,2}

Concerns regarding skin cancer development, and adverse events that have seen phototherapy become a common source of legal claims in dermatology, have emphasised the importance of fastidious monitoring of its delivery.^{3,4}

Many hospitals rely on paper records for this purpose, though electronic systems have been developed to capture data entry at a patient level. This study aimed to analyse the AMNCH phototherapy Puvamate database to identify treatment, outcome and safety trends at a hospital level. A further aim was to identify the datapoints required to fully digitise phototherapy in a manner supportive of care delivery and monitoring of its safety.

Methodology: After obtaining ethical approval, the AMNCH database was professionally anonymised. The data was processed and mined using advanced data mining techniques. Models to find associations between treatment and adverse event occurrence and clusters of patients were implemented and reviewed with clinicians.

Results: Treatment records over 12 years and 955 patients were analysed. 3% of records had inconsistencies requiring their exclusion from analysis. The most common indications for phototherapy were psoriasis and eczema. Side effects were encountered in 12% of treatments.

Conclusion: This study demonstrates the value of phototherapy to dermatology and the richness of the data recorded during its delivery. An initial dataset to inform the development of user-centric software to digitise phototherapy delivery was also identified. It is suggested that such software, if widely adopted, could be capable of informing and supporting a national phototherapy network to efficiently and safely deliver phototherapy, while providing data to advocate for resources and facilitate research.

References:

- 1 Parrish JA et al. Photochemotherapy of Psoriasis with Oral Methoxsalen and Longwave Ultraviolet Light. *New England Journal of Medicine* 1974; 291: 1207-11.
- 2 Lee E et al. UVB phototherapy and skin cancer risk: a review of the literature. *International journal of dermatology* 2005; 44: 355-60.
- 3 Hearn RMR et al. Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy. *British Journal of Dermatology* 2008; 159: 931-5.
- 4 Ong S, Coulson I. Legal claims in English dermatological practice. *British Journal of Dermatology* 2011; 164: 217-9.

Case Presentations

INTODUCING TALTZ

A targeted IL-17A inhibitor with high binding affinity (kd<3 pM)

OUR GOAL IS CLEAR. TOUCHABLE. SKIN.

Taltz is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy

TALTZ® (ixekizumab) ABBREVIATED PRESCRIBING INFORMATION Presentation Ixekizumab solution for injection in a pre-filled syringe or pre-filled pen. Each single use pre-filled syringe and pre-filled pen contains 80 mg of ixekizumab in 1mL solution. The solution is clear and colourless to slightly yellow. **Uses** Taltz is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. **Dosage and Administration** **Posology** The recommended dose is 160 mg by subcutaneous injection (two 80 mg injections) at Week 0, followed by 80 mg (one injection) at Weeks 2, 4, 6, 8, 10, and 12, then maintenance dosing of 80 mg (one injection) every 4 weeks. Consideration should be given to discontinuing treatment in patients who have shown no response after 16 to 20 weeks of treatment. Some patients with initially partial response may subsequently improve with continued treatment beyond 20 weeks. **Elderly:** No dose adjustment is required. **Renal or hepatic impairment:** Taltz has not been studied in these patient populations. No dose recommendations can be made. **Paediatric population:** The safety and efficacy of Taltz in children and adolescents aged 6 to 18 years have not yet been established. No data are available. **Method of administration** Taltz is for subcutaneous injection. Injection sites may be alternated. If possible, areas of the skin that show psoriasis should be avoided as injection sites. The solution/the syringe must not be shaken. After proper training in subcutaneous injection technique, patients may self-inject Taltz if a healthcare professional determines that it is appropriate. However, the physician should ensure appropriate follow-up of patients. Comprehensive instructions for administration are given in the package leaflet. **Contraindications** Serious hypersensitivity to the active substance or to any of the excipients. Clinically important active infections (e.g. active tuberculosis). **Warnings and Special Precautions** **Infections:** Treatment with Taltz is associated with an increased rate of infections such as upper respiratory tract infection, oral candidiasis, conjunctivitis, and tinea infections. Taltz should be used with caution in patients with clinically important chronic infection. If such an infection develops, monitor carefully and discontinue Taltz if the patient is not responding to standard therapy or the infection becomes serious. Taltz should not be resumed until the infection resolves. Taltz must not be given to patients with active tuberculosis (TB). Consider anti-TB therapy prior to

initiation of Taltz in patients with latent TB. **Hypersensitivity:** Serious hypersensitivity reactions, including some cases of angioedema, urticaria and, rarely, late (10-14 days following injection) serious hypersensitivity reactions including widespread urticaria, dyspnea and high antibody titres have been reported. If a serious hypersensitivity reaction occurs, administration of Taltz should be discontinued immediately and appropriate therapy initiated. **Inflammatory Bowel Disease:** Cases of new or exacerbations of Crohn's disease and ulcerative colitis have been reported. Caution should be exercised when prescribing Taltz to patients with inflammatory bowel disease, including Crohn's disease and ulcerative colitis, and patients should be monitored closely. **Immunisations:** Taltz should not be used with live vaccines. No data are available on the response to live vaccines; there are insufficient data on response to inactivated vaccines. **Excipients:** This medicinal product contains less than 1 mmol sodium (23 mg) per 80 mg dose, i.e., essentially "sodium-free". Please see Summary of Product Characteristics (SPC) for full information on excipients. **Interactions** The safety of Taltz in combination with other immunomodulatory agents or phototherapy has not been evaluated. **Fertility, Pregnancy, and Lactation** **Women of childbearing potential:** Women of childbearing potential should use an effective method of contraception during treatment and for at least 10 weeks after treatment. **Pregnancy:** It is recommended to avoid the use of Taltz during pregnancy. **Breast-feeding:** A decision should be made whether to discontinue breast-feeding or to discontinue Taltz. **Fertility:** The effect of ixekizumab on human fertility has not been evaluated. Animal studies do not indicate direct or indirect harmful effects with respect to fertility. **Effects on ability to drive and use machines** Taltz has no or negligible influence on the ability to drive and use machines. **Undesirable Effects** **Summary of the safety profile:** The most frequently reported adverse drug reactions were injection site reactions and upper respiratory tract infections (most frequently nasopharyngitis). **Injection site reactions:** The most frequent injection site reactions observed were erythema and pain. These reactions were predominantly mild to moderate in severity and did not lead to discontinuation of Taltz. **Infections:** In the placebo-controlled period of the phase III clinical studies in plaque psoriasis, infections were reported in 27.2 % of patients treated with Taltz for up to 12 weeks compared with 22.9 % of patients treated with

placebo. The majority of infections were non-serious and mild to moderate in severity, most of which did not necessitate treatment discontinuation. Serious infections occurred in 13 (0.6 %) of patients treated with Taltz and in 3 (0.4 %) of patients treated with placebo. **Very common (≥1/10):** Upper respiratory tract infection, injection site reactions. **Common (≥1/100 to <1/10):** Tinea infection, oropharyngeal pain, nausea. For full details of these and other side-effects, please see the Summary of Product Characteristics, which is available at <http://www.medicines.org.uk/emc/>. **Legal Category** POM **Marketing Authorisation Numbers** EU/1/15/1085/002 EU/1/15/1085/004 **Basic NHS Cost** £2,250 per pack of 2 pre-filled pens £1,125 per pack of 1 pre-filled syringe **Date of Preparation or Last Review** April 2016 **Full Prescribing Information is Available From** Eli Lilly and Company Limited, Lilly House, Priestley Road, Basingstoke, Hampshire, RG24 9NL Telephone: Basingstoke (01256) 315 000 E-mail: ukmedinfo@lilly.com TALTZ® (ixekizumab) is a registered trademark of Eli Lilly and Company.

● UKTLZ00094 September 2016

Adverse events should be reported. Reporting forms and further information can be found at: www.mhra.gov.uk/yellowcard.
Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.

Adverse events and product complaints should be reported. To report an adverse event or a product complaint about a Lilly medicine, please call Lilly on: 01 664 0446.

Adverse events and product complaints may also be reported to the Health Products Regulatory Authority. Reporting forms and information can be found at www.hpra.ie.

01. 11.30am Resolving hepatic hemangiomas and hypothyroidism after treatment with propranolol and levothyroxine
V. Cambell, R. Beckett, N. Abid, S. Hoey.
Department of Dermatology, Royal Victoria Hospital, Belfast. Department of Endocrinology, Growth and Diabetes, Royal Belfast Hospital for Sick Children

02. 11.40am A case of paraneoplastic elastosis perforans serpiginosa associated with ovarian malignancy
C. Quinlan, J. Boggs, M. Finan, N. Mulligan, M. O'Kane, N. Ralph.
Mater Misericordiae University Hospital, Dublin. Connolly Hospital, Blanchardstown, Dublin. Mater Misericordiae University Hospital, Dublin.

03. 11.50am High-grade follicular lymphoma in a patient receiving adalimumab and methotrexate for pityriasis rubra pilaris
E Nic Dhonncha,¹ K Fadalla,² C Murray,³ P Gou,³ D Gibbons,³ A Fabre,³ B Moriarty,¹ P Collins¹
Departments of ¹Dermatology, ²Haematology and ³Histopathology, St. Vincent's University Hospital, Dublin

04. 12.00pm Back to the bible
I. Timoney, L. Timoney, N. Allen, E. Storan, A-M. Murphy. Dermatology, University Hospital Galway. Dermatology, Queen Elizabeth University Hospital, Glasgow. Infectious Disease, University Hospital Galway.

05. 12.10pm Epithelioid Angiosarcoma Arising on the Back of a Young Caucasian Male
A. Kelly, G. Murphy, C. Gulmann. Beaumont Hospital Dublin.

06. 12.20pm Abatacept: a novel treatment in severe limited scleroderma and morphea
S. McCarthy, L.Roche, L. Griffin, N. Leonard, M. Lynch, C. Hackett.
Dermatology Department, University Hospital Limerick. Pathology Department, St James' Hospital, Dublin

07. 12.30pm Subcutaneous Sweet's syndrome in pregnancy
J. Boggs, M. Sabah, M. Redmond, F. Moloney, M. O'Kane.
Connolly Hospital Blanchardstown/Beaumont Hospital. Connolly Hospital Blanchardstown. Beaumont Hospital. Connolly Hospital Blanchardstown/Mater Hospital. Connolly Hospital Blanchardstown/Beaumont Hospital.

08. 12.40pm Febrile ulceronecrotic Mucha-Habermann disease
Muriel Sadlier, Grainne O'Regan, Fiona Browne
Department of Dermatology, Our Lady's Children's Hospital Crumlin, Dublin.

09. 12.50pm Systemic and cutaneous amyloid presenting with palmar bullae
Roche L, Leen E, Quinn J, Keogan M, O'Kane M
Connolly Hospital Blanchardstown, Beaumont Hospital Dublin

▼ This medication is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare Professionals are asked to report any suspected adverse reactions.

EFFACLAR DUO [+]

With La Roche-Posay thermal spring water

Suitable for sensitive skin

Corrective Unclogging Care.
Anti-Imperfections, Anti-Marks.



6 actions in 1 application

- 1 Keratolytic: Lipo Hydroxy Acid
- 2 Fortifying: Niacinamide
- 3 Anti-hyperpigmentary: PROCERAD™
- 4 Anti-bacterial: Piroctone Olamine
- 5 Sebum normaliser: Linoleic Acid
- 6 Sebum regulator: Zinc PCA

INDICATIONS

- Oily, blemish-prone skin
- Comedones & blackheads
- Red & brown marks
- Excess sebum
- Inflammatory & non-inflammatory lesions
- Clogged pores
- Uneven skin texture

NO ALCOHOL
NO COLOURANTS
NO PARABENS
NON-COMEDOGENIC

LA ROCHE-POSAY. COMMITTED TO DERMATOLOGY.

Oral Case Presentations Abstracts

Resolving hepatic hemangiomas and hypothyroidism after treatment with propranolol and levothyroxine

V. Cambell, R. Beckett, N. Abid, S. Hoey.

Department of Dermatology, Royal Victoria Hospital, Belfast. Department of Endocrinology, Growth and Diabetes, Royal Belfast Hospital for Sick Children.

Infantile hepatic hemangiomas (IHH) particularly the diffuse subtype, can in severe cases be associated with hepatic and cardiac failure, compartment syndrome, and consumptive hypothyroidism. Early recognition and treatment of these pathologies is paramount in order to minimise the risk of longterm sequelae. Thyroid hormones are crucial for growth and neurodevelopment, with three to five IQ points lost for each month hypothyroidism remains untreated in the first year of life. This developmentally sensitive period parallels the proliferative phase of hemangiomas, and highlights a window of opportunity to screen for, and aggressively treat hypothyroidism in the context of diffuse IHH.

We report a female twin conceived through in-vitro fertilization who presented aged eight weeks with systemic compromise and hepatomegaly in the absence of large or obvious cutaneous infantile hemangiomas (IH). Abdominal ultrasound showed innumerable hypoechoic nodules and increased vascularity within the liver, confirmed on CT and MRI. AFP was markedly elevated with associated derangement of her LFTs and coagulation profile. Findings were consistent with a diagnosis of diffuse infantile hepatic hemangiomatosis. Subsequent to this, assessment of her thyroid function confirmed consumptive hypothyroidism. She was promptly treated with levothyroxine 9.6 micrograms/kg/day and oral propranolol at an initial dose of 1mg/kg once daily in two divided doses, escalated to 2mg/kg after five days. Treatment was well tolerated with no adverse effects, and rapid improvement in her clinical parameters.

This case reiterates the importance of investigating for consumptive hypothyroidism in an infant diagnosed with IHH, particularly when there is systemic compromise in the absence of cutaneous clues. Consultation with endocrinology for specialist management is imperative if growth and intellectual retardation are to be prevented. In accordance with a growing body of evidence, we advocate propranolol as a single agent for IHH, supported by thyroid replacement when appropriate. More research is needed to fully understand the pathophysiology underlying systemic decompensation in diffuse IHH, and to understand the exact mechanism of action of propranolol when used as a first line treatment.

A case of paraneoplastic elastosis perforans serpiginosa associated with ovarian malignancy

C. Quinlan, J. Boggs, M. Finan, N. Mulligan, M. O'Kane, N. Ralph. Mater Misericordiae University Hospital, Dublin. Connolly Hospital, Blanchardstown, Dublin. Mater Misericordiae University Hospital, Dublin.

Introduction: Elastosis perforans serpiginosa is a rare skin disorder in which there is transepithelial elimination of elastin fibres.¹ There have been no previous reports of elastosis perforans ser-

piginosa occurring as a paraneoplastic phenomenon. We report a case of paraneoplastic elastosis perforans serpiginosa in the setting of ovarian cancer.

Case Report: A 42-year-old female presented with proximal muscle weakness, difficulty swallowing and an erythematous eruption on the chest and shoulders. The clinical impression was of dermatomyositis. Myositis panel revealed positive anti-nuclear antibody and positive anti-transcription intermediary factor-1 γ . She also had a cutaneous eruption affecting the flexures, which consisted of superficial erosions on an erythematous base.

She was treated with three days of pulsed methylprednisolone at a dose of 1g daily, followed by oral prednisolone at a dose of 1mg/kg/day. As there was no clinical improvement, she received 5 days of intravenous immunoglobulin (IVIg) at a dose of 400mg/kg/day. Muscle weakness improved significantly, however the skin eruption was persistent.

Skin biopsy showed increased amount and size of dermal elastic fibres with fragmented fibres being eliminated through transepidermal channels. Verhoeffs-van gieson (VEG) stain was performed and this demonstrated transepidermal elimination of elastin fibres.

MRI pelvis findings showed likely ovarian malignancy, extensive peritoneal metastases and extensive metastatic lymphadenopathy. Biopsy of the omentum revealed poorly differentiated adenocarcinoma.

The patient was diagnosed with stage IV high grade serous papillary ovarian carcinoma and commenced on neo-adjuvant chemotherapy with weekly taxol and 3-weekly carboplatin. On review at cycle 1 day 16 of treatment her skin eruption had almost fully healed.

Discussion: Elastosis perforans serpiginosa (EPS) is a rare skin disorder in which there is transepithelial elimination of elastin fibres. It belongs to the group of perforating disorders of which there are 4 classic types; EPS, perforating folliculitis, Kyrles disease and reactive perforating collagenosis. Reactive perforating collagenosis has been reported, rarely, in association with malignancy.²

In our case the onset of symptoms shortly before diagnosis of underlying malignancy and the rapid response of the skin following chemotherapy are consistent with a paraneoplastic dermatosis. The failure of the skin to respond to high dose steroids and IVIg also supports this proposal.

In conclusion, we present a case of paraneoplastic elastosis perforans serpiginosa in association with ovarian malignancy. To our knowledge this is the first case of paraneoplastic elastosis perforans serpiginosa reported.

1. Mehta R.K. et al Elastosis perforans serpiginosa and associated disorders Clin Exp Dermatol. 2001 Sep;26(6):521-4.
2. Yazdi S et al Acquired reactive perforating collagenosis associated with papillary thyroid cancer. Clin Exp Dermatol 2010 March;35(2):152-5

LIPIKAR BAUME AP+

with La Roche-Posay thermal spring water

Innovative emollient balm suitable for eczema-prone skin prevents the relapse of dry skin and spaces out flare ups

20% Shea butter
2% Canola oil

▶ Repairs the hydrolipidic film function

7% Glycerine

▶ Restores the skin's suppleness

4% Niacinamide

▶ Helps the skin to restore its natural strength and resilience

0.2% Aqua Posae Filiformis lysate

▶ Restores microbial diversity

50% La Roche-Posay thermal spring water

▶ Soothes skin

LA ROCHE-POSAY
LABORATOIRE DERMATOLOGIQUE

innovation

LIPIKAR
BAUME AP+

Avec de l'eau thermale de La Roche-Posay

LIPID-REPLENISHING BALM
ANTI-IRRITATION
ANTI-SCRATCHING

Soothes immediately
Spaces out flare-ups
of severe dryness

Atopy-prone skin
Babies, children and adults
Fragrance-free, paraben-free

400 ml . Made in France

LA ROCHE-POSAY. COMMITTED TO DERMATOLOGY.

Oral Case Presentations Abstracts

■ High-grade follicular lymphoma in a patient receiving adalimumab and methotrexate for pityriasis rubra pilaris

E Nic Dhonncha,¹ K Fadalla,² C Murray,³ P Gou,³ D Gibbons,³ A Fabre,³ B Moriarty,¹ P Collins¹

Departments of ¹Dermatology, ²Haematology and ³Histopathology, St. Vincent's University Hospital, Dublin

In April 2014, a 52-year-old male presented with an itchy erythematous facial eruption, which subsequently spread to involve his trunk and limbs. He had a history of hypertension for which he took telmisartan and amlodipine.

Examination revealed erythroderma with islands of sparing, follicular hyperkeratotic papules and palmoplantar hyperkeratosis, consistent with pityriasis rubra pilaris (PRP). Histopathology supported the diagnosis. Acitretin 40mg OD was started and adalimumab 40mg weekly subcutaneously was added four weeks later. Within 3 months, a significant clinical improvement was noted. The dose of adalimumab was reduced to 40mg on alternate weeks and methotrexate 15mg weekly replaced acitretin therapy. In February 2015, his skin was almost clear and treatment was continued with no adverse effects. At routine clinical review in February 2016, he reported a 2-month history of a right-sided neck swelling in the absence of B symptoms. Examination revealed palpable neck nodes and a left-sided axillary swelling. Adalimumab and methotrexate were withdrawn. Laboratory tests were normal apart from lymphopenia. Urgent CT scan revealed a 3.2cm mass originating from the superior right parotid gland with four other enhancing soft tissue parotid mass lesions and a 5.1cm left sided axillary mass. Excisional lymph node biopsy from the left axilla diagnosed a high-grade follicular lymphoma. Seven months later he has received 6 cycles of RCHOP to which he is responding well. His skin remains clear to date.

PRP is a rare papulosquamous disorder and treatment is challenging. Established therapeutic options include acitretin, methotrexate, ciclosporin and phototherapy. More recently, several case reports have noted the efficacy of anti-TNF α agents in PRP, either as monotherapy or in combination with acitretin or methotrexate.^{1,2} Although PRP has been reported in association with solid and haematologic malignancies in case reports, it has not been described in association with follicular lymphoma which occurred in our patient while receiving adalimumab and methotrexate.

References:

1. Petrof G, Almaani N, Archer CB, Griffiths WA, Smith CH. A systematic review of the literature on the treatment of pityriasis rubra pilaris type 1 with TNF-antagonists. *J EADV* 2013;27:131-135.
2. Eastham AB, Femia AN, Qureshi A, Vleugels RA. Treatment options for pityriasis rubra pilaris including biologic agents: A retrospective analysis from an academic medical centre. *JAMA Dermatol* 2014; 150:92-94.

■ Back to the bible

I. Timoney, L. Timoney, N. Allen, E. Storan, A-M. Murphy. Dermatology, University Hospital Galway. Dermatology, Queen Elizabeth University Hospital, Glasgow. Infectious Disease, University Hospital Galway.

A 27-year-old female presented to her general practitioner with a two-year history of a gradually extending rash. This consisted of several erythematous annular plaques, involving much of the right arm.

There was no response to various topical treatments including steroids and anti-fungals. She continued to develop new similar, smaller plaques on the right arm as well as on her wrists, knees, face and back.

She was systemically well and otherwise asymptomatic. She had no significant medical history. She was originally from Bangladesh and had moved to Ireland nine years previously.

On examination, large annular erythematous plaques with well-defined raised borders, subtle surface scale and central clearing were present on the right arm. Similar, smaller plaques were noted elsewhere on the body. Hypo-aesthesia was demonstrated in affected areas.

A punch biopsy was taken from the right forearm. Histopathology showed non-necrotizing epithelioid granulomas throughout the dermis and extending into the subcutaneous tissue. Granulomas were seen within and destroying subcutaneous nerves.

The case was discussed at the Hospital for Tropical Diseases in London histopathology meeting and the opinion of a leprosy specialist was sought. Histological features were diagnostic of leprosy, most probably borderline leprosy (BB) subtype.

Discussion: Leprosy was first described in antiquity. It is rarely seen in Ireland with this being only the third reported case for decades.

Infection is caused by the bacillus *Mycobacterium leprae*. Clinical manifestation of the disease is determined by the nature of the host immune response, with poor cell mediated immunity resulting in lepromatous leprosy.

Global prevalence of leprosy has reduced by almost 90% in the last two decades however it continues to afflict developing countries where it remains a huge source of stigma.

The disease mainly affects the skin, peripheral nerves and the eyes. Peripheral neuropathy results in the classical, biblical deformities associated with leprosy.

The patient was commenced on dapsone and rifampicin. It is expected that skin lesions will resolve; indeed, they have improved significantly. Nerve damage is unfortunately permanent.

The cultural diversity we now enjoy in Ireland can present diagnostic challenges. It is necessary to be mindful of prevalent diseases in the countries from which patients have emigrated, particularly when faced with unusual or non-resolving symptoms.

Skin improved¹

Structural joint damage inhibited²

My time to holiday with friends

Psoriatic arthritis

HUMIRA is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. HUMIRA has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease and to improve physical function.¹

Psoriasis

HUMIRA is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy.¹

Some patients may not be suitable for Humira. You are strongly advised to read the prescribing information (PI) below.

Prescribing Information (PI) Humira (adalimumab) 40 mg solution for injection in pre-filled pen or pre-filled syringe or paediatric vial containing 40 mg solution for injection. Refer to Summary of Product Characteristics (SmPC) for full information.

Presentation: Each single dose pre-filled pen (0.4 ml), pre-filled syringe (0.4 ml) or vial (0.8 ml) contains 40 mg of adalimumab. **Indications:** Rheumatoid arthritis (RA), adults: In combination with methotrexate (MTX) for moderate to severe, active RA with inadequate response to disease-modifying anti-rheumatic drugs (DMARDs) including MTX. In combination with MTX for severe, active and progressive RA when not previously treated with MTX. Can be given as monotherapy if intolerance to or when continued treatment with MTX is inappropriate. Reduces rate of progression of joint damage on X-ray and improves physical function, in combination with MTX. **Polyarticular juvenile idiopathic arthritis (pJIA), paediatrics 2 years and above:** In combination with MTX, for active pJIA with inadequate response to one or more DMARDs; or monotherapy if intolerance to or when continued treatment with MTX is inappropriate. **Enthesitis-related arthritis (ERA), paediatrics 6 years and above:** For active ERA with inadequate response or intolerance to conventional therapy. **Ankylosing spondylitis (AS), adults:** For severe active AS with inadequate response to conventional therapy. **Axial spondyloarthritis without radiographic evidence of AS (nr-axSpA), adults:** For severe nr-axSpA with objective signs of inflammation (elevated CRP and/or MRI), and an inadequate response to or intolerance to nonsteroidal anti-inflammatory drugs (NSAIDs). **Psoriatic arthritis (PsA), adults:** For active and progressive PsA with inadequate response to DMARDs. Reduces rate of progression of peripheral joint damage on X-ray in polyarticular symmetrical subtypes of the disease and improves physical function. **Psoriasis, adults:** For moderate to severe chronic plaque psoriasis who are candidates for systemic therapy. **Psoriasis, paediatrics 4 years and above:** For severe chronic plaque psoriasis with inadequate response, or if topical therapy and phototherapies are inappropriate. **Hidradenitis suppurativa (HS), adults:** For active moderate to severe hidradenitis suppurativa (acne inversa) in patients with an inadequate response to conventional systemic HS therapy. **Crohn's disease (CD), adults:** For moderately to severely active CD with inadequate response, contraindication or intolerance to corticosteroid and/or an immunosuppressant therapy. **Crohn's disease (CD), paediatrics 6 years and above:** For moderately to severely active CD with inadequate response, contraindication or intolerance to conventional therapy including primary nutrition therapy and a corticosteroid, and/or an immunomodulator. **Ulcerative colitis (UC), adults:** For moderately to severely active UC with inadequate

response, contraindication or intolerance to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA). **Uveitis, adults:** For the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. **Dosage and administration:** A specialist physician experienced in diagnosis and treatment of the indicated condition, to initiate and supervise treatment. Provide patients with special alert card. Patients may self-inject after proper injection training, with physician approval and appropriate medical follow-up. Optimise other concomitant therapies. **RA, adults:** 40 mg dose every other week. Concomitant MTX should be continued. During monotherapy, patients may require 40 mg each week if they have experienced a decrease in clinical response. Treatment beyond 12 weeks should be reconsidered if no clinical response in that time. Consider need for dose interruption, e.g. before surgery or if serious infection occurs. Reintroduction after 70 day dose interruption gave same magnitudes of clinical response and similar safety profile as before dose interruption. **pJIA, paediatrics 2 years and above:** Treatment beyond 12 weeks reconsidered if no clinical response in that time. **pJIA, paediatrics 2-4 years:** 24 mg/m² body surface area up to 20 mg maximum single dose every other week (see SmPC for height/weight dosing chart). **pJIA, paediatrics 4-12 years:** 24 mg/m² body surface area up to 40 mg maximum single dose every other week (see SmPC for height/weight dosing chart). **pJIA, paediatrics 13 years and above:** 40 mg every other week regardless of body surface area. **ERA, paediatrics 6 years and above:** 24 mg/m² body surface area up to 40 mg maximum single dose every other week (see SmPC for height/weight dosing chart). **AS, nr-axSpA and PsA, adults:** 40 mg every other week. Treatment beyond 12 weeks should be reconsidered if no clinical response in that time. **Psoriasis, adults:** 80 mg induction dose at week 0, 40 mg every other week from week 1. Treatment beyond 16 weeks should be reconsidered if no clinical response in that time. Beyond 16 weeks, patients with inadequate response can increase dosing frequency to 40 mg every week. If adequate response is achieved with an increased dosing frequency, the dose may subsequently be reduced to 40 mg every other week. If there is inadequate response to the increased frequency, carefully reconsider treatment. **Psoriasis, paediatrics 4 years and above:** 0.8 mg/kg body weight (maximum 40 mg/dose) weekly for the first 2 doses then every other week (see SmPC for weight dosing chart). Treatment beyond 16 weeks should be reconsidered if no response in that time. **HS, adults:** 160 mg initially at Day 1 (given as four 40 mg injections in one day or as two 40 mg injections per day for two consecutive

days), followed by 80 mg two weeks later at Day 15 (given as two 40 mg injections in one day). Two weeks later (Day 29) continue with a dose of 40 mg every week. Antibiotics may be continued if necessary. Concomitant topical antiseptic wash on HS lesions should be used on a daily basis. Treatment beyond 12 weeks should be reconsidered in a patient with no improvement in that time. Reintroduction after interruption: 40 mg every week. Evaluate periodically the benefit and risk of continued long-term treatment. **CD, adults:** Induction: 80 mg Week 0 and 40 mg at Week 2. For a more rapid response: 160 mg at Week 0 (either as 4 injections in 1 day or 2 injections/day for 2 consecutive days) and 80 mg at Week 2; risk of adverse events higher during induction. Maintenance: 40 mg every other week. If decrease in clinical response, can increase dose to 40 mg weekly. Corticosteroids may be tapered in maintenance phase in accordance with clinical guidelines. Patients with no response by Week 4 may benefit from continued therapy to Week 12. Treatment beyond 12 weeks should be reconsidered if no clinical response in that time. **CD, paediatrics 6 years and above < 40 kg:** Induction: 40 mg Week 0, 20 mg at Week 2. For a more rapid response: 80 mg Week 0 (2 injections in 1 day), 40 mg at Week 2; risk of adverse events higher during induction. Maintenance: 20 mg every other week. If insufficient response, consider 20 mg every week. Treatment beyond 12 weeks should be reconsidered if no clinical response in that time. **CD, paediatrics 6 years and above > 40 kg:** Induction: 80 mg Week 0, 40 mg at Week 2. For a more rapid response: 160 mg at Week 0 (4 injections in 1 day or 2 injections/day for 2 consecutive days), 80 mg at Week 2; risk of adverse events higher during induction. Maintenance: 40 mg every other week. If insufficient response, consider 40 mg every week. Treatment beyond 12 weeks should be reconsidered if no clinical response in that time. **Uveitis, adults:** 80mg induction dose at week 0, maintenance dose: 40 mg every other week starting at week 1. Treatment can be initiated in combination with corticosteroids and/or with other non-biologic immunomodulatory agents. Concomitant corticosteroids may be tapered in accordance with clinical practice starting two weeks after initiating treatment with Humira. **Contraindications:** Active tuberculosis (TB), severe infections (e.g. sepsis), and opportunistic infections; moderate to severe heart failure (NYHA class III/IV); hypersensitivity to adalimumab or any excipients.

Warnings and precautions: Clearly record trade name and batch number of administered product to improve traceability of biological products. **Infections:** Patients are more susceptible to serious infections especially if impaired lung function. Monitor for infections, including TB, before, during and for 4 months after treatment. Do not initiate treatment with an active infection, until it is controlled. Consider risk/benefit prior to treatment in patients exposed to high risk of TB or endemic mycoses. Evaluate new infections during treatment and monitor closely. Stop treatment if new serious infection or sepsis, and treat appropriately. Exercise caution in patients with a history of recurring infections or who are predisposed to infections. **Serious infections:** Serious infections, including those with hospitalisation or death, reported in patients receiving treatment. **TB:** Consult SmPC for details. Reactivation and new onset TB, both pulmonary and extra-pulmonary (disseminated) reported. Screen all patients before therapy initiation for active or latent TB. If latent TB suspected, consult physician with appropriate expertise and follow local treatment recommendations for prophylaxis prior to initiation of Humira. Despite prophylaxis, TB reactivation has occurred on Humira. If active TB is diagnosed, do not initiate treatment. **Other opportunistic infections:** Opportunistic infections observed in patients receiving Humira. Stop treatment in patients with signs and symptoms of such infections. Consult with physician with appropriate expertise for diagnosis and administration of empiric antifungal therapy in these patients. **Hepatitis B reactivation:** Reactivation has occurred in chronic carriers (surface antigen positive) tested for HBV infection before initiating treatment. HBV carriers should consult a specialist physician and be closely monitored for reactivation of HBV infection throughout therapy and for several months following termination of treatment. If reactivation occurs stop treatment and initiate appropriate anti-viral and supportive treatment. **Neurological events:** Caution in patients with pre-existing or recent-onset central or peripheral nervous system demyelinating disorders. Rare association with new onset or exacerbation of symptoms and/or radiographic evidence of central and peripheral demyelinating disease. Discontinuation of treatment should be considered if any of these disorders develop. Neurologic evaluation should be performed in patients with non-infectious intermediate uveitis prior to initiation of treatment and regularly during treatment, to assess for existing or developing central demyelinating disorders. **Allergic reactions:** Reports of serious allergic reactions including anaphylaxis received. For serious allergic or anaphylactic reaction stop Humira immediately and initiate appropriate therapy. **Malignancies and lymphoproliferative disorders:** A possible risk of malignancy, including lymphomas and leukaemia, in all patients, including

paediatric patients, treated with TNF antagonists. Examine all patients, especially those with a medical history of extensive immunosuppressant or PUVA treatment, for non-melanoma skin cancer prior to and during treatment; caution in COPD patients, and in patients with increased risk for malignancy due to heavy smoking. Consider the potential risk with the combination of AZA or 6-MP and Humira (hepatosplenic T-cell lymphoma has occurred). Risk of hepatosplenic T-cell lymphoma cannot be excluded. Caution in patients with a history of malignancy. Risk of developing dysplasia or colon cancer is unknown. Patients with UC, history of dysplasia or colon carcinoma to be screened for dysplasia before and during treatment. **Haematologic reactions:** Adverse events of the haematologic system reported with Humira. Patients should seek immediate medical attention if signs and symptoms of blood dyscrasias. **Vaccinations:** Patients may receive concurrent vaccinations, except for live vaccines. Bring paediatric patients up to date with all immunisations prior to Humira treatment. **Congestive heart failure:** See contraindications. Caution is advised with mild heart failure (NYHA class I/II). Discontinue treatment for new or worsening symptoms of congestive heart failure. **Autoimmune processes:** Autoimmune antibodies may form. Stop treatment if development of a lupus-like syndrome with positive antibodies against double-stranded DNA. **Surgery:** Consider the long half-life of Humira for planned surgical procedures. Monitor for infections. **Small bowel obstruction:** Failure to respond to treatment for CD may indicate the presence of fixed fibrotic stricture requiring surgical treatment. **Elderly patients:** Serious infections were higher in patients over 65 years of age, some of whom had a fatal outcome. Consider risk of infections. **Interactions:** Combination of adalimumab with other biologic DMARDs (e.g. anakinra and abatacept) or other TNF-antagonists is not recommended. **Fertility, pregnancy and lactation:** Not recommended during pregnancy. Women of childbearing age to use adequate contraception, and continue its use for at least 5 months after the last treatment. Women must not breast feed for at least 5 months after the last treatment. **Side effects:** Very common ≥ 1/10: Infections, leucopenia, anaemia, lipids increased, headache, abdominal pain, nausea and vomiting, elevated liver enzymes, rash (including exfoliative rash), musculoskeletal pain, injection site reaction. Common ≥ 1/100 to < 1/10: skin cancer excluding melanoma (including basal cell carcinoma and squamous cell carcinoma), benign neoplasm, leucocytosis, thrombocytopenia, hypersensitivity, allergies (including seasonal allergy), hypokalaemia, uric acid increased, blood sodium abnormal, hypocalcaemia, hyperglycaemia, hyposphoaphaemia, dehydration, mood alterations (including depression), anxiety, insomnia, paraesthesias, migraine, nerve root

compression, visual impairment, conjunctivitis, blepharitis, eye swelling, vertigo, tachycardia, hypertension, flushing, haematoma, asthma, dyspnoea, cough, GI haemorrhage, dyspepsia, gastroesophageal reflux disease, sicca syndrome, worsening or new onset of psoriasis (including palmoplantar pustular psoriasis), urticaria, bruising (including purpura), dermatitis (including eczema), onychoclasia, hyperhidrosis, alopecia, pruritus, muscle spasms (including blood creatine phosphokinase increased), renal impairment, haematuria, chest pain, oedema, pyrexia, coagulation and bleeding disorders, autoantibody test positive, blood lactate dehydrogenase increased, impaired healing. **Serious, including fatal, side effects have been reported** including infections/sepsis, intestinal perforation, opportunistic infections, TB, endemic mycoses, demyelinating disease, malignancies including lymphoma, (including hepatosplenic T-cell lymphoma), leukaemia and skin cancer (including melanoma and Merkel cell carcinoma), cytopenias, worsening heart failure, myocardial infarction, pulmonary embolism, pleural effusion, pulmonary fibrosis, cerebrovascular accident, interstitial lung disease, Stevens-Johnson syndrome, angioedema, anaphylaxis, sarcoidosis, hepatitis, liver failure and worsening of symptoms of dermatomyositis. **Other less common and rarely reported side effects are listed in the SmPC. Basic NHS price:** £704.28 (for 2 pens or 2 syringes or 2 vials). **Legal category:** POM. **Marketing Authorisation numbers:** EU/1/03/256/001, EU/1/03/256/013, EU/1/03/256/017. **Further information:** available from AbbVie Ltd., Maidenhead, SL6 4UB, United Kingdom. **Date of revision of PI:** July 2016, PI/Humira(combined)/36.

References: 1. Humira Summary of Product Characteristics, AbbVie Limited 2. Mease, P.J. et al Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis. 2005 *Arthritis and Rheumatism*, 52, 3279-3289.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to AbbVieUKadverseevents@abbvie.com

For the Republic of Ireland adverse events should be reported to HPRA Pharmacovigilance, Earlsfort Terrace, Dublin 2. Tel. +353 16764971; Fax +353 16762517; Email medsafety@hpra.ie. Adverse events should also be reported to IRPharmacovigilance@abbvie.com

Date of preparation: June 2016

AXHUD161207

■ Epithelioid Angiosarcoma Arising on the Back of a Young Caucasian Male

A. Kelly, G. Murphy, C. Gulmann. *Beaumont Hospital Dublin.*

Introduction: Epithelioid angiosarcoma is a rare and unique subtype of angiosarcoma in which the malignant endothelial cells have an epithelioid appearance. This subtype can histologically mimic non-vascular malignancies and can make diagnosis extremely challenging. Traditionally, angiosarcoma is a disease of older men, arising on sun-damaged skin often on the scalp and forehead. Epithelioid angiosarcomas have an aggressive clinical course and often demonstrate early nodal and solid organ metastasis thus early recognition and diagnosis is critical. We describe the case of an atypical angiosarcoma in a young man and highlight the importance of rethinking diagnoses and sampling lesions, which are not resolving.

Case: A forty-year-old Caucasian male was sent by his family doctor to the emergency department with a non-resolving and repeatedly infected sebaceous cyst. After incision and drainage of the lesion it was evidently not cystic and he was referred to dermatology.

On examination a 2.5 cm by 2.5 cm wide and 1.5 cm in height, solid, violaceous nodule on the right scapula was seen with an area of surrounding erythema. The lesion was indurated and painful to touch.

Biopsy of the nodule showed an ulcerated poorly differentiated malignant tumor with spindle cells and multiple mitoses. No pigment was seen and the cells stained positive for CD31 and S100. Four mapping biopsies of the surrounding erythema were then performed which showed inflammation and no tumor cells. A staging CT TAP was performed two weeks later that showed by now a 3.4 by 4.2 cm soft tissue mass arising from the subcutaneous tissues in the posterior right supra scapula area.

On review, three weeks post initial presentation the lesion had almost doubled in size, now measuring 5cm by 4.5cm, highlighting the aggressive nature of this tumour.

Following discussion at the skin cancer multidisciplinary meeting, a decision was made to treat with neo-adjuvant radiotherapy followed by excision.

Conclusion: Epithelioid angiosarcoma is a rare tumour, which can mimic benign and other malignant lesions, as a result correct diagnosis can be severely delayed. Despite the diagnostic challenges early detection is essential due to the aggressive nature and poor prognosis associated with this tumour. In this case, the tumour presented mimicking sebaceous cyst, which was not resolving. This case is an excellent description of a rare malignancy and also highlights the importance of rethinking diagnoses and sampling lesions that are not resolving.

■ Abatacept: a novel treatment in severe limited scleroderma and morphoea

S. McCarthy, L. Roche, L. Griffin, N. Leonard, M. Lynch, C. Hackett. *Dermatology Department, University Hospital Limerick. Pathology Department, St James' Hospital, Dublin*

Limited scleroderma and morphoea can have significant morbidity. Early treatment is essential to avoid this. The aetiology of both conditions is poorly understood however new insights into the key role of effector T-cells in scleroderma, in particular Th-17, suggest T-cell directed therapies are expected to have promising effects. We describe four cases and their response to abatacept, a CTLA-4 antibody.

Case 1: A 60-year-old female with a nine-month history of progressive hardening of the skin of the right breast on a background of invasive ductal right breast cancer treated with lumpectomy and radiotherapy. Woody induration of the right breast with an inflammatory violaceous edge was noted and a diagnosis of morphoea profundus was made clinically and on histology. Despite initial reluctance to start immunosuppression, due to her history of malignancy, methotrexate in combination with corticosteroids was commenced due to progression of disease. This failed to control her condition and she was commenced on abatacept, which halted progression.

Case 2: A 40-year-old male with a six-month history of skin tightness of the hands and feet. There was sclerosis, with failure of extension of the hands and feet, and fixed flexion of the neck. A diagnosis of limited scleroderma was made. The patient completed three days of intravenous methylprednisolone therapy followed by a reducing course of steroids and methotrexate. Abatacept was commenced with significant improvement in symptoms.

Case 3: A 58-year-old female with extensive sclerosis of the lumbosacral spine and abdomen and a diagnosis of deep morphoea was made. The patient developed adenocarcinoma of the colon requiring a right hemi-colectomy and radiotherapy. Initial treatment with plaquenil failed and her condition progressed. With much consideration she was commenced her on immunosuppression with corticosteroids, methotrexate, and abatacept with significant improvement.

Case 4: A 65-year-old female presented with skin tightening of the wrists and forearms consistent with severe linear morphoea. Progression was noted and she was commenced on abatacept with excellent response.

Abatacept is a fusion protein of the extracellular domain of CTLA-4 and human IgG1 that binds to the antigen-presenting cell, inhibiting T-cell function and used in the treatment of rheumatoid and juvenile arthritis. Small case series of treatment with abatacept have shown promise in systemic sclerosis with case reports suggesting success in localised scleroderma. We have found abatacept very effective in preventing the progression of sclerosing process in all four cases. It shows promise in the treatment of both systemic sclerosis and localized scleroderma.

■ Subcutaneous Sweet's syndrome in pregnancy

J. Boggs, M. Sabah, M. Redmond, F. Moloney, M. O'Kane. *Connolly Hospital Blanchardstown/Beaumont Hospital. Connolly Hospital Blanchardstown. Beaumont Hospital. Connolly Hospital Blanchardstown/Mater Hospital. Connolly Hospital Blanchardstown/Beaumont Hospital.*

A 31 year old woman at 29 weeks gestation developed a large left breast mass, fever, painful swollen joints and a tender eruption of the skin over a period of 5 days. There was no personal or family history of skin, joint or autoimmune disease. Previous pregnancies were uneventful. She originated from Pakistan, had no foreign travel in 7 months and denied sick contacts or new medications.

On examination she was tachycardic with persistent high grade pyrexia. Tender erythematous subcutaneous nodules and plaques were observed on the limbs with marked swelling of the hands and feet. She had bilateral conjunctival injection, later confirmed as nodular episcleritis. A 10cm firm, non-fluctuant, non-tender mass was palpable in the left breast. Investigations revealed peripheral neutrophilia and elevated inflammatory markers. Broad spectrum antibiotics were commenced for presumed breast abscess with disseminated infection, with no effect on pyrexia, skin, neutrophilia or inflammatory markers over the following 5 days. Breast ultrasound confirmed an irregular mass, suggestive of partially treated abscess or malignancy; 6 core biopsies were performed. Histology revealed a dense acute and chronic mixed inflammatory collection with no evidence of malignancy and negative PAS, Gram and ZN stains. Foetal wellbeing was confirmed by ultrasound. Deep skin biopsy of a limb nodule demonstrated normal epidermis and dermis, with extensive lobular inflammation in the subcutis, comprising a dense neutrophilic infiltrate with microabscesses. No granulomas, giant cells or leucocytoclastic vasculitis were noted; stains for infective organisms were negative. A diagnosis of subcutaneous Sweet's syndrome was made and prednisolone 40mg commenced; fever and tachycardia resolved within 16 hours and pain and swelling of the hands and feet improved over the following 24 hours. The breast mass resolved slowly over the following weeks. A CT TAP and Haematology review postpartum out-ruled malignancy.

Subcutaneous Sweet's syndrome is a rare variant of acute febrile neutrophilic dermatosis in which the pathologic changes are either localised within the adipose tissue only, or involve both the dermis and the subcutaneous fat. Although Sweet's syndrome may rarely be associated with pregnancy, to our knowledge there are no previous reports of subcutaneous Sweet's syndrome in association with pregnancy.

1 Cohen PR. Sweet's syndrome – a comprehensive review of an acute febrile neutrophilic dermatosis. *Orphanet Journal of Rare Diseases* 2007, 2:34

■ Febrile ulceronecrotic Mucha-Habermann disease

Muriel Sadlier, Grainne O'Regan, Fiona Browne. *Department of Dermatology, Our Lady's Children's Hospital Crumlin, Dublin.*

Febrile ulceronecrotic Mucha-Habermann disease (FUMHD) is a rare severe variant of pityriasis lichenoides characterized by the sudden onset of fevers and papulonecrotic skin lesions. We describe a 12-year-old boy who presented with classical pityriasis lichenoides et varioliformis acuta (PLEVA) that rapidly evolved to FUMHD. He presented with a 2-week history of haemorrhagic red-brown papules and plaques, concentrated on the trunk and proximal extremities, that were impetiginized and painful. He was admitted for intensive topical care (paraffin gel, fusidic acid/beclomethasone, potassium permanganate baths) and intravenous antibiotics (flucloxacillin and benzylpenicillin). This resulted in significant reduction in pain and partial resolution of the skin lesions. He was discharged on oral erythromycin.

Three weeks after the initial onset of PLEVA however he developed high fevers (39.5°C) associated with myalgia, malaise, and a confluent lace-like erythematous eruption on his trunk. Flexural accentuation was noted with extensive painful erosions and fissures present in the axillae, groin, and neck. Painful oral ulcers also developed. Inflammatory markers and white cell count were persistently normal. He had a mild and self-limiting transaminitis on both admissions. Serology for EBV IgM, CMV, parvovirus B19, varicella, hepatitis B&C, HIV, and HSV1&2 were negative. Bacterial cultures from impetiginized sites on first presentation grew *E. coli*, but were negative on the subsequent admission. Viral skin cultures were also negative. Sequential histology showed severe interface dermatitis with prominent vacuolar change, necrotic keratinocytes, and parakeratotic scale consistent with PLEVA. His fever settled within 48 hours after administration of intravenous flucloxacillin, benzylpenicillin, and acyclovir. He was commenced on oral methotrexate 15mg/week, and topical steroids were withdrawn. His skin and general condition have improved with no new skin lesions developing.

Pityriasis lichenoides represents a group of uncommon acquired inflammatory skin disorders that include acute (PLEVA, FUMHD) and chronic (PLC) variants. Its aetiology is unknown, although both hypersensitivity to foreign antigens and T-cell dyscrasia have been postulated. FUMHD is a potentially lethal form of PL with mortality rates of up to 25% reported. Children and adolescents tend to have a more favourable prognosis. There is no established standard treatment. Systemic steroids, oral antibiotics (erythromycin, tetracycline), phototherapy, methotrexate, intravenous immunoglobulins, and anti-TNF agents have all been reported to be effective in case reports and small case series.

Reference:

Nofal A, Alakad R, Assaf M, Nofal E. A fatal case of febrile ulceronecrotic Mucha-Habermann disease in a child. *JAAD Case Reports*. 2016;2(2):181-185.

That Enstilar® moment

NEW
Enstilar®
calcipotriol/betamethasone dipropionate
CUTANEOUS FOAM

Discover what the NEW foam spray Enstilar® can do for your plaque psoriasis patients

Extraordinary Delivery

Visit www.enstilar.ie

Abbreviated Prescribing Information for Enstilar® 50 micrograms/g + 0.5 mg/g cutaneous foam Please refer to the full Summary of Product Characteristics (SmPC) (www.medicines.ie) before prescribing.

Indication: Topical treatment of psoriasis vulgaris in adults.

Active ingredients: 50 µg/g calcipotriol (as monohydrate) and 0.5 mg/g betamethasone (as dipropionate).

Dosage and administration: Apply by spraying onto affected area once daily. Recommended treatment period is 4 weeks. The daily maximum dose of Enstilar should not exceed 15 g, i.e. one 60 g can should last for at least 4 days. 15 g corresponds to the amount administered from the can if the actuator is fully depressed for approximately one minute. A two-second application delivers approximately 0.5 g. As a guide, 0.5 g of foam should cover an area of skin roughly corresponding to the surface area of an adult hand. If using other calcipotriol-containing medical products in addition to Enstilar, the total dose of all calcipotriol-containing products should not exceed 15 g per day. Total body surface area treated should not exceed 30%. Safety and efficacy in patients with severe renal insufficiency or severe hepatic disorders have not been evaluated. Safety and efficacy in children below 18 years have not been established. Shake the can for a few seconds before use. Apply by spraying, holding the can at least 3 cm from the skin, in any orientation except horizontally. Spray directly onto each affected skin area and rub in gently. Wash hands after use (unless Enstilar is used to treat the hands) to avoid accidentally spreading to other parts of the body. Avoid application under occlusive dressings since systemic absorption of corticosteroids increases. It is recommended not to take a shower or bath immediately after application.

Contraindications: Hypersensitivity to the active substances or any of the excipients. Erythrodermic and pustular psoriasis. Patients with known disorders of calcium metabolism. Viral (e.g. herpes or varicella) skin lesions, fungal or bacterial skin infections, parasitic infections, skin manifestations in relation to tuberculosis, perioral dermatitis, atrophic skin, striae atrophicae, fragility of skin veins, ichthyosis, acne vulgaris, acne rosacea, rosacea, ulcers and wounds.

Precautions and warnings: Adverse reactions found in connection with systemic corticosteroid treatment, e.g. adrenocortical suppression or impaired glycaemic control of diabetes mellitus, may occur also during

topical corticosteroid treatment due to systemic absorption. Application under occlusive dressings should be avoided since it increases the systemic absorption of corticosteroids. Application on large areas of damaged skin, or on mucous membranes or in skin folds should be avoided since it increases the systemic absorption of corticosteroids. Due to the content of calcipotriol, hypercalcaemia may occur. Serum calcium is normalised when treatment is discontinued. The risk of hypercalcaemia is minimal when the maximum daily dose of Enstilar (15 g) is not exceeded. Enstilar contains a potent group III-steroid and concurrent treatment with other steroids on the same treatment area must be avoided. Skin on the face and genitals are very sensitive to corticosteroids. Enstilar should not be used in these areas. Instruct the patient in the correct use of the product to avoid application and accidental transfer to the face, mouth and eyes. Wash hands after each application to avoid accidental transfer to these areas. When lesions become secondarily infected, they should be treated with antimicrobial therapy. However, if infection worsens, treatment with corticosteroids should be discontinued. When treating psoriasis with topical corticosteroids, there may be a risk of rebound effects when discontinuing treatment. Medical supervision should therefore continue in the post-treatment period. Long-term use of corticosteroids may increase the risk of local and systemic adverse reactions. Treatment should be discontinued in case of adverse reactions related to long-term use of corticosteroid. There is no experience with the use of Enstilar in guttate psoriasis. During Enstilar treatment, physicians are recommended to advise patients to limit or avoid excessive exposure to either natural or artificial sunlight. Topical calcipotriol should be used with UVR only if the physician and patient consider that the potential benefits outweigh the potential risks. Enstilar contains butylhydroxytoluene (E321), which may cause local skin reactions (e.g. contact dermatitis), or irritation to the eyes and mucous membranes.

Pregnancy and lactation: There are no adequate data from the use of Enstilar in pregnant women. Enstilar should only be used during pregnancy when the potential benefit justifies the potential risk. Caution should be exercised when prescribing Enstilar to women who breast-feed. The patient should be instructed not to use Enstilar on the breast when breast-feeding.

Side effects: There are no common adverse reactions based on the clinical studies. The most frequently reported adverse reactions are application site

reactions. Uncommon (≥1/1,000 to <1/100): Folliculitis, hypersensitivity, hypercalcaemia, skin hypopigmentation, rebound effect, application site pruritus, application site irritation. Not known frequency: Hair colour changes. **Calcipotriol:** Adverse reactions include application site reactions, pruritus, skin irritation, burning and stinging sensation, dry skin, erythema, rash, dermatitis, psoriasis aggravated, photosensitivity and hypersensitivity reactions, including very rare cases of angioedema and facial oedema. Systemic effects after topical use may appear very rarely causing hypercalcaemia or hypercalciuria. **Betamethasone (as dipropionate):** Local reactions can occur after topical use, especially during prolonged application, including skin atrophy, telangiectasia, striae, folliculitis, hypertrichosis, perioral dermatitis, allergic contact dermatitis, depigmentation and colloid milium. When treating psoriasis with topical corticosteroids, there may be a risk of generalised pustular psoriasis. Systemic reactions due to topical use of corticosteroids are rare in adults; however, they can be severe. Adrenocortical suppression, cataract, infections, impaired glycaemic control of diabetes mellitus, and increase of intra-ocular pressure can occur, especially after long-term treatment. Systemic reactions occur more frequently when applied under occlusion (plastic, skin folds), when applied on large areas, and during long-term treatment.

Precautions for storage: Do not store above 30°C. Extremely flammable aerosol. Pressurised container. May burst if heated. Protect from sunlight. Do not expose to temperatures exceeding 50°C. Do not pierce or burn, even after use. Do not spray on an open flame or other ignition source. Keep away from sparks/open flames. No smoking.

Legal category: POM.
Marketing authorisation number and holder: PA 1025/5/1. LEO Pharma A/S, Ballerup, Denmark.

Last revised: May 2016

Further information can be found in the Summary of Product Characteristics or from: LEO Pharma, Cashel Road, Dublin 12, Ireland. e-mail: medical-info.ie@leo-pharma.com

© Registered trademark
MAT-04779
Date of preparation: September 2016

Reporting of Suspected Adverse Reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRa Pharmacovigilance, Earlsfort Terrace, Dublin 2, Tel: +353 1 6764971, Fax: +353 1 6762517, Website: www.hpra.ie, e-mail: medsafety@hpra.ie. Adverse events should also be reported to Drug Safety at LEO Pharma by calling +353 1 4908924 or e-mail medical-info.ie@leo-pharma.com

■ Systemic and cutaneous amyloid presenting with palmar bullae

Roche L, Leen E, Quinn J, Keogan M, O’Kane M
Connolly Hospital Blanchardstown, Beaumont Hospital Dublin

A 74-year-old man presented with marked palmar erythema and haemorrhagic bullae on minor trauma, confined to both palms. He described onset of tender, red palms after a day of physical work several weeks previously. Blisters would develop filled with ‘black fluid’ at sites of mild trauma. There was no associated pruritus; skin elsewhere was uninvolved. He was under investigation for myeloma; he had IgG lambda paraproteinaemia (18.8g/L) with immune paresis and serum free light chain ratio of 0:1, lambda>kappa. Bone marrow trephine showed 60% plasma cells. Inflammatory markers were raised. Three serum samples were negative for cryoglobulins.

Examination revealed significant fragility of palmar skin, five circumscribed blood filled bullae were noted on the palmar skin and a sixth appeared as he untied his shoelace. We also noted an atypical pigmented lesion at the right jawline. Perilesional skin biopsies taken from a bulla on the right palm revealed a split in the corneal layer, no inflammatory cell infiltrate and mild epidermal spongiosis, essentially nonspecific. Direct immunofluorescence was grossly abnormal with very bright positivity of IgG and lambda throughout the dermis raising the possibility of a paraprotein. There was clumpy positivity (C3, IgM, fibrin and kappa) along the dermo-epidermal junction and in dermal papillae, suggesting additional deposition of immunoreactants. We suspected myeloma-associated bullous amyloid as a cause of his blistering, however no amyloid was seen on Congo red stain. Since biopsy of the pigmented lesion on the jawline had revealed cytological atypia, further excision was performed some weeks later and Congo red staining was requested on that skin specimen. Histology revealed a junctional melanocytic lesion with Congo red stain highlighting extensive dermal vascular amyloid deposition. When he returned for histology results his palmar blistering had improved on corticosteroids prescribed for his myeloma, however he had developed periocular pinch purpura and subsequent echocardiogram revealed findings typical of cardiac amyloidosis.

Our patient was diagnosed with cutaneous bullous amyloidosis in association with systemic amyloid light chain (AL) amyloidosis on a background of multiple myeloma.

There is considerable variability in the cutaneous manifestations of amyloidosis and bullous lesions are rare. Palmoplantar bullae formation as a presenting feature of systemic amyloidosis has not been previously reported. Diagnosis of cutaneous amyloid can be challenging and ultrastructural methods may be required for confirmation. In this case, amyloid deposition was detected serendipitously on subsequent naevus excision remote from affected skin.

THE AIM IS CLEAR

TARGET IL-17A

Cosentyx®

• The first and only fully human IL-17A inhibitor approved for the treatment of adults with moderate to severe plaque psoriasis and psoriatic arthritis¹

Cosentyx 300mg:

- Demonstrated superior efficacy against both ustekinumab and etanercept up to 52 weeks^{2,3}
 - 79% of psoriasis patients achieved almost clear skin at week 16²
 - Sustained efficacy up to 3 years⁴
- Rapid and sustained relief from joint and skin symptoms of PsA⁵⁻⁷

 **Cosentyx**®
secukinumab

COSENTYX® (SECUKINUMAB) PRESCRIBING INFORMATION. Please refer to the Summary of Product Characteristics before prescribing. **Indication:** Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy; the treatment of active psoriatic arthritis in adult patients, alone or in combination with methotrexate (MTX), when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate. **Presentations:** Cosentyx 150 mg solution for injection in pre-filled syringe; Cosentyx 150 mg solution for injection in pre-filled pen. **Dosage & Method of Administration:** Psoriasis: The recommended dose is 300 mg via subcutaneous injection. Dosing is given at weeks 0, 1, 2 and 3, followed by monthly maintenance dosing starting at Week 4. Each 300 mg dose is given as two subcutaneous injections of 150 mg. If possible, areas of the skin that show psoriasis should be avoided as injection sites. **Psoriatic Arthritis:** For patients with concomitant moderate to severe plaque psoriasis or who are anti-TNF α inadequate responders (IR), the recommended dose is 300 mg by subcutaneous injection with initial dosing at Weeks 0, 1, 2 and 3, followed by monthly maintenance dosing starting at Week 4. Each 300 mg dose is given as two subcutaneous injections of 150 mg. For other patients, the recommended dose is 150 mg by subcutaneous injection with initial dosing at Weeks 0, 1, 2 and 3, followed by monthly maintenance dosing starting at Week 4. Consideration should be given to discontinuing treatment in patients who have shown no response up to 16 weeks of treatment. Some patients with an initial partial response may subsequently improve with continued treatment beyond 16 weeks. Safety and efficacy in patients below the age of 18 years have not been established. **Contraindications:** Severe hypersensitivity reactions to the active substance or to any of the excipients. Clinically important, active infection. **Warnings & Precautions:** Infections: Cosentyx has the potential to increase the risk of infections. In clinical studies, most of these were mild or moderate upper respiratory tract infections such as nasopharyngitis and did not require treatment discontinuation. Nonserious mucocutaneous candida infections were more frequently reported for secukinumab than placebo in the psoriasis clinical studies. Caution in patients with a chronic infection or a history of recurrent infection. Advise patients to seek medical advice if signs or symptoms suggestive of an infection occur. If a patient develops a serious infection, the patient should be closely monitored and Cosentyx should not be administered until the infection resolves. Cosentyx should not be given to patients with active tuberculosis. Anti-tuberculosis therapy should be considered prior to initiation of Cosentyx in patients with latent tuberculosis. **Crohn's disease:** Caution in patients with Crohn's disease - exacerbations of Crohn's disease, in some cases serious, were observed in clinical studies. Patients who are treated with Cosentyx and have Crohn's disease should be followed closely. **Hypersensitivity reactions:** Rare cases of anaphylactic reactions have been observed. If anaphylactic or other serious allergic reactions occur, discontinue immediately and initiate appropriate therapy. **Vaccinations:** Live vaccines should not be given concurrently with Cosentyx. Patients receiving Cosentyx may receive concurrent inactivated or non-live vaccinations. **Latex-Sensitive Individuals:** The removable needle cap of the Cosentyx pre-filled syringe and the pre-filled pen contains a derivative of natural rubber latex. **Concomitant immunosuppressive therapy:** Combination with immunosuppressants, including biologics, or phototherapy - have not been evaluated. **Interactions:** Live vaccines should not be given concomitantly with Cosentyx. No interaction studies have been performed in humans. The formation of some CYP450 enzymes are suppressed by increased levels of cytokines during chronic inflammation. Thus normalisation of CYP450 levels may be anticipated during secukinumab treatment, with accompanying lower exposure of CYP450

metabolised co-medications. Therefore, a clinically relevant effect on CYP450 substrates with a narrow therapeutic index, where the dose is individually adjusted (e.g. warfarin) cannot be excluded. On initiation of secukinumab therapy in patients being treated with these types of medicinal products, therapeutic monitoring should be considered. No interaction was seen when Cosentyx was administered concomitantly with methotrexate and/or corticosteroids in arthritis studies. **Fertility, Pregnancy and Lactation:** *Women of childbearing potential:* Women of childbearing potential should use an effective method of contraception during treatment and for at least 20 weeks after treatment. **Pregnancy:** It is preferable to avoid the use of Cosentyx in pregnancy, due to lack of adequate data. **Breast feeding:** Clinical decision on continuation of breast feeding during secukinumab treatment (and up to 20 weeks after discontinuation) in nursing mothers must be made, taking into account the benefit of breast feeding to the child and the benefit of Cosentyx therapy to the woman. It is not known if secukinumab is excreted in human breast milk. **Fertility:** The effect of secukinumab on human fertility has not been evaluated. **Adverse Events:** *Very Common (>1/10):* Upper respiratory tract infection. *Common (>1/100 to <1/10):* Oral herpes, rhinorrhoea, diarrhoea. *Rare (<1/10,000 to <1/1,000):* Anaphylactic reactions. **Infections:** In the placebo controlled period of clinical studies in plaque psoriasis, infections were reported. The majority of infections consisted of non-serious and mild to moderate upper respiratory tract infections, such as nasopharyngitis, which did not necessitate treatment discontinuation. There was an increase in mucosal or cutaneous candidiasis, but the cases were mild or moderate in severity, non-serious, responsive to standard treatment and did not necessitate treatment discontinuation. Serious infections were reported in a small proportion of patients in both the Cosentyx and placebo groups. Over the entire treatment period (up to 52 weeks), infections were reported in 47.5% of patients treated with Cosentyx (0.9 per patient year of follow up). Serious infections were reported in 1.2% of patients treated with Cosentyx (0.015 per patient years of follow up). Infection rates observed in psoriatic arthritis clinical studies were similar to those observed in the psoriasis studies. **Neutropenia:** Neutropenia was more frequently observed with secukinumab than with placebo, but most cases were mild, transient and reversible. The frequency of neutropenia in psoriatic arthritis is similar to psoriasis. Rare cases of neutropenia CTCAE Grade 4 were reported. **Immunogenicity:** Less than 1% of patients treated with Cosentyx developed antibodies to secukinumab up to 52 weeks of treatment. **Other Adverse Effects:** Please consult the Summary of Product Characteristics for a detailed listing of all adverse events before prescribing. **Legal Category:** POM. **MA Number & List Price:** EU/1/14/980/005 - 150 mg pre-filled pen x 2 £1,218.78; EU/1/14/980/003 - 150 mg pre-filled syringe x 2 £1,218.78. **PI Last Revised:** December 2015 [COS15-C128]. Full prescribing information, including a SmPC is available from: Novartis Pharmaceuticals UK Limited, Frimley Business Park, Frimley, Camberley, Surrey, GU16 7SR. Telephone: (01276) 692255. Fax: (01276) 692508. **References:** 1. Cosentyx Summary of Product Characteristics, April 2016. 2. Blauvelt A et al. Secukinumab demonstrates superior sustained efficacy vs. ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: 52-week results from the CLEAR study. Abstract presented at the 74th Annual Meeting of the American Academy of Dermatology, 2016 March 4-8; Washington DC. 3. Langley RG, et al. N Eng J Med 2014; 371 (4) 326-338. 4. Bissonnette R, et al. Secukinumab maintains high levels of efficacy through three years of treatment. Abstract presented at EADV 2015; 7th-11th October; Copenhagen, Denmark. 5. Kavanaugh A, et al. Ann Rheum Dis 2015;74(S2):345-6. Poster THU0411 at European League Against Rheumatology (EULAR), 10 June, 2015, Rome, Italy. 6. Kavanaugh A, et al. Arthritis Rheum 2015;67(S10):2673. Oral presentation 2146 at the American College of Rheumatology (ACR), 9 November 2015, San Francisco, USA. 7. Mease P & McInnes I. Rheumatology and Therapy, 2016;3:5. doi:10.1007/s40744-016-0031-5. **Date of Preparation:** August 2016. COS16-C143

ADVERSE EVENT REPORTING: Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis Pharmaceuticals UK Ltd on 01276 69 8370 or via medinfo@novartis.com

Poster Presentations - Running Order

P 01. Deeper than a contact reaction...

W Abdelrahman¹, S E Hoey¹, D O'Kane¹

¹ Department of Dermatology, Royal Victoria Hospital, Northern Ireland

P 02. What's behind this rash? A case series of 6 patients with drug-induced subacute lupus erythematosus

Dr Bryan Murphy, Dr Collette McCourt, Dr Donal O'Kane

Royal Victoria Hospital, Grosvenor Road, Belfast, Northern Ireland

P 03. Acute genital swelling heralding C1 esterase inhibitor deficiency in a child.

A. Murad, R. Leahy, P. Lenane.

Department of Dermatology, Children's University Hospital, Temple Street, Dublin. Department of Pediatric Immunology, Children's University Hospital, Temple Street, Dublin.

P 04. A retrospective review on the management of hidradenitis suppurativa

Dr. Rachel Dawson CMT¹ Dr. Wedad Abdelrahman SpR Dermatologist

Dr. Collette McCourt Consultant Dermatologist Belfast City Hospital, Dermatology Department.

P 05. Springing up in two shakes of a lamb's tail

E Nic Dhonncha,¹ J Clowry,¹ M Donnelly,² S Field¹

Departments of ¹Dermatology and ²Otolaryngology, University Hospital Waterford

P 06. Acute generalised exanthematous pustulosis presenting without pustules: A variant revealed on biopsy.

S. McCarthy, L. Griffin, L. Roche, S. Ryan, M. Lynch, C. Hackett.

Dermatology Department, University Hospital Limerick

P 07. A case of multicentric reticulohistiocytosis

A. Flynn, AM. Tobin, R. Mullan, M. Connolly.

Adelaide and Meath Hospital, Tallaght

P 08. Airborne contact urticaria resulting from occupational exposure to sodium benzoate

R. O'Connor, S. McCarthy, J. Bourke, M. Murphy.

SIVUH Cork

P 09. Omalizumab: A New Therapeutic Option for Aquagenic Pruritus

R. O'Connor, S. McCarthy, J. Bourke, M. Murphy.

SIVUH Cork

P 10. AN AUDIT OF TRANSPLANT CLINICS 2014

Dr R Brennan, Dr S Clements and Dr A Corry

Royal Victoria Hospital, Belfast.

P 11. Challenges in Triaging Paediatric Acne Vulgaris Referrals to a Secondary Care Dermatology Department

Gillhooley E, Collins S.

Our Lady of Lourdes Hospital, Drogheda, Co Louth.

P 12. Sweet's Syndrome presenting in IBD, a rarity?

L. Nestor, J. Clowry, M. Connolly, A. Salim, AM. Tobin

Tallaght Hospital, Dublin

P 13. Unilateral hyperhidrosis as a presenting symptom in Ross' syndrome

I. Timoney, L. Timoney, C. Lane, A. Liew.

University Hospital Galway

P 14. Paediatric psoriasis is associated with multiple comorbidities and impaired quality of life

L Griffin, A Grogan, L Roche, S McCarthy, M Lynch, K Ahmad, C Hackett, B Ramsay.

Department of Dermatology, University Hospital Limerick.

P 15. Audit of Cutaneous Allergy Service in a Regional Dermatology Department

A. Havelin, P. Marren.

Department of Dermatology, University Hospital Galway

P 16. Recalcitrant cutaneous sarcoidosis, with response to daylight photodynamic therapy.

Conor Broderick¹, Catherine Quinlan¹, Christian Gulmann¹, Marina O'Kane¹

Poster Presentations

■ Deeper than a contact reaction...

W Abdelrahman¹, S E Hoey¹, D O'Kane¹

¹ Department of Dermatology, Royal Victoria Hospital, Northern Ireland

Pyoderma gangrenosum (PG) is a rare inflammatory neutrophilic dermatosis that is often misdiagnosed. It is uncommon in infants and children accounting for only 4% of cases (1).

A one year old male in-patient in paediatric ICU ventilated for bronchopneumonia was referred with areas of ulceration on his neck and axilla. These corresponded to sites of recent removal of central and arterial lines. The working diagnosis from the referring doctors was a contact allergic dermatitis to the dressing used to secure the lines. He had a complicated past medical history including chromosomal duplication disorder and visual impairment. On examination he had areas of deep ulceration with a violaceous undermined border in keeping with the classical appearance of PG. This was supported by a skin biopsy which showed a neutrophilic infiltrate both in the deeper dermis and subcutaneous fat particularly at the edge of the biopsy; the epidermis was intact. Topical clobetasol propionate was commenced and a dramatic improvement was noted within 24 hours. The central line was re-sited to the left side and a few days later a similar lesion appeared, again with a good response to topical therapy. Blood results showed a markedly elevated WCC 29.7- a differential WCC showed toxic granulation in neutrophils with myeloid left shift; immunoglobulins showed an elevated IgG 23 and IgA 4.86. The elevated WCC made us consider a possible leukaemic trigger, however, with treatment of the underlying infection, the patient's WCC settled. Furthermore, 1 month later he was re-admitted with pneumonia requiring IV antibiotics but fortunately did not develop any further lesions.

PG in children is more likely to have an atypical distribution involving the head and neck (26.6%) or buttocks (15%), and in a similar fashion to adults, it is also associated with systemic illness such as ulcerative colitis, leukaemia, Crohn's disease, IgA deficiency. Another interesting feature in this case is the presence of pathergy. Pathergy is a term used to describe the induction or exacerbation of PG at sites of iatrogenic or incidental trauma. It is seen in 31% of patients with PG.

In summary, we present this case with classic features of PG in an uncommon age group.

References:

(1) Graham JA, Hansen KK, Rabinowitz LG, Esterly NB. Pyoderma gangrenosum in infants and children. Paediatric Dermatology. 1994;11(1):10-7.

■ What's behind this rash? A case series of 6 patients with drug-induced subacute lupus erythematosus

Dr Bryan Murphy, Dr Collette McCourt, Dr Donal O'Kane

Royal Victoria Hospital, Grosvenor Road, Belfast, Northern Ireland

Introduction: Drug induced subacute lupus (DISCLE) is thought to be one of the commonest forms of drug induced lupus. The number of medications recognised to cause it is certainly increas-

ing but frequently reported culprits include anti-hypertensives, proton-pump inhibitors and anti-fungals. Considering medications as a trigger and stopping offending drugs could prevent a patient from a prolonged rash and potentially toxic treatments, however, it is difficult to differentiate between drug induced and idiopathic subacute lupus given their similar clinical, histological and autoantibody profiles. Frequent polypharmacy, particularly in older patients, with multiple potential DISCLE-inducing medications causes further confusion for clinicians.

Methods: As part of a departmental retrospective review of our cutaneous lupus patients we identified six who developed DISCLE which cleared when the offending drugs were stopped.

Results: Our six patients developed classical scaling, annular/polycyclical rash affecting photosensitive sites. All had biopsies for histology, showing interface dermatitis, and 5 had immunofluorescence. 5/6 were anti-Ro positive. Medication histories revealed Lansoprazole, Naproxen, Capcitabine, Anastrozole and recent Terbinafine use in two patients; one of the latter was also prescribed Naproxen in preceding months. All such drugs were stopped and gradual clearance of rashes was observed, alongside transient use of topical, in all, and oral steroids in one. Photographs are available for 3 of these cases.

Discussion: This review highlights the importance of a careful drug history in managing new subacute lupus patients and demonstrates the resolution of rash following cessation of triggering medication. Our cases were similar to previously reported drug classes; however, we found only 6 other examples of Capcitabine and 1 of Anastrozole DISCLE thus adding further robust evidence for their potential culpability in subacute lupus.

Conclusion: Management can be simplified for this group of patients by readily identifying a drug trigger, stopping it, and perhaps short-term use of topical or oral steroids. We agree that more persistent or difficult-to-treat cases may actually present a case of idiopathic lupus being exacerbated by a drug.

Acute genital swelling heralding C1 esterase inhibitor deficiency in a child.

A. Murad, R. Leahy, P. Lenane.

Department of Dermatology, Children's University Hospital, Temple Street, Dublin. Department of Pediatric Immunology, Children's University Hospital, Temple Street, Dublin.

A healthy 5-year-old presented to the emergency department with acute genital swelling. He had a history of joint swelling treated as presumed septic arthritis which resolved a few days later. He had mild atopic dermatitis and asthma. He had no relevant family history. Examination revealed profound non-pitting oedema of the penile shaft and foreskin with partial narrowing of the distal urethral meatus. His full blood count, routine biochemistry and inflammatory markers were all normal or negative. His genital swelling subsided slightly a few hours later. A provisional diagnosis of angioedema was made based on his clinical presentation and preliminary investigation results. His remaining investigation results showed a reduced C4 level, C1

esterase inhibitor level and functional C1 esterase inhibitor activity. A diagnosis of type 1 hereditary angioedema (HAE), most likely arising de novo was made. He was treated with tranexamic acid (50mg/kg/day) which has resulted in less severe and infrequent episodes.

Angioedema is a localised and self-limiting soft tissue swelling as a result of transient increase in vascular permeability which is either mediated by mast cell or bradykinin. HAE most commonly affects the skin on the extremities with the onset of symptoms usually in childhood. A child presenting with acute genital swelling could pose a diagnostic challenge to clinicians. Other causes of genital swelling reported in childhood included cellulitis, idiopathic lymphoedema, metastatic Crohn's, juvenile dermatomyositis and fixed drug eruptions. Non-cutaneous involvement of HAE such as the gastrointestinal tract, brain, kidney and pancreas often causes a delay in the diagnosis. The 2 most common types of HAE are type 1, with reduced C1 esterase inhibitor (C1-INH) protein and functional levels and type 2 HAE with normal C1-INH protein levels but reduced C1-INH functional levels.

The treatment strategy of HAE should include management of acute attacks and prophylaxis. It is a bradykinin-mediated angioedema which does not improve with antihistamines, glucocorticoids or epinephrine. Approved therapies for paediatric patients are limited but recent studies support the use of self administered plasma derived C1-INH at home. Tranexamic acid and attenuated androgens have been used as long term prophylaxis with some benefit in symptom control. C1-inhibitor concentrates, higher doses of tranexamic acid or attenuated androgens have been recommended for short term prophylaxis.

■ A retrospective review on the management of hidradenitis suppurativa

Dr. Rachel Dawson CMT¹ Dr. Wedad Abdelrahman SpR Dermatology

Dr. Collette McCourt Consultant Dermatologist

Belfast City Hospital, Dermatology Department.

Background: Hidradenitis suppurativa (HS) is a chronic inflammatory disease characterised by abscesses and nodules developing into sinuses with scarring and contractures in severe cases. It can be debilitating and psychologically distressing, greatly impacting on quality of life. There is a lack of published guidelines on HS. This review was designed to assess current management in the Belfast Trust.

Methods: A retrospective review of both paper and electronic charts was performed on 33 patients including five on biological therapy over one year. Hospital numbers were retrieved from the coding department in Royal Victoria Hospital.

Results: Seventy-five percent of patients were female with disease duration ranging from <1 to >20 years. Co-morbidities documented included; obesity (45%), Crohn's disease (15%) and diabetes (3%). Eighty percent received weight reduction advice, 48% smoking cessation advice and 39% received British Association of Dermatologist's patient information leaflet on HS. 61% had at least one cardiovascular risk factor. The most common site of involvement was the axilla (70%), groin (61%) and submammary regions (15%). Only 2 patients had a Hurley stage documented. Tetracyclines were used as first line in 60%

of cases whilst Rifampicin/Clindamycin combination was used as second line in 21%. Thirteen percent received oral retinoids, a better response was noted with 6-9 month duration of treatment. Twenty percent of patients received dapsone with good effect. Six percent received oral immunosuppressants - One patient used methotrexate in addition to infliximab with good effect, one patient used ciclosporin at 3mg/kg with good response, 5 patients required biological treatment, with 3 cases required combination with another agent including doxycycline, acitretin and methotrexate. All 5 patients had a DLQI >10 and Hurley stage 3 disease.

Discussion: The management parallels the findings of a survey performed on UK dermatologists' management of HS published in 2015. Improvement in documentation of severity assessment, DLQI, weight reduction/ smoking cessation advice, as well as providing information leaflets is needed. Association with cardiovascular disease is recognised in HS and as such a risk assessment for modifiable cardiovascular risk factors should be undertaken in all patients. A checklist has been designed to improve future documentation. Up to date guidelines on the management of HS are awaited.

References

1. Management of Hidradenitis suppurativa: a U.K. survey of current practice. Ingram, R et al Br J Dermatol. 2015 Oct;173(4):1070-2

■ Springing up in two shakes of a lamb's tail

E Nic Dhonncha,¹ J Clowry,¹ M Donnelly,² S Field¹

Departments of ¹Dermatology and ²Otolaryngology, University Hospital Waterford

A 56-year-old farmer presented to ENT and was referred for a dermatology opinion that day following ENT review. He had a 2-week history of a rapidly enlarging lesion on his nose at a site of recent trauma. He denied any associated pruritus or pain. He was systemically well. He had no past medical or dermatological history of note, and took no regular medications. On examination he had a well demarcated, crusted, exophytic, firm, non-tender, nodule on the right side of his nose measuring 2cm, with surrounding cellulitis extending to involve 80% of his nose. An incisional punch biopsy was taken which showed hyperkeratosis with eosinophilic cytoplasmic inclusions, probably representative of viral inclusions, suggestive of orf. The surrounding cellulitis responded rapidly to a one-week course of oral flucloxacillin and co-amoxiclav. With conservative management only, the lesion had significantly reduced in size within 3 weeks, and had completely resolved within 10 weeks.

Orf is a zoonotic parapoxvirus that is endemic in sheep and goats worldwide. Transmission to humans occurs when abraded skin comes into contact with infected animals or contaminated objects. Orf is most common during spring and summer months, co-occurring with lambing season. The true prevalence of orf infection is almost certainly underestimated, as it is a self-limiting condition and can be easily recognised by people at risk who do not always seek medical care. Orf typically occurs on the fingers and hands. Rarely, as in our case, the disease presents on the face. The main differential diagnosis in our case was a very rapidly growing squamous cell carcinoma, an excision of which would have required extensive surgery. Histologically, orf is char-

acterised by the appearance of hyperkeratosis and eosinophilic inclusion bodies in the cytoplasm of vacuolated epidermal cells in the upper epidermis. The disease course consists of 6 clinical stages each lasting approximately 1 week. Orf is usually self-limiting and no specific treatment is indicated. The natural history of the disease in an immunocompetent patient is spontaneous resolution without scarring within 4-6 weeks. Reported complications include secondary bacterial infection, erythema multiforme or lymphangitis.

Taking an accurate history and having high index of suspicion are both crucial for diagnosing orf. Awareness of orf at unusual sites is important to allow for prompt diagnosis of this benign condition, and avoidance of over treatment.

References:

1. Diven DG. An overview of poxviruses. *J Am Acad Dermatol* 2001; 44(1):1-16

■ Acute generalised exanthematous pustulosis presenting without pustules: A variant revealed on biopsy.

S. McCarthy, L. Griffin, L. Roche, S. Ryan, M. Lynch, C. Hackett. Dermatology Department, University Hospital Limerick

Acute generalized exanthematous pustulosis (AGEP) is a severe cutaneous adverse reaction (SCAR) that presents with the simultaneous development of a high-grade fever and erythematous plaques and papules studded with numerous pinpoint pustules following administration of a medication. AGEP is often diagnosed clinically, and confirmed on biopsy, as the appearance of these small sterile pustules is characteristic. We present two cases of AGEP who failed to develop clinically evident pustules, with the diagnosis made on biopsy, and one case of delayed onset of pustulosis.

An 83-year old female was referred to dermatology with a widespread erythematous rash of the trunk and limbs. She was admitted with an NSTEMI and had sustained a fractured left hip following a fall at home. During the course of her treatment she had received teicoplanin, ceftriaxone and metronidazole. She had erythema of the trunk and limbs with vesiculation at the flanks with epidermal detachment. Nikolsky sign was positive and no pustules were noted. Clinically a diagnosis of toxic epidermal necrolysis (TEN) was suspected and a biopsy was undertaken. The patient responded readily to conservative measures and her histology suggested AGEP, with no evidence of epidermal necrosis.

An 84-year old male was referred with a six-week history of an erythematous eczematous rash of the trunk and limbs on a background of progressive pro-lymphocytic leukaemia. His treatment included idealisib, a phosphoinositide 3-kinase inhibitor, and rituximab, which were stopped three months later due to progression of the rash. He presented with widespread macular erythema without pustules. Histology showed a large subcorneal pustule and dermal oedema confirming a diagnosis of AGEP, likely secondary to idealisib.

An 86-year old male was reviewed with a five-day history of a widespread erythematous rash of the trunk and limbs with epidermal detachment and no pustules. The patient was recently treated with five days of flucloxacillin for an infected sacral pressure ulcer. A clinical diagnosis of toxic epidermal necrolysis was

made and a biopsy was undertaken. Four days after admission the patient developed widespread pustules over 90% of the body surface area. The biopsy confirmed subcorneal pustule formation and neutrophil polymorphs in the upper dermis in keeping with AGEP. The patient died of sepsis.

Cases of TEN-like AGEP have been described in the literature, with absence of the characteristic pustules. Furthermore, confluent pustules may mimic the bullae formation of TEN. We describe these atypical cases to demonstrate the spectrum of presentations of AGEP.

■ A case of multicentric reticulohistiocytosis

A. Flynn, AM. Tobin, R. Mullan, M. Connolly. Adelaide and Meath Hospital, Tallaght

A 62-year-old Caucasian female was admitted to hospital under the general medical team with a 3-month history of weight loss, fatigue and joint pain. Haematological investigations demonstrated an iron deficiency anaemia. She had significant lower limb oedema with an associated albumin level of 17 g/l (35-50). Erythrocyte sedimentation rate (ESR) was elevated at 17 mm/hr (1-15). Rheumatoid factor, anti-cyclic citrullinated peptide, anti-nuclear antibody and anti-neutrophilic cytoplasmic antibody were all negative. She underwent multiple investigations including a CT thorax abdomen pelvis, colonoscopy, capsule endoscopy and bone marrow biopsy, all of which were normal. X-rays of her hands demonstrated a bilateral erosive arthropathy.

On examination it was noted she had papules and nodules over her metacarpal and elbow joints. A right knee aspirate demonstrated macrophages, lymphocytes, neutrophils and scant negatively birefringent crystals. Given the atypical appearance of the papules and nodules, dermatology were consulted.

Full skin examination demonstrated non-tender pink and fleshy coloured papules on the distal aspect of her fingers and encircling her right helical rim. There were firm pink nodules on the extensor surface of her left elbow, as well as mild periungual telangiectasia along her fingernails. There was no palpable lymphadenopathy. Biopsies from both a papule and nodule were performed.

Histopathological examination showed a prominent dermal-based histiocytic lesion comprised of histiocytic cells with abundant eosinophilic cytoplasm. There was no significant associated lymphocytic or plasma cell infiltrate, neutrophilic component or granulomas seen. The lesional cells expressed CD68 and melan A. CD1a, S100 or HMB45 were all negative, consistent with the diagnosis of multicentric reticulohistiocytosis (MRH).

Reticulohistiocytoses are a rare group of non-langerhans cell histiocytoses. MRH is an aggressive systemic condition primarily affecting the skin and joints. It typically presents with a symmetrical erosive polyarthritides and cutaneous papules. There is a predominance in middle-aged Caucasian females. Internal organs are rarely affected, however up to 30% of cases are associated with internal malignancy. The condition may rapidly progress to cause a destructive arthritis, leaving patients crippled with significant joint pain and deformity. There may be associated constitutional symptoms including fever, malaise and weight loss, as well as anaemia and raised ESR.

Different treatments have been reported including methotrexate, prednisolone, cyclosporine, azathioprine and bisphosphonates. Non-steroidal anti-inflammatory drugs can be useful for associated arthritis. A review published in 2016 concluded that methotrexate was the most effective initial treatment. Anti-TNF agents have recently been reported as effective.

■ Airborne contact urticaria resulting from occupational exposure to sodium benzoate

R. O'Connor, S. McCarthy, J. Bourke, M. Murphy. SIVUH Cork

A 32-year old gentleman presented to the dermatology department with a history of transient erythema and burning of his face while working on a new process at work introduced a few months previously. He was employed as a process operator at a pharmaceutical plant for three years and recently started a new role within the plant. He was sieving sodium benzoate while wearing a hairnet, mask and nitrile gloves. The environment was quiet dusty. One morning shortly after starting the procedure he became hot and red and quickly moved outside. His face and neck became red and he attended the general practitioner. The reaction settled over an hour and half. No other staff members were affected but the process was only new in the company and only carried out every few months. An urticarial reaction to sodium benzoate was diagnosed on clinical grounds. Other workers were also at risk of developing a similar reaction and we recommended full protective PPE, an enclosed method for carrying out the procedure and improved ventilation of the area. There have been no reported problems since that time.

There is only one report of a similar reaction from the US, also in a pharmaceutical plant, where three workers exposed to airborne contact with sodium benzoate developed transient urticaria (Nethercott JR, Lawrence MJ, Roy AM, Gibson BL, Airborne contact urticaria due to sodium benzoate in a pharmaceutical manufacturing plant, *J Occup Med.* 1984 Oct;26(10):734-6)

■ Omalizumab: A New Therapeutic Option for Aquagenic Pruritus

R. O'Connor, S. McCarthy, J. Bourke, M. Murphy. SIVUH Cork

Aquagenic pruritus is a rare skin condition characterised by intense itch, burning or stinging sensation after contact with water without visible skin changes. The pathogenesis is unknown. Anti-histamines are the mainstay of treatment but other reported therapeutic options include phototherapy and immunosuppression.

A 57-year-old male patient presented with a 10-year history of generalised pruritus that was precipitated by contact with water. The itch started immediately after showering. It severely impacted on his activities of daily living and he was unable to wash or swim. It was not associated with urticarial wheals or skin changes. His medical history included multiple sclerosis, depression, hypertension and mild psoriasis. He was systemically well and investigations revealed a normal haemoglobin, B12, folate, ferritin, renal and liver profile. Coeliac screen was also negative. Previous treatment included antihistamines to which he reported

an initial partial response but then lost effectiveness. Given his history of intractable itch triggered by contact with water, a modified itch provocation test was performed which was positive and a diagnosis of aquagenic pruritus was made. He was initially treated with ketotifen 1mg OD and montelukast was added with no improvement in symptoms. He was subsequently treated with narrowband UVB and completed 26 exposures. He reported an initial improvement in pruritus on phototherapy but as treatment was weaned to once weekly his symptoms relapsed. As the pruritus was having a very significant impact on his quality of life we commenced him on ciclosporin 100mg BD, which after one month was further increased to 150mg BD. Within two months of commencing treatment with ciclosporin his pruritus was markedly improved and he remained itch free while on treatment. However, he developed severe hypertension which necessitated discontinuation of ciclosporin. His intense pruritus reoccurred which was unresponsive to high dose antihistamines. He was commenced on omalizumab 300mg subcutaneously every four weeks. Visual analogue scale for pruritus was performed before and after starting treatment with omalizumab and he reported resolution of his symptoms within 2 weeks of the initial dose. He is tolerating the medication well with no adverse events and his aquagenic pruritus remains in remission.

We report the first case of aquagenic pruritus refractory to conventional therapies that was successfully treated with omalizumab.

■ AN AUDIT OF TRANSPLANT CLINICS 2014

Dr R Brennan, Dr S Clements and Dr A Corry. Royal Victoria Hospital, Belfast.

Background: Post-transplant patients are known to have 50-100x increased risk of developing SCC compared to the normal population. In addition, skin tumours are often multiple and may behave more aggressively.¹ Harwood et al. noted a cumulative incidence of NMSC at 5, 10, 20 and 30 years of 11%, 25%, 54% and 74% respectively in post-transplant patients.² Statistically significant risk factors include skin phototype, ultraviolet radiation exposure, age at transplant and the duration of transplant. Specialist dermatology clinics for organ transplant recipients have been shown to significantly improve compliance with photoprotection and levels of skin cancer awareness.³ Therefore, a new dermatology service was initiated in the Belfast City Hospital in 2013 specifically for immunosuppressed transplant patients with a background of skin cancer. The new clinics were developed due to a large cohort of renal transplant patients in the general dermatology clinics who had complex skin cancer management requirements.


Aims: To improve the quality of care for patients including:

- Education of their risk and of precautions instituted for prevention of skin cancer
- Early and successful management of pre-malignant lesions
- Early diagnosis and treatment of skin cancers, comparing standards outlined in NHS cancer care guidelines 2007

Methods: Retrospective audit of 33 patients on immunosuppression who attended a transplant clinic in 2014.

Nourish and protect sensitive baby skin

Formulated with natural oatmeal



Aveeno
Baby®
Naturally Beautiful Babies

Results:

- Average length of time on immunosuppression = 19.8 years
- Average age of patient = 61.6 years
- 73% had previous skin cancer (BCC/SCC/MM)
- 73% prescribed vitamin D
- 76% patients received appropriate information leaflets
- 63% patients had AK
- 39% had Bowens
- 42% patients had new diagnosis of skin cancer
- 18% had BCC all treated with excision, 83% within 62 days
- 27% had SCC, 13 T1a, 6 T2a and 1 T4
- 95% SCCs excised within 62 days
- 62% skin cancers excised on same day

Conclusion/ Recommendations:

- Majority of skin cancers (62%) excised on same day.
- 95% of SCCs excised within 62 days.
- Audit findings highlight the need to improve advice and prescription of sun protection, provision of PILs and monitoring/prescription of vitamin D.
- ? role for a specific key worker to help coordinate more complex skin cancer patients

References

1. Skin cancers after organ transplantation. Euvrard S et al. N Engl J Med. 2003;348:1681-91
2. A Surveillance Model for Skin Cancer in Organ Transplant Recipients: A 22-Year Prospective Study in an Ethnically Diverse Population C. A. Harwood et al. American Journal of Transplantation Vol13 Issue 1 p119-129 January 2013
3. Specialist dermatology clinics for organ transplant recipients significantly improve compliance with photoprotection and levels of skin cancer awareness. Ismail F1 et al. 2006 Nov;15(5):916-25

■ Challenges in Triaging Paediatric Acne Vulgaris Referrals to a Secondary Care Dermatology Department

Gilhooley E, Collins S.

Our Lady of Lourdes Hospital, Drogheda, Co Louth.

Acne vulgaris is a common inflammatory skin condition affecting up to 90% of teenagers. The psychological impact of acne is subjective and often considerable. Dermatology services nationally are under resourced and subject to long delays in access, currently up to 15 months for paediatric referrals to our institution. Waiting list management can be enhanced by improving appropriateness of referrals and with the inclusion of clinical information relevant for triage. The AAD and EADV have recently issued or updated existing acne management guidelines that provide evidence based referral guidelines for clinical practice (1). In order to identify measures to improve access we analysed our paediatric acne referrals designated as routine, for documentation of first line/primary care management. We examined the inclusion of information necessary for appropriate triage. Over a 6-month period a total of 464 paediatric referrals were triaged as routine. 7% (34/464) of referrals were made in relation to acne. 29% (9/34) included information on severity/presence of scarring while 9% detailed psychological impact. Regarding documentation of therapies commenced in primary care, topical agents were listed in 62% of referrals (21/34). The most com-

monly used were combination topical retinoid and antibiotic products (41%), topical retinoid (26%), monotherapy with topical antibiotic (21%) and benzoyl peroxide in 9%. Dermatology input was requested following a single oral antibiotic in 68% and further to two courses in 12%. Duration of antibiotic course was detailed in 9% of referrals (3/34).

Discussion: Current acne guidelines recommend avoiding antibiotic monotherapy, limitation of oral antibiotic therapy duration and the use of concomitant topical retinoids. Monotherapy with topical and oral antibiotics was commonly practiced while topical retinoids were prescribed in a quarter of patients. Appropriateness of referral for isotretinoin was difficult to determine as less than a third recorded an assessment of severity, scarring and details of antibiotic usage. Details of psychological impact were found in less than 10%.

Conclusion: In the setting of delayed access and increasing referrals from primary care to secondary paediatric dermatology services, the inclusion of relevant triage information is fundamental in ensuring services are accessed by clinical priority. Algorithms for management, referral criteria and pathways have the potential to reduce unnecessary referrals and improve patient care. National educational initiatives to promote internationally accepted acne clinical care pathways and referral criteria are required.

- 1) Guidelines of care for the management of acne vulgaris. Zaenglein AL et al. J Am Acad Dermatol. 2016 May;74(5):945-73.e33. doi:10.1016/j.jaad.2015.12.037.

■ Sweet's Syndrome presenting in IBD, a rarity?

L. Nestor, J. Clowry, M. Connolly, A. Salim, AM. Tobin Tallaght Hospital, Dublin

Background: Almost one third of patients with Inflammatory Bowel Disease will suffer dermatological complications. Sweet's syndrome has been described as a rare extra intestinal manifestation of Crohn's Disease. This was first described in 1964 by Robert Douglas Sweet in the British Journal of Dermatology as an acute febrile neutrophilic dermatosis, its eponym, Gomm Button disease. It is characterized by the acute onset of fever, neutrophilia and tender erythematous skin lesions (papules, nodules, and plaques) predominantly affecting the upper extremities, face and neck. In addition to painful and oedematous nodules and plaques, vesicles, bullae, or pustules may also be present. Regardless of the aetiology, typical histopathological findings include a diffuse infiltrate consisting predominantly of mature neutrophils located in the upper dermis. We present a case series of patients presenting with Sweet's syndrome on a background of inflammatory bowel disease.

Methods: We retrospectively collected data on our adult patients with Sweet's Syndrome presenting on a background of IBD (both Crohn's Disease and Ulcerative Colitis) who attended our dermatology and gastroenterology service by means of chart review. Clinical photography was also carried out with informed consent.

Conclusions: Although Sweet's syndrome occurring in IBD has been described as a rare extra intestinal manifestation of IBD we found this to be a relatively common presentation to our service. In addition, Sweet's Syndrome has been described as occurring

more frequently in patients with Crohn's Disease, however, in our series Sweet's Syndrome was equally as common in both UC and CD. Overall there was a notable female predominance. In all but one of our patients, IBD was quiescent at the time of onset of Sweet's Syndrome. One case was attributed to treatment with Azathioprine, an important entity in Sweet's Syndrome occurring in IBD. Overall, this case series highlights the importance of a multidisciplinary approach in treating patients with Sweet's Syndrome occurring in the setting of IBD. With prompt diagnosis and management, Sweet's Syndrome responds well to intensification of immunosuppression, with some patients requiring only topical corticosteroid agents. Overall our case series outlines the most common presenting features of Sweet's Syndrome in IBD and also that most patients present with Sweet's Syndrome in the setting of established IBD, however, one must have a low threshold for screening for underlying IBD in all patients with Sweet's syndrome.

■ Unilateral hyperhidrosis as a presenting symptom in Ross' syndrome

*I. Timoney, L. Timoney, C. Lane, A. Liew.
University Hospital Galway*

A 50 year old woman was referred by her G.P with a three year history of hyperhidrosis, confined to her right hand side. Symptoms were progressing and significantly impacting her quality of life. Hyperhidrosis occurred at ambient temperatures and was exacerbated by minimal exertion, increase in temperature and anxiety. It was unilateral and segmental. Skin in unaffected areas was anhidrotic. Previous trials of beta-blockers and clonidine had been unsuccessful in ameliorating her condition. She had no other symptoms of autonomic dysfunction.

The patient was seen previously in the ophthalmology department having been referred with incidentally-noted anisocoria. She was diagnosed with bilateral Adie's pupils (confirmed with denervation hypersensitivity to pilocarpine) and had been discharged. She had no other significant past medical history.

On full skin examination, hyperhidrosis was noted in the right face and neck, right flank and right lower limb with these areas being notably moist to touch. Remaining skin was anhidrotic. Ophthalmological examination showed slow pupillary reaction to light, with normal reaction to accommodation. Neurological examination demonstrated loss of deep tendon reflexes.

Investigations revealed urinary and plasma catecholamines/metanephrines, thyroid function tests, cortisol, urinary 5-hydroxyindoleacetic acid, C reactive protein and lactate dehydrogenase were all within normal limits. Follicle-stimulating hormone and luteinising hormone indicated the patient was peri-menopausal. CT Brain and MRI Brain were normal.

The unilateral, segmental hyperhidrosis coupled with the bilateral tonic pupils and deep tendon reflex loss led to a diagnosis of Ross syndrome. The patient was referred to the dermatology department for further management.

Discussion: Ross syndrome is a rare dysautonomic syndrome characterised by a triad of: unilateral or bilateral anhidrosis,

deep tendon hypo- or areflexia and Adie's tonic pupil/pupils- which typically show slow reaction to light, but normal response to accommodation. One of the most common presenting and troubling symptoms is segmental compensatory hyperhidrosis. The exact mechanism is unknown, however it has been postulated that peripheral autonomic nervous system degeneration may be contributory. Since first described in 1958, as few as 50 cases of Ross syndrome have been reported in the literature. Patients typically present to neurology and dermatology. The aim of management is to control disabling hyperhidrosis with a range of treatment strategies including medications (clonazepam, propantheline), iontophoresis, botulinum toxin and endoscopic thoracic sympathectomy having been tried with varying results.

■ Paediatric psoriasis is associated with multiple co-morbidities and impaired quality of life

*L Griffin, A Grogan, L Roche, S McCarthy, M Lynch, K Ahmad, C Hackett, B Ramsay.
Department of Dermatology, University Hospital Limerick.*

Introduction: Considerable advances in therapy and knowledge of associated co morbidities of adult psoriasis have occurred over the last 2 decades yet a paucity of studies exists for paediatric disease. Psoriasis is a chronic inflammatory condition that is typically described as having bimodal onset with the first peak between ages 16 and 22 and the second between 57 and 62 years. Childhood disease is considered to have an irregular disease course with a tendency to be difficult to treat. Experiences from our adult patients with severe disease suggest that early onset in childhood may be a predicting factor for recalcitrant disease. We completed a literature review of childhood onset psoriasis which highlighted an increased rate of psychiatric disorders and poorer quality of life compared to controls, with younger children more severely affected. A higher prevalence of co-morbidities, such as Crohn's disease, hyperlipidaemia, hypertension and obesity was seen compared to healthy controls. To date differences in age groups used and methods defining severity in published literature have made studies on severity of childhood onset disease too heterogenous to draw conclusion from.

Methodology and results: A search of our letters database confirmed 69 cases of patients less than 16 with a definite diagnosis of psoriasis. Females were more commonly affected (n=41) with a female: male ratio of 1.46:1. Plaque psoriasis predominated (55%), followed by guttate (19%), flexural (13%), scalp (10%) and napkin (3%). 37% had moderate-severe disease with four patients (7.2%) requiring systemic treatment with methotrexate, 22 patients (32%) referred for phototherapy and one requiring treatment with a Biologic agent. Almost two thirds of the moderate-severe group required long-term follow up (61.50%). A positive family history was recorded in 38% of patients. Co-morbidities were detailed for 14% of the patients (2 arthritis, 1 Crohn's disease, 2 alopecia areata, 1 asthma, 1 congenital heart disease). 11% made reference to significant impact on quality of life primarily affecting the child's ability to participate in school.

Conclusions: Our experience demonstrates a significant impact in children when affected with psoriasis with 37% requiring systemic therapy or phototherapy, the majority still attending our

service. Unlike children with atopic eczema those with psoriasis have significant co morbidities prompting us to re think the way we monitor these patients and consider screening for risk factors for metabolic syndrome as we do in adult psoriasis. Collaboration with our paediatric colleagues and longitudinal studies in this age group are required.

■ Audit of Cutaneous Allergy Service in a Regional Dermatology Department

*A. Havelin, P. Marren.
Department of Dermatology, University Hospital Galway*

Background: Allergic contact dermatitis (ACD) is a delayed type hypersensitivity reaction accounting for 4-7% of dermatological consultations. Diagnosis is by meticulous history taking and interpretation of appropriate cutaneous allergy tests.

Objectives: To review the Cutaneous Allergy Service in our University Tertiary Centre in 2015 to confirm compliance with the British Society of Cutaneous Allergy minimum standards guidelines (BSCA) and to identify current allergen prevalence and trends in our catchment area patient population (800,000).
Methods: Cutaneous allergy testing was performed one week each month for 10 months during that calendar year. Information was obtained from each patient's final clinic report.

Results: Patients were seen on days 0, 2, and 4 by a Consultant Dermatologist. Patches were applied on day 0 by a trained dermatology nurse. BSCA protocols were followed in preparation and procedural methodology. Results were read and interpreted by the same Consultant Dermatologist. Data on 96 patients, 41 male and 55 female, was available for analysis. The median age in our cohort was 45 years (range 7-87 years). The majority of referrals, 75%, were from consultant dermatologists within our department. The remainder came from GP referrals (15%) and non-dermatology hospital consultants (10%). The most common sites affected were face (36%) and hands (26%). All patients were tested to the BSCA standard series and to a range of other allergens as deemed individually appropriate. A positive reaction was documented in 54% of patients. Allergens of current clinical relevance were diagnosed in 65% (35/54) of patients with a positive reaction. The most common allergens in our cohort were nickel (20%), fragrances (17%) and Balsam of Peru (10%) followed by preservatives MCI/MI (9%), MI (7%) and PPD (3%).

Conclusion: Allergic contact dermatitis remains a prevalent condition affecting males and females across all age groups. Our prevalence figures reflect our referral base ie. 75% of patients are selected referrals from dermatologists. This is determined by limited available resources. As confirmed internationally, positive reactions to nickel, fragrances and Balsam of Peru remain amongst the most common allergens causing ACD. The prevalence of positive reactions to PPD and MCI/MI and MI may be beginning to show a downward trend compared to recent previous years. If this downward trend continues, can it be attributed to increasing patient awareness with increased avoidance of these allergens or does it reflect a tardy response finally emerging from our cosmeceutical industry.

■ Recalcitrant cutaneous sarcoidosis, with response to daylight photodynamic therapy.

Conor Broderick¹, Catherine Quinlan¹, Christian Gulmann¹, Marina O'Kane¹

1. Beaumont Hospital Dublin

A 37 year-old Zimbabwean woman with type V skin presented to Dermatology with a two year history of symmetrical, uncomfortable papules and plaques on her face, ears and neck. Her past medical history was significant for HIV and chronic hepatitis B co-infection, multiple opportunistic infections, including pulmonary tuberculosis and cryptococcal meningitis, iron-deficiency anaemia and multiple laparotomies for ovarian cysts and adhesional small bowel obstruction. Her medications included efavirenz, lamivudine/zidovudine, fluconazole and co-trimoxazole. Previous treatments included topical clobetasol. Examination revealed juicy, symmetrical, erythematous and skin-coloured papules and plaques, which subsequently developed dyspigmentation. The lesions were both annular and umbilicated in parts.

Skin biopsy confirmed cutaneous sarcoidosis, with numerous upper dermal granulomata and occasional focal necrosis, with a background mild chronic inflammatory infiltrate. Special stains and cultures were negative for mycobacteria, fungi, cryptococcus and spirochetes. Repeat biopsies were consistent with sarcoid. Investigations showed an undetectable HIV viral load, CD4 count of 250-300, normal serum angiotensin-converting enzyme and adjusted calcium and negative Mantoux test. Chest imaging demonstrated bilateral and mediastinal lymphadenopathy and pulmonary function tests indicated a restrictive pattern. Respiratory review deemed there to be no requirement for ongoing oral steroids. She was evaluated by rheumatology who confirmed sarcoid dactylitis, treated with non-steroidal anti-inflammatories. Ophthalmological assessment excluded ocular sarcoidosis.

Trials of topical clobetasol propionate and tacrolimus were moderately effective but led to skin atrophy, intralesional trimacrolone was ineffective. Her skin would respond well to intermittent 6-week courses of oral prednisolone but she developed Cushingoid facies and suffered rapid relapses on discontinuation. Oral methotrexate (10mg/week) was poorly tolerated and discontinued (leukopenia and monitoring difficulties) and hydroxychloroquine (200mg BD) was ineffective. Anti-TNF agents were considered an unacceptable risk given her history of pulmonary tuberculosis, chronic hepatitis B infection and cryptococcal meningitis. Given her significant disfigurement, psychological distress and limited therapeutic options, and being aware of case reports (1,2,3) citing success with photodynamic therapy (PDT) treatment, a test patch of conventional PDT (methyl-aminolevulinate; Metvix and Aktilite) to the right cheek successfully flattened a plaque leaving cosmetically acceptable post-inflammatory hyperpigmentation, which faded with time. This was followed with daylight PDT with further flattening of lesions, most markedly on her maxillary prominences and forehead. She will have further sessions of daylight PDT. There are no reported cases of daylight PDT being used to treat cutaneous sarcoidosis.

- 1) Karrer, S et al; Arch. Dermatol. 2002
- 2) Wilsman-Theis, D et al; Dermatology. 2008
- 3) Penrose, C et al; J Am Acad Dermatol. 2011



Skinnies are a unique range of specialist medical garments for the treatment and management of serious conditions affecting the skin. Our range is:

- **Skinnies Silk** (antimicrobial protection)
- **Skinnies Viscose** (wet or dry wrapping)
- **Skinnies WEB** (dressing retention)

All Available On Prescription

Dermacea Ltd (Skinnies) Tel:01562 884898 Fax: 0121 259 0292
 Email: infor@skinniesuk.com Web: www.skinniesuk.com



IAD President Dr Kevin McKenna & guest speaker Dr Sandy McBride



Guest speaker Dr Sandy McBride & Prof Brian Kirby



Dr Kevin McKenna & guest speaker Prof Brian Kirby



Dr Anne-Marie Tobin & guest speaker Dr Sandy McBride



Dr Kevin McKenna & guest speaker Prof Chris Griffiths



Past & Present IAD Presidents Dr Rosemarie Watson & Dr Kevin McKenna



Dr's Ian McDonald & Genevieve Kelly

IAD Dinner Aula Maxima





Discover a skin friendly^{1,2} formula to treat acne in line with latest guidelines^{3,4*}



Treclin[®] is a unique formulation⁵ that:

- combines a topical antibiotic with a topical retinoid⁶
- has a rapid onset of action vs its component monotherapies⁷
- effectively treats both inflammatory and non-inflammatory lesions⁶
- is alcohol free⁶

* NICE and PCDS recommend a combined topical treatment (topical antibiotic plus topical retinoid or benzoyl peroxide) for patients with moderate-severe acne when there is a risk of scarring

Prescribing Information: Treclin[®] 1 %/0.025 % w/w gel (clindamycin/tretinoin) **Presentation:** Each gram of gel contains 10 mg (1%) clindamycin (as clindamycin phosphate) and 0.25 mg (0.025%) tretinoin. **Indications:** For the topical treatment of acne vulgaris when comedones, papules and pustules are present in patients 12 years or older. **Dosage and administration:** Adults and adolescents (≥ 12 years) - Once daily at bedtime the entire face should be washed with mild soap and dried. A pea-sized amount of medication should be squeezed onto one fingertip, dot onto the chin; cheeks, nose, and forehead, then gently rub over the entire face. Treatment with Treclin should not exceed 12 weeks of continuous use without careful evaluation. **Contraindications:** In patients, who have a history of hypersensitivity to the active substances clindamycin and/or tretinoin or to any of the excipients or lincosamides; with regional enteritis, ulcerative colitis, or history of antibiotic-associated colitis; who have a personal or familial history of skin cancer; who have a history of acute eczemas, rosacea and perioral dermatitis; with pustular and deep cystic nodular acne varieties (acne conglobata and acne fulminans). **Precautions:** Treclin is not for oral, ophthalmic, intranasal or intravaginal use and is not recommended in treatment of mild acne vulgaris. It should not be used in pregnancy, especially during the first trimester, and in women of childbearing potential not using contraception.

Contact with the mouth, eyes and mucous membranes and with abraded or eczematous skin should be avoided. Use of more than the recommended amount or too frequent application may cause redness, stinging and discomfort. Because of increased susceptibility to UV radiation, photosensitivity may occur during treatment. Exposure to sunlight should therefore be minimised by using appropriate apparel and sunscreen products with a SPF of at least 30. Long-term use of clindamycin may cause resistance and/or overgrowth of non-susceptible dermal bacteria or fungi although this is a rare occurrence. Cross resistance may occur with other antibiotics such as lincosamides or erythromycin. **Undesirable effects: Uncommon:** May include acne, dry skin, erythema, seborrhoea, photosensitivity reaction, pruritus, rash, exfoliative rash, skin exfoliation, sunburn. Application site reactions such as burning, dermatitis, dryness, erythema. For a complete list of warnings and adverse reactions, you should consult the Summary of Product Characteristics. **Package quantity and basic NHS price:** Treclin 1% / 0.025% w/w gel, 30g at £11.94 **Product licence number:** PL15142/0249 **Legal category:** POM **Marketing authorisation holder:** Meda Pharmaceuticals Ltd, Skyway House, Parsonage Road, Takeley, Bishops Cleeve, CM22 6PU **Date of preparation of prescribing information:** February 2016 UK/TRE/14/0013(1)

References: 1. Del Rosso J, et al. *Cutis* 2008; 81:405-408. 2. Schlessinger J, et al. *J Drug Dermatol* 2007; 6:607-15. 3. NICE Clinical Knowledge Summaries. Acne vulgaris. cks.nice.org.uk/acne-vulgaris (accessed Jan 2016). 4. Primary Care Dermatology Society. Acne vulgaris. www.pcids.org.uk/clinicalguidance/acne-vulgaris (accessed Jan 2016). 5. US Patent No 5,721,275, 1998. 6. Treclin[®] SPC. 7. Dréno B, Layton A. Onset of action and efficacy of novel clindamycin 1% tretinoin 0.025% formulation for acne vulgaris. Presented at AAD 2013 Poster 6406.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Meda's Medical Information line on 01748 828810.

UK/TRE/16/0023 Date of preparation: Apr 2016.



abbvie Spring Symposium



Prof Brian Kirby



Barbara Horvatt



Janneke Huizinga



Spring Symposium



Dr Michelle Murphy, Prof Brian Kirby, Janneke Huizinga and Barbara Horvatt



Abvie Spring Symposium

Pharmaceutical Exhibition







IAD SPRING MEETING WINNERS



Dr Kevin McKenna presenting to Dr Gemma McIntyre, Burrows Cup runner up



Dr Kevin McKenna presenting to Dr Maeve Lynch 1st place poster prize



Dr Maeve McAleer Burrows Cup Winner presented by Dr Kevin McKenna



IAD SpR's

Cetraben.

Helping patients to **completely** understand emollient therapy.



Cetraben's approach to Complete Emollient Therapy:

- Providing a clinically effective, uniquely formulated and comprehensive emollient range that users prefer
- 96% of patients with problematic skin prefer Cetraben cream to their previous emollient¹
- Cetraben ointment ranked as the most preferred ointment versus leading brands²
- An ongoing commitment to the development of innovative tools and support materials to help HCPs and patients better manage problematic dry skin conditions

To find out what Cetraben can do for you and your patients and to order samples, please visit www.cetraben.co.uk

SLS, lanolin and paraben free



1. Preference study, September 2013. Data on file. 2. Preference study, August 2014. Data on file.

ABBREVIATED PRESCRIBING INFORMATION:

Cetraben® Ointment Presentation: An opaque white ointment. **Main ingredients:** White soft paraffin 35.0% w/w, Light liquid paraffin 45.0% w/w. **Indications:** An emollient used to moisturise and soften dry skin in eczema, dry cases of psoriasis and other dry skin conditions. Also used as a skin cleanser or bath additive. **Dosage and Administration:** Adults, the elderly and children: As an emollient: Apply to the affected areas as often as required. Smooth gently into the skin, following direction of the hair growth. As a bath additive: Melt about 4g in hot water in a suitable container then add to the bath. As a soap substitute: Take a small amount of the ointment and lather it under warm water and use as required when washing or in the shower. Pat skin dry. **Contraindications:** Hypersensitivity to any of the ingredients. **Precautions:** For external use only. May cause local skin reactions. Avoid contact with eyes. Baths and showers may become slippery when used. If this product comes into contact with dressings and clothes, it can be more easily ignited with a naked flame. Keep away from fire when using this product. Do not use if you are allergic to any of the ingredients listed. Talk to your doctor before use if the skin is badly cracked, infected or bleeding. **Pregnancy and breastfeeding:** Unlikely to have any ill effect when used as directed. If unsure, talk to your doctor or pharmacist. **Side effects:** None known. **Pack size:** 50g, 125g & 450g. **Trade Price:** 125g: £3.49 450g: £5.39 **Medical Device:** Class I. **Manufacturer:** Thornton & Ross Limited, Huddersfield, HD7 5QH, UK. **Date of preparation:** 05.11.2015.

Cetraben® Emollient Bath Additive Light Liquid Paraffin Please refer to Summary of Product Characteristics before prescribing. **Presentations:** Bath additive – Clear liquid containing light liquid paraffin 82.8% w/w. **Indications:** Symptomatic relief of red, inflamed, damaged, dry or chapped skin, especially when associated with endogenous or exogenous eczema. **Dosage:** Bath additive – Adults: Add one or two capfuls; Children: add half/one capful to a warm water bath or apply with a wet sponge to wet skin before showering. **Contra-indications:** Hypersensitivity to any of the ingredients. **Special Warnings and Precautions:** Care should be taken if allergy to any of the ingredients is suspected. Care should also be exercised when entering or leaving the bath. Avoid contact with the eyes. **Side Effects:** Very rarely, mild skin reactions have been seen. **Marketing Authorisation Numbers:** Cetraben Emollient Bath Additive: PL 06831/0260 **Basic NHS Price:** £5.75 **Legal Category:** GSL. **Date of Preparation:** November 2015. **Further Information is available from:** Genus Pharmaceuticals Ltd, Linthwaite, Huddersfield, HD7 5QH, UK. Cetraben® is a registered trademark. CETBA, APLV11.

Cetraben® Cream Presentation: A thick white cream. **Main ingredients:** White soft paraffin 13.2% w/w, Light liquid paraffin 10.5% w/w. **Indications:** An emollient, moisturising and protective cream for the symptomatic relief of red, inflamed, dry or chapped skin, especially when associated with eczema. **Dosage and Administration:** Adults, the elderly and children: Apply to dry skin areas as often as required and rub in. **Contra-indications:** Hypersensitivity to any of the ingredients. **Precautions:** For external use only. May cause local skin reactions. Avoid contact with eyes. Talk to your doctor before use if the skin is badly cracked, infected or bleeding. Do not use if allergic to any of the ingredients. Children under 1 year should be treated under medical supervision. **Pregnancy and breastfeeding:** Using Cetraben Cream during pregnancy and breastfeeding is unlikely to have any ill effects. If unsure, talk to your doctor or pharmacist. **Side effects:** Mild allergic skin reactions. **Pack size:** 50g, 150g, 500g, 1050g Rx packs, 50ml, 200ml & 500ml (with 475ml fill) OTC packs. **Trade Price:** 50g: £1.40 150g: £3.98 500g: £5.99 1050g: £11.62 50ml OTC: £3.00 200ml OTC: £4.80 500ml (with 475ml fill) OTC: £7.25 **Medical Device:** Class I. **Legal Manufacturer:** Thornton & Ross Limited, Huddersfield, HD7 5QH, UK. **Date of preparation:** 13.05.2016.

Cetraben® Lotion Presentation: A smooth white lotion. **Main ingredients:** White soft paraffin 5.0% w/w, Light liquid paraffin 4.0% w/w. **Indications:** For the relief of the symptoms of eczema, dermatitis and other dry skin conditions. **Dosage and Administration:** Adults, the elderly and children: Apply to the skin and gently rub in until absorbed. Use as often as required, or as directed by your doctor or pharmacist. **Contra-indications:** Hypersensitivity to any of the ingredients. **Precautions:** For external use only. Do not swallow. Avoid contact with eyes. May cause local skin reactions. Talk to your doctor before use if the skin is badly cracked, infected or bleeding. Do not use if allergic to any of the ingredients. **Pregnancy and breastfeeding:** Using Cetraben Lotion during pregnancy and breastfeeding is unlikely to have any ill effects. If unsure, talk to your doctor or pharmacist. **Side effects:** Mild allergic skin reactions. **Pack size:** 200ml & 500ml Rx packs, 50ml, 200ml & 500ml (with 475ml fill) OTC packs. **Trade Price:** 200ml: £4.00 500ml: £5.64 50ml OTC: £3.00 200ml OTC: £4.80 500ml (with 475ml fill) OTC: £7.25 **Medical Device:** Class I. **Legal Manufacturer:** Thornton & Ross Limited, Huddersfield, HD7 5QH, UK. **Date of preparation:** 05.11.2015.

Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk. Adverse events should also be reported to Medical Information on 0870 851 207




Thornton & Ross
DERMATOLOGY

Real-world patients remain on Stelara® longer compared to anti-TNF therapies^{1,2}

Newly published BADBIR* data shows better drug persistency for Stelara compared to anti-TNF therapies¹

- Predictors of discontinuation were analyzed using a multivariate Cox proportional hazards model.¹
- Compared to adalimumab\$:
 - Stelara was a **predictor of drug survival**
 - Infliximab[†] and Etanercept[‡] were both predictors of discontinuation.



Adapted from Warren RB et al. 2015

* BADBIR (British Association of Dermatologists Biologic Interventions Register) is a prospective, longitudinal, pharmacovigilance register for the UK and the Republic of Ireland. Over 3,500 biologic-naïve patients are enrolled, with a median 1.4 years of follow-up.¹

** Study limitations: BADBIR is primarily used as a pharmacovigilance register, therefore limitations include: the intention behind concomitant medication; potential variability in classifying reason for drug withdrawal across centres; recall and reporting bias may occur with patient-reported characteristics; non-randomisation may introduce selection bias; unmeasured confounders cannot be ruled out; patient adherence was not measured; the infliximab cohort is small.¹

\$ Adalimumab was the reference standard to which the other biologics were compared with because it was the most commonly prescribed biologic in the registry.

† Infliximab was a predictor for discontinuation overall and due to adverse events.

‡ Etanercept was a predictor for discontinuation overall and due to ineffectiveness

STELARA® solution for injection PRESCRIBING INFORMATION ACTIVE INGREDIENT(S): Ustekinumab

Please refer to Summary of Product Characteristics (SmPC) before prescribing.

INDICATION(S): **Plaque psoriasis adults:** Treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate or PUVA. **Plaque psoriasis paediatrics:** Moderate to severe plaque psoriasis in adolescent patients from the age of 12 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies. **Psoriatic arthritis:** Alone or in combination with methotrexate for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate. **DOSE AND ADMINISTRATION:** Under the guidance and supervision of a physician experienced in diagnosis and treatment of psoriasis or psoriatic arthritis. Subcutaneous injection. Avoid areas with psoriasis. Self-injecting patients or caregivers ensure appropriate training. Physicians are required to follow-up and monitor patients. **Plaque psoriasis, adults & elderly:** Patients <100kg, 45 mg at week 0 followed by a 45 mg dose at week 4, then every 12 weeks. Patients >100 kg, 90 mg at week 0 followed by a 90 mg dose at week 4, then every 12 weeks (45 mg was less effective in these patients). **Plaque psoriasis paediatrics (12 years and older):** Patients <60 kg, 0.75 mg/kg at week 0, followed by 0.75 mg/kg at week 4 then every 12 weeks thereafter. Patients ≥60- <100kg, 45 mg at week 0 followed by 45 mg at week 4, then every 12 weeks. Patients >100 kg, 90mg at week 0, followed by 90mg at week 4, then every 12 weeks. **Psoriatic arthritis, adults & elderly:** 45 mg at week 0 followed by a 45 mg dose at week 4, then every 12 weeks. Alternatively, 90 mg may be used in patients with a body weight >100 kg. Consider discontinuation if no response after 28 weeks. **Children <12 years:** Not recommended. **Renal & Hepatic impairment:** Not studied. **CONTRAINDICATIONS:** Hypersensitivity to product; clinically important, active infection. **SPECIAL WARNINGS & PRECAUTIONS:** **Infections:** Potential to increase risk of infections and reactivate latent infections. Caution in patients with a chronic infection or history of recurrent infection, particularly TB. Patients should be evaluated for tuberculosis prior to initiation of STELARA. Consider anti-tuberculosis therapy prior to initiation of STELARA in

patients with past history of latent or active tuberculosis. Patients should seek medical advice if signs or symptoms suggestive of an infection occur. If a serious infection develops, they should be closely monitored and STELARA should not be administered until infection resolves. **Malignancies:** Potential to increase the risk of malignancy. No studies in patients with a history of malignancy or in patients who develop malignancy while receiving STELARA. Monitor all patients, in particular those older than 60, patients with a medical history of prolonged immunosuppressant therapy or those with a history of PUVA treatment for non-melanoma skin cancer. **Concomitant immunosuppressive therapy:** Caution, including when changing immunosuppressive biologic agents. **Hypersensitivity reactions:** Serious hypersensitivity reactions (anaphylaxis and angioedema) reported, in some cases several days after treatment. If these occur appropriate therapy should be instituted and, STELARA discontinued immediately. **Latex sensitivity:** Needle cover contains natural rubber (latex), may cause allergic reactions. **Immunotherapy:** Not known whether STELARA affects allergy immunotherapy. **Serious skin conditions:** Exfoliative dermatitis has been reported following treatment. Discontinue STELARA if a drug reaction is suspected. **SIDE EFFECTS: Common:** dental infections, upper respiratory tract infection, nasopharyngitis, dizziness, headache, oropharyngeal pain, diarrhoea, nausea, pruritus, back pain, myalgia, arthralgia, fatigue, injection site erythema, injection site pain, antibodies to ustekinumab. **Other side effects include:** cellulitis, serious hypersensitivity reactions (including anaphylaxis, angioedema), skin exfoliation, exfoliative dermatitis. Studies show adverse events reported in ≥12 year olds with plaque psoriasis were similar to those seen in previous studies in adults with plaque psoriasis. **Refer to SmPC for other side effects.** **FERTILITY:** The effect of ustekinumab has not been evaluated. **PREGNANCY:** Should be avoided. Women of childbearing potential: Use effective contraception during treatment and for at least 15 weeks post-treatment. **LACTATION:** Limited data in humans. **INTERACTIONS:** *In vitro*, STELARA had no effect on CYP450 activities. **Vaccinations:** Live vaccines should not be given concurrently with STELARA, and should be withheld for at least 15 weeks after last dose of STELARA. STELARA can resume at least 2 weeks after such vaccinations. No data on secondary transmission of infection by live vaccines in patients receiving STELARA. **Concomitant immunosuppressive therapy:** Psoriasis: The safety and efficacy of STELARA in combination with other

immunosuppressants, including biologics, or phototherapy have not been evaluated. **Refer to SmPC for full details of interactions.** **LEGAL CATEGORY:** Prescription Only Medicine. **PRESENTATIONS, PACK SIZES, MARKETING AUTHORISATION NUMBER:** 45 mg: 1 x vial. EU/1/08/494/001, 45mg; 1 x 0.5ml pre-filled syringe. EU/1/08/494/003, 90mg; 1 x 1.0ml pre-filled syringe. EU/1/08/494/004. **MARKETING AUTHORISATION HOLDER:** JANSSEN-CILAG INTERNATIONAL NV, Turnhoutseweg 30, B-2340 Beerse, Belgium. **FURTHER INFORMATION IS AVAILABLE FROM:** Janssen-Cilag Ltd, 50 – 100 Holmers Farm Way, High Wycombe, Buckinghamshire, HP12 4EG UK. © Janssen-Cilag Ltd 2015

Adverse events should be reported. Healthcare professionals are asked to report any suspected adverse events via: HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2, Tel: +353 1 6764971, Fax: +353 1 6762517, Website: www.hpra.ie, E-mail: medsafety@hpra.ie
Adverse events should also be reported to Janssen-Cilag Ltd on +44 1494 567447.

Prescribing information last revised: 06/2015

References: 1. Warren RB et al. J Inv Dermatol. Accepted article: June 2015; doi: 10.1038/jid.2015.208. 2. Menter A et al. P1705: Poster presented at the AAD Annual Meeting, 20-24 March 2015; San Francisco, California. 3. Stelara Summary of Product Characteristics, available at www.medicines.ie

Date of preparation: March 2016 | PHIR/STE/1015/0007a